A biological antagonist containing an aromatic ring, a method for its production and its use
Patent Information
- Application Number
- EA202490496
- Authority / Receiving Office
- EA · EA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-06-06
- Filing Date
- 2022-08-26
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-08-26
AI Technical Summary
Existing treatments for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy have poor response, significant side effects, and no effective approved treatment options, leading patients to progress to chronic renal failure and require long-term dialysis or kidney transplantation , bringing economic burden to families and society.
Develop an AT1/ETA dual-target antagonist that combines angiotensin receptor blocker (ARB) and endothelin receptor antagonist (ERA) by blocking the activities of angiotensin II and endothelin-1. Synergistic effect to treat kidney diseases such as FSGS and IgA nephropathy.
This AT1/ETA dual-target antagonist can effectively improve the proteinuria level in FSGS patients, and has shown anti-glomerular fibrosis effects in clinical practice, providing better therapeutic effects and lower side effects, and can potentially be used to treat many diseases. kind of kidney disease.
Smart Images

Figure CLAIM-11112026-IMGC0001 
Figure CLAIM-11112026-IMGC0002 
Figure CLAIM-11112026-IMGC0003
Abstract
Description
Aromatic ring-containing biological antagonist, preparation method and application thereof Technical Field
[0001] The present invention belongs to the field of biomedicine, and in particular relates to an aromatic ring-containing biological antagonist, a preparation method and application thereof. Background Art
[0002] Focal segmental glomerulosclerosis (FSGS) is one of the manifestations of nephrotic syndrome and the main cause of end-stage renal disease. Its pathogenesis is complex and has not yet been fully understood. Current drug treatments, mainly glucocorticoids and immunosuppressants, have poor responses and cannot ideally control the occurrence and progression of FSGS, and also have significant side effects. There is currently no approved treatment for FSGS, and the complete remission rate for FSGS treatment is less than 30%. One-third of patients progress to chronic renal failure after five years and require long-term dialysis or kidney transplantation to maintain life, which brings a serious economic burden to families and society. Exploring new treatment options has become a priority.
[0003] In addition to FSGS, other kidney diseases or conditions characterized by glomerular damage include IgA nephropathy and idiopathic membranous nephropathy. IgA nephropathy, also known as Berger's disease, is caused by the accumulation of immunoglobulin A (IgA) in the kidneys. The presence of IgA in the kidneys can lead to inflammation, damage to the kidney's glomeruli, and impaired renal function, including proteinuria. In some cases, patients with IgA nephropathy may progress to end-stage renal disease (ESRD). IgA nephropathy is the most common glomerulonephritis worldwide. In approximately 30% of patients, a decrease in glomerular filtration rate of approximately 50% over 10 years is observed. Patients with IgA nephropathy develop IgG autoantibodies against galactose-deficient IgA1 antibodies. This leads to the deposition of these antibodies in the mesangium and activation of complement. The primary treatment for patients with IgA nephropathy involves eliminating risk factors, particularly hypertension, by blocking the renin-angiotensin-aldosterone system (RAAS). Various studies have also investigated immunosuppression, but no clear benefit has been observed. Common side effects of hormonal therapy include increased blood sugar, osteoporosis, and infection. Thus, there remains a need for compositions and methods for treating various renal diseases or disorders, such as FSGS, IgA nephropathy, and IMN.
[0004] The endogenous vasoactive peptides angiotensin II (AngII) and endothelin-1 (ET-1) are two potent vasoconstrictors and are thought to play a role in controlling vascular tone and pathological tissue remodeling associated with a variety of diseases, including diabetic nephropathy, heart failure, and chronic or persistently elevated blood pressure. The renin-angiotensin-aldosterone system (RAAS) regulates blood pressure, fluid, and sodium balance. Excessive activation of the RAAS can promote systemic and regional glomerular capillary hypertension, causing glomerular hemodynamic impairment and leading to kidney damage and renal fibrosis through profibrotic and proinflammatory pathways. RAAS system drugs, such as angiotensin receptor blockers (ARBs), have been used to treat diabetic nephropathy, heart failure, and chronic or persistently elevated blood pressure. In addition, a growing body of data demonstrates the potential therapeutic benefits of ET receptor antagonists (ERAs) in hypertension and diabetic nephropathy.
[0005] Studies have shown that the combination of ARB and ERA produces a synergistic effect, and AngII and ET-1 work together in blood pressure control and pathological tissue remodeling. Increased levels of Ang II promote ET-1 synthesis and vasoconstriction. ETA blocking ET receptors can reduce AngII-induced vasoconstriction and reduce plasma aldosterone. ARB not only blocks the effect of AngII on its AT1 receptor, but also limits the production of ET-1. Therefore, simultaneous blocking of AngII and ET-1 activity may provide better efficacy than blocking either substance alone. In addition, although ARB is the standard treatment for patients with diabetic nephropathy, dual antagonists (ARB and ERA) have been reported in Phase II clinical development to improve proteinuria changes in FSGS patients. Therefore, drugs with AT1 / ETA dual-target antagonism mechanisms have potential for treating kidney disease and are of significance for drug development.
[0006] International application WO2018071784 reports that Retrophin's AT1 / ETA dual-target antagonist, Sparsentan, has demonstrated promising anti-glomerular fibrosis effects in preclinical trials. In Phase II clinical trials, it has been shown to improve proteinuria in patients with FSGS, and Phase III clinical trials are underway for the treatment of FSGS and IgA nephropathy. This project aims to develop an AT1 / ETA dual-target antagonist for the treatment of nephrotic syndrome (including FSGS, IgA nephropathy, and diabetic nephropathy).
[0007] Summary of the Invention
[0008] The object of the present invention is to provide a compound represented by general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, whose structure is as follows:
[0009] in:
[0010] X1 is N or CR 1 ;
[0011] X2 is N or CR 2 ;
[0012] X3 is N or CR 3 ;
[0013] R 1 、R 2 and R 3 each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups may be further substituted;
[0014] L1 is selected from -(CR a R b ) n1 -、-(CR a R b ) n1 O-、-O(CR a R b ) n1 -、-(CR a R b ) n1 S-、-S(CR a R b ) n1 -、-(CH2) n1 C(O)NR a -、-(CH2) n1 NR a C(O)-、-(CH2) n1 S(O) m1 -、-(CH2) n1 S(O) m1 NR a -、-(CH2) n1 NR a S(O) m1 -or-(CH2) n1 NR a -;
[0015] L2 is selected from -(CH2) n2 -、-(CH2) n2 NR c -、-(CH2) n2 C(O)NR c -、-(CH2) n2C(O)NR c S(O) m2 -、-(CH2) n2 NR c C(O)-、-(CH2) n2 S(O) m2 -、-(CH2) n2 S(O) m2 NR c -、-(CH2) n2 S(O) m2 NR c C(O)-, -(CH2) n2 S(O) m2 NR c C(O)NR d -、-(CH2) n2 S(O) m2 NR c C(O)O(CH2) n3 -、-(CH2) n2 NR c S(O) m2 -or-(CH2) n2 NR c S(O) m2 NR d C(O)-;
[0016] Ring A is selected from cycloalkyl, heterocyclyl, aryl or heteroaryl, and the cycloalkyl, heterocyclyl, aryl and heteroaryl may be further substituted;
[0017] R a independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, oxo, thio, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -(CH2) n4 C(O)R A1 、-(CH2) n4 C(O)OR A1 、-(CH2) n4 C(O)NR A1 R B1 or -(CH2) n4 C(=S)NR A1 R B1 , the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups may optionally be further substituted;
[0018] R1 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -(CH2) n5 R A2 -、-(CH2) n5 O(CH2) n6 R A2 -、-(CH2) n5 C(O)R A2 、-(CH2) n5 NR A2 C(O)R B2 、-(CH2) n5 C(O)NR A2 R B2 、-(CH2) n5 OC(O)NR A2 R B2 or -(CH2) n5 NR A2 C(O)OR B2 , the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups may optionally be further substituted;
[0019] Alternatively, R1 and R a Linked to form a cycloalkyl, heterocyclic, aryl or heteroaryl group, wherein the cycloalkyl, heterocyclic, aryl and heteroaryl groups may be further substituted;
[0020] R2, R3, R4 and R5 are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, and the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups may be further substituted;
[0021] R6 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, and the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups may be further substituted;
[0022] R a 、R b 、R c 、R d 、RA1 、R A2 、R B1 and R B2 each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the amino, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups may be further substituted;
[0023] x is 0, 1, 2, 3, 4, or 5;
[0024] n1-n6 are 0, 1, 2, 3, 4 or 5; and
[0025] m1 and m2 are 0, 1, or 2.
[0026] In one embodiment of the present invention, R2 and R5 form a heterocyclic group with adjacent atoms, and the heterocyclic group may be further substituted.
[0027] In a preferred embodiment of the present invention, the ring A is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 The aryl group and the 5-14 membered heteroaryl group are substituted by one or more substituents.
[0028] In a further preferred embodiment of the present invention, the ring A is selected from a 5-10 membered heterocyclic group or a 5-10 membered heteroaryl group.
[0029] In a further preferred embodiment of the present invention, the ring A is selected from a 5-6 membered nitrogen-containing monoheterocyclic group, a 6-10 membered nitrogen-containing spiroheterocyclic group or a 5-6 membered nitrogen-containing heteroaryl group.
[0030] In a further preferred embodiment of the present invention, the ring A is selected from pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl,
[0031] R a are independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, oxo, thio, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-12 membered heteroaryl, -(CH2) n4 C(O)R A1 、-(CH2) n4 C(O)OR A1 、-(CH2) n4 C(O)NR A1 R B1 or -(CH2) n4 C(=S)NR A1 R B1 , the amino group, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-12 membered heteroaryl, optionally further substituted; R A1 and R B1 are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14Aryl, 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-12 membered heteroaryl, optionally further substituted;
[0032] Preferably, R a independently selected from amino, nitro, hydroxy, cyano, oxo, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, -(CH2) n4 C(O)OR A1 , and (CH2) n4 C(=S)NR A1 R B1 ; R A1 and R B1 Each independently selected from hydrogen or C 1-6 alkyl;
[0033] More preferably, R a Independently selected from oxo, C 1-4 Alkyl, C 1-3 Hydroxyalkyl, -(CH2) n4 C(O)OR A1 , and (CH2) n4 C(=S)NR A1 R B1 ; R A1 and R B1 are each independently selected from hydrogen, C 1-6 alkyl;
[0034] Most preferably, R a independently selected from oxo, n-propyl, n-butyl, carboxyl, ethyl, -CH2OH, -C(O)NH2, -C(O)NHCH3,
[0035] In a further preferred embodiment of the present invention, the compound, its stereoisomer or pharmaceutically acceptable salt thereof is further represented by general formula (II):
[0036]
[0037] X1 is N or CR 1 ;
[0038] X2 is N or CR 2 ;
[0039] X3 is N or CR 3 ;
[0040] R 1 、R 2 and R 3 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl;
[0041] L1 is selected from -(CR a R b ) n1 -、-(CR a R b ) n1 O-、-O(CRa R b ) n1 -、-(CR a R b ) n1 S-、-S(CR a R b ) n1 -、-(CH2) n1 C(O)NR a -、-(CH2) n1 NR a C(O)-、-(CH2) n1 S(O) m1 -、-(CH2) n1 S(O) m1 NR a -、-(CH2) n1 NR a S(O) m1 -or-(CH2) n1 NR a -;
[0042] R1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-14 membered heteroaryl, -(CH2) n5 R A2 -、-(CH2) n5 O(CH2) n6 R A2 -、-(CH2) n5 C(O)R A2 、-(CH2) n5 NR A2 C(O)R B2 、-(CH2) n5 C(O)NR A2 R B2 、-(CH2) n5 OC(O)NR A2 R B2 or -(CH2) n5 NR A2 C(O)OR B2, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl;
[0043] R7 and R8 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl;
[0044] Alternatively, R7 and R8 are linked to form C 3-8 Cycloalkyl, 5-8 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 3-8 Cycloalkyl, 5-8 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, optionally further substituted;
[0045] R a and R b are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl;
[0046] R A2 and R B2 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl;
[0047] n1, n5 and n6 are 0, 1, 2 or 3; and
[0048] m1 is 0, 1, or 2.
[0049] In a further preferred embodiment of the present invention, the compound is further represented by formula (VIII-1) or formula (VIII-2), or a compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
[0050]
[0051] Wherein, the definitions of L1, X1, X2, X3, R7 and R8 are as described in claim 2;
[0052] For the general formula (VIII-1), when L1 is CH2, R7 and R8 are both methyl, and R1 is When , at least one of X1, X2, and X3 is not CH.
[0053] In a preferred embodiment of the present invention, the L1 is selected from -CR a R b -、-CR a R b O-、-OCR a R b -、-CR a R b S-or-SCR a R b -.
[0054] In a further preferred embodiment of the present invention, said L1 is selected from -CH2-, -CD2- or -CH2O-;
[0055] The R a and R b are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 The aryl group and the 5-10 membered heteroaryl group are substituted by one or more substituents.
[0056] In a preferred embodiment of the present invention, R1 and R7 are linked to form an 8-20 membered heterocyclic group, wherein the heterocyclic group is optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 The aryl group and the 5-14 membered heteroaryl group are substituted by one or more substituents.
[0057] In a further preferred embodiment of the present invention, R1 and R7 are linked to form a heterocyclic group selected from 8-14 members.
[0058] In a further preferred embodiment of the present invention, R1 and R7 are linked to form an 8-14 membered oxygen-containing heterocyclic group.
[0059] In a preferred embodiment of the present invention, X1, X2 and X3 are all CH;
[0060] L1 is selected from -CH2- or -CD2-;
[0061] R1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-14 membered heteroaryl, -(CH2) n5 R A2 、-(CH2) n5 O(CH2) n6 R A2 、-(CH2) n5 C(O)R A2 、-(CH2) n5 NR A2 C(O)R B2 、-(CH2) n5 C(O)NR A2 R B2 、-(CH2) n5 OC(O)NR A2 R B2 or -(CH2) n5 NR A2 C(O)OR B2 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl;
[0062] Preferably, the R1 is selected from H, -CH3, -CH2CH3,
[0063] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;
[0064] Preferably, said R7 is selected from deuterium, fluorine, chlorine, bromine or methyl;
[0065] The R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;
[0066] Preferably, R8 is selected from methyl, ethyl or cyclopropyl.
[0067] In a further preferred embodiment of the present invention, the compound, its stereoisomer or pharmaceutically acceptable salt thereof is further represented by general formula (II-1):
[0068]
[0069] L1 is selected from -CH2- or -CD2-;
[0070] R1 is selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-14 membered heteroaryl, -(CH2) n5 R A2 、-(CH2) n5 O(CH2) n6 R A2 、-(CH2) n5 C(O)R A2 、-(CH2) n5 NR A2 C(O)R B2 、-(CH2) n5 C(O)NR A2 R B2 、-(CH2) n5 OC(O)NR A2 R B2 or -(CH2) n5 NR A2 C(O)OR B2 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl;
[0071] Further, R1 is preferably selected from -CH3, -CH2CH3, More preferred
[0072] R7 is selected from halogen, preferably fluorine, chlorine, bromine, more preferably chlorine;
[0073] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, preferably methyl, ethyl or cyclopropyl, more preferably methyl.
[0074] In a further preferred embodiment of the present invention, in the general formula (II-1),
[0075] L1 is selected from -CH2- or -CD2-;
[0076] R1 is -(CH2) n5 O(CH2) n6 R A2 , n5 is 1 or 2, n6 is 0, R A2 Selected from C 1-3 Alkyl, C 1-3 Deuterated alkyl or C 1-3 alkyl halide;
[0077] R7 is selected from fluorine, chlorine, bromine, preferably chlorine;
[0078] R8 is methyl, ethyl or cyclopropyl, preferably methyl.
[0079] In a further preferred embodiment of the present invention, in the general formula (II-1),
[0080] L1 is selected from -CH2- or -CD2-;
[0081] R1 is
[0082] R7 is selected from fluorine, chlorine, bromine, preferably chlorine;
[0083] R8 is methyl.
[0084] In a further preferred embodiment of the present invention, the compound, its stereoisomer or pharmaceutically acceptable salt thereof is further represented by general formula (III):
[0085]
[0086] in:
[0087] L2 is selected from -(CH2) n2 C(O)NR c -、-(CH2) n2 C(O)NR c S(O) m2 -、-(CH2) n2 NR c C(O)-、-(CH2) n2 S(O) m2 -、-(CH2) n2 S(O) m2 NR c -、-(CH2) n2 S(O) m2 NR c C(O)-、-(CH2) n2 S(O) m2 NR c C(O)NR d -、-(CH2) n2 S(O) m2 NR c C(O)O(CH2) n3 -、-(CH2) n2 NR c S(O) m2 -or-(CH2) n2 NR c S(O) m2 NR d C(O)-;
[0088] R6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl;
[0089] R c and R d are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl or 5-14 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl;
[0090] n2 and n3 are 0, 1, 2, or 3;
[0091] m2 is 0, 1 or 2.
[0092] In a preferred embodiment of the present invention, the L2 is selected from -C(O)NR c -、-C(O)NR c S(O)2-、-NR c C(O)-、-S(O)2-、-S(O)2NR c -、-S(O)2NR c C(O)-、-S(O)2NR c C(O)NR d -、-S(O)2NR c C(O)OCH2-、-NR c S(O)2- or -NR c S(O)2NR d C(O)-;
[0093] In a further preferred embodiment of the present invention, L2 is selected from -C(O)NH-, -C(O)NHS(O)2-, -S(O)2NH-, -S(O)2NHC(O)-, -S(O)2NHC(O)NH-, -S(O)2NHC(O)O-, -S(O)2NHC(O)OCH2-, -NHS(O)2- or -NHS(O)2NHC(O)-;
[0094] The R c and R d are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 The aryl group or the 5-10 membered heteroaryl group is substituted by one or more substituents.
[0095] In a preferred embodiment of the present invention, the R6 is selected from amino, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the amino, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10Aryl and 5-10 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 substituted by one or more substituents of aryl or 5-10 membered heteroaryl;
[0096] In a further preferred embodiment of the present invention, R6 is selected from amino, methyl, ethyl, propyl, isopropyl, cyclopropyl, oxazolyl, isoxazolyl, triazolyl, phenyl, pyridyl, pyrazinyl, tetrazolyl, dihydrotetrazolyl, 1,2,4-oxadiazol-5(2H)-one or 5,6-dihydro-4H-cyclopenta[d]isoxazolyl, and the amino, methyl, ethyl, propyl, isopropyl, cyclopropyl, oxazolyl, isoxazolyl, triazolyl, phenyl, pyridyl, pyrazinyl, tetrazolyl, dihydrotetrazolyl, 1,2,4-oxadiazol-5(2H)-one or 5,6-dihydro-4H-cyclopenta[d]isoxazolyl is optionally further substituted with one or more substituents selected from oxo, methyl, ethyl, propyl or cyclopropyl.
[0097] In a further preferred embodiment of the present invention, the compound, its stereoisomer or pharmaceutically acceptable salt thereof is characterized in that the compound is further represented by general formula (IV):
[0098]
[0099] R1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-14 membered heteroaryl, -(CH2) n5 R A2 、-(CH2) n5 O(CH2)n6 R A2 、-(CH2) n5 C(O)R A2 、-(CH2) n5 NR A2 C(O)R B2 、-(CH2) n5 C(O)NR A2 R B2 、-(CH2) n5 OC(O)NR A2 R B2 or -(CH2) n5 NR A2 C(O)OR B2 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl,
[0100] Preferred are hydrogen, -CH3, -CH2CH3,
[0101] R7 is selected from halogen, preferably fluorine, chlorine, bromine.
[0102] In a further preferred embodiment of the present invention, the compound, its stereoisomer or pharmaceutically acceptable salt thereof is characterized in that the compound is further represented by general formula (V):
[0103]
[0104] R9 and R 10 are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, oxo, thio, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-12 membered heteroaryl, -(CH2) n4 C(O)R A1 、-(CH2) n4 C(O)OR A1 、-(CH2) n4 C(O)NR A1 R B1 or -(CH2) n4 C(=S)NR A1 R B1 , the amino group, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-12 membered heteroaryl, optionally further substituted; R A1 and R B1 are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-12 membered heteroaryl, the amino, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-12 membered heteroaryl, optionally further substituted,
[0105] Preferably, it is selected from amino, nitro, hydroxy, cyano, oxo, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, -(CH2) n4 C(O)OR A1 , and (CH2) n4 C(=S)NR A1 R B1 ; R A1 and R B1 are each independently selected from hydrogen, C 1-6 alkyl,
[0106] More preferably, selected from oxo, C 1-4 Alkyl, C 1-3 Hydroxyalkyl, -(CH2) n4 C(O)OR A1 , and (CH2) n4 C(=S)NR A1 R B1 ; R A1 and R B1 are each independently selected from hydrogen, C 1-6 alkyl,
[0107] Most preferably, selected from methyl, ethyl, propyl, carboxyl, R1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-14 membered heteroaryl, -(CH2) n5 R A2 、-(CH2) n5 O(CH2) n6 R A2 、-(CH2)n5 C(O)R A2 、-(CH2) n5 NR A2 C(O)R B2 、-(CH2) n5 C(O)NR A2 R B2 、-(CH2) n5 OC(O)NR A2 R B2 or -(CH2) n5 NR A2 C(O)OR B2 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl,
[0108] Preferred are hydrogen, -CH3, -CH2CH3,
[0109] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl,
[0110] Preferably deuterium, fluorine, chlorine, bromine or methyl;
[0111] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl,
[0112] Preferred are methyl, ethyl or cyclopropyl.
[0113] The present invention also provides a compound represented by general formula (VI), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
[0114]
[0115] L1 is selected from -(CR a R b ) n1 -、-(CR a R b ) n1 O-、-O(CR a R b ) n1 -、-(CR a R b ) n1 S-、-S(CR a R b ) n1 -、-(CH2) n1 C(O)NR a -、-(CH2) n1 NR a C(O)-、-(CH2) n1 S(O) m1 -、-(CH2) n1 S(O) m1 NR a -、-(CH2) n1 NR a S(O) m1 -or-(CH2)n1 NR a -,
[0116] Preferably -CRaRb-, -CRaRbO-, -OCRaRb-, -CRaRbS- or -SCRaRb-,
[0117] More preferably -CH2- or -CD2-;
[0118] R1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-14 membered heteroaryl, -(CH2) n5 R A2 、-(CH2) n5 O(CH2) n6 R A2 、-(CH2) n5 C(O)R A2 、-(CH2) n5 NR A2 C(O)R B2 、-(CH2) n5 C(O)NR A2 R B2 、-(CH2) n5 OC(O)NR A2 R B2 or -(CH2) n5 NR A2 C(O)OR B2 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl,
[0119] Preferred are hydrogen, -CH3, -CH2CH3,
[0120] More preferably, hydrogen, -CH3, -CH2CH3 or
[0121] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl,
[0122] Preferably deuterium, fluorine, chlorine, bromine or methyl;
[0123] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl,
[0124] Preferred are methyl, ethyl or cyclopropyl.
[0125] The present invention also provides a compound represented by general formula (VII), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
[0126]
[0127] L1 is selected from -(CR a R b ) n1 -、-(CR a R b ) n1 O-、-O(CR a R b ) n1 -、-(CR a R b ) n1 S-、-S(CR a R b ) n1 -、-(CH2) n1 C(O)NR a -、-(CH2) n1 NR a C(O)-、-(CH2) n1 S(O) m1 -、-(CH2) n1 S(O) m1 NR a -、-(CH2) n1 NR a S(O) m1 -or-(CH2) n1 NR a -,
[0128] Preferred-CR a R b -、-CR a R b O-、-OCR a R b -、-CR a R b S-or-SCR a R b -,
[0129] More preferably -CH2- or -CD2-;
[0130] R1 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl, 5-14 membered heteroaryl, -(CH2) n5 R A2 、-(CH2) n5 O(CH2) n6 R A2 、-(CH2) n5 C(O)R A2 、-(CH2) n5 NR A2 C(O)R B2 、 -(CH2) n5 C(O)NR A2 R B2 、-(CH2) n5 OC(O)NR A2 R B2 or -(CH2) n5 NR A2 C(O)OR B2 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, optionally further substituted with deuterium, halogen, amino, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-14 substituted by one or more substituents of aryl and 5-14 membered heteroaryl,
[0131] Preferred are hydrogen, -CH3, -CH2CH3,
[0132] More preferably, hydrogen, -CH3, -CH2CH3 or
[0133] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl,
[0134] Preferably deuterium, fluorine, chlorine, bromine or methyl;
[0135] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Halogenated alkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Halogenated alkoxy, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl,
[0136] Preferred are methyl, ethyl or cyclopropyl.
[0137] In certain embodiments of the present invention, the compound, its stereoisomer or pharmaceutically acceptable salt thereof, when R7 and R8 are both methyl, R1 is not When R1 is selected from
[0138]
[0139] When R7 and R8 are both methyl, R1 is When L1 contains deuterium or at least one of X1, X2 or X3 is N or R 3 Not hydrogen.
[0140] In a further preferred embodiment of the present invention, the compound, its stereoisomer or pharmaceutically acceptable salt thereof is selected from the following compounds:
[0141]
[0142]
[0143]
[0144]
[0145]
[0146] The present invention further provides compounds represented by general formula (M-1) or (M-2), stereoisomers thereof, or pharmaceutically acceptable salts thereof:
[0147]
[0148] L1, X1, X2, X3, R1, R7, and R8 are as described above;
[0149] R9 is selected from halogen or Preferably bromine, chlorine or
[0150] Pg is selected from amino protecting groups; preferably (trimethylsilyl)ethoxymethyl, methoxymethyl ether, allyloxycarbonyl, trifluoroacetyl, 2,4-dimethoxybenzyl, nitrobenzenesulfonyl, trityl, methoxycarbonyl, p-toluenesulfonyl, formate, acetyl, benzyloxycarbonyl, tert-butoxycarbonyl, benzyl or p-methoxyphenyl; more preferably (trimethylsilyl)ethoxymethyl or methoxymethyl ether.
[0151] In one embodiment of the present invention, L1 is selected from -CH2- or -CD2-; R1 is
[0152] R9 is
[0153] Pg is selected from (trimethylsilyl)ethoxymethyl or methoxymethyl ether groups.
[0154] The present invention further provides a method for preparing the compound of the aforementioned general formula (II) or its stereoisomers and pharmaceutically acceptable salts thereof, comprising the following steps:
[0155]
[0156] The general formula (M-1) reacts with the general formula (M-3) to obtain the general formula (M-2), and the general formula (M-2) is deprotected to obtain the general formula (II); L1, X1, X2, X3, R1, R7, and R8 are as described above;
[0157] R 2’ Selected from or halogen, preferably chlorine or bromine;
[0158] R9 is selected from or halogen, preferably chlorine or bromine;
[0159] Pg is selected from amino protecting groups; preferably (trimethylsilyl)ethoxymethyl, methoxymethyl ether, allyloxycarbonyl, trifluoroacetyl, 2,4-dimethoxybenzyl, nitrobenzenesulfonyl, trityl, methoxycarbonyl, p-toluenesulfonyl, formate, acetyl, benzyloxycarbonyl, tert-butoxycarbonyl, benzyl or p-methoxyphenyl; more preferably (trimethylsilyl)ethoxymethyl, methoxymethyl ether.
[0160] The present invention further provides a method for preparing the compound of the aforementioned general formula (II) or its stereoisomers and pharmaceutically acceptable salts thereof, comprising the following steps:
[0161]
[0162] The general formula (M-4) reacts with the general formula (M-5) to obtain the general formula (M-2), and the general formula (M-2) is deprotected to obtain the general formula (II);
[0163] L1, X1, X2, X3, R1, R7, and R8 are as described above;
[0164] R 1’ is selected from methanesulfonyloxy or halogen, preferably methanesulfonyloxy or bromine;
[0165] Pg is selected from amino protecting groups; preferably (trimethylsilyl)ethoxymethyl, methoxymethyl ether, allyloxycarbonyl, trifluoroacetyl, 2,4-dimethoxybenzyl, nitrobenzenesulfonyl, trityl, methoxycarbonyl, p-toluenesulfonyl, formate, acetyl, benzyloxycarbonyl, tert-butoxycarbonyl, benzyl or p-methoxyphenyl; more preferably (trimethylsilyl)ethoxymethyl, methoxymethyl ether.
[0166] The present invention further relates to a pharmaceutical composition comprising a therapeutically effective dose of a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.
[0167] On the other hand, the present invention also aims to provide a compound of formula (I), its stereoisomers or pharmaceutically acceptable salts, or pharmaceutical compositions thereof for use in the preparation of a method for treating and / or preventing angiotensin II (AT) dependence.
[0168] On the other hand, the present invention also aims to provide a use of a compound of general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in the preparation of a drug for treating and / or preventing endothelin (ET)-dependent diseases.
[0169] On the other hand, the present invention also aims to provide a use of a compound of general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in the preparation of a drug for treating and / or preventing dual-acting angiotensin-dependent and endothelin (DARA)-dependent diseases.
[0170] On the other hand, the present invention also aims to provide a compound of general formula (I), its stereoisomers or pharmaceutically acceptable salts, or its pharmaceutical composition for use in the preparation of a medicament for treating and / or preventing pain, sexual dysfunction, hypoxic and ischemic diseases, dementia, neurological diseases, liver diseases, cancer, hypertension, diabetes or kidney diseases and other related diseases.
[0171] The present invention also relates to a method for treating and / or preventing pain, sexual dysfunction, hypoxic and ischemic diseases, dementia, neurological diseases, liver diseases, cancer, hypertension, diabetes or kidney diseases and other related diseases.
[0172] On the other hand, the present invention also aims to provide a compound of general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for use in treating and / or preventing pain, sexual dysfunction, hypoxic and ischemic diseases, dementia, neurological diseases, liver diseases, cancer, hypertension, diabetes or kidney diseases and other related diseases.
[0173] In the above technical solution, the kidney-related disease is selected from diseases or disorders related to kidney, glomerulus or mesangial cell function, more preferably focal segmental glomerulosclerosis or IgA nephropathy.
[0174] Detailed Description of the Invention
[0175] Unless otherwise stated, the terms used in the specification and claims have the following meanings.
[0176] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, more preferably an alkyl group containing 1 to 8 carbon atoms, further preferably an alkyl group containing 1 to 6 carbon atoms, and most preferably an alkyl group containing 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 4-heptyl, 1-propylbutyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, pentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched-chain isomers thereof. More preferred are lower alkyl groups containing 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, n-heptyl, 4-heptyl, 1-propylbutyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like.The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. The substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate groups. Methyl, ethyl, isopropyl, tert-butyl, haloalkyl, deuterated alkyl, alkoxy-substituted alkyl and hydroxy-substituted alkyl are preferred.
[0177] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, and more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like; polycyclic cycloalkyls include spirocyclic, fused, and bridged cycloalkyls, preferably cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, and cycloheptyl.
[0178] The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring attached to the parent structure is a cycloalkyl, non-limiting examples of which include indanyl, tetrahydronaphthyl, benzocycloheptanyl, etc. The cycloalkyl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.
[0179] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen, C(O) or S(O). m (wherein m is an integer from 0 to 2) heteroatoms, excluding the ring portion of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, it contains 3 to 8 ring atoms; most preferably, it contains 3 to 8 ring atoms; further preferably, it is a 3-8 membered heterocyclic group containing 1-3 nitrogen atoms, optionally substituted with 1-2 oxygen atoms, sulfur atoms, or oxo groups, including nitrogen-containing monocyclic heterocyclic groups, nitrogen-containing spiro heterocyclic groups, or nitrogen-containing fused heterocyclic groups.
[0180] Non-limiting examples of monocyclic heterocyclic groups include oxetanyl, azetidinyl, thietanyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, azepanyl, 1,4-diazepanyl, pyranyl or tetrahydrothiopyran dioxide; preferably oxetanyl, azetidinyl, thietanyl, tetrahydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, azepanyl, 1,4-diazepanyl, pyranyl or tetrahydrothiopyran dioxide; Furanyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydrothiopyran dioxide, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, hexahydropyrazinyl, hexahydropyrimidinyl, azepanyl, 1,4-diazepanyl and piperazinyl; more preferably piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, azetidinyl, dihydrotetrazolyl, pyrimidin-4(3H)-one, 1,2,4-oxadiazol-5(2H)-one or 5,6-dihydro-4H-cyclopenta[d]isoxazole. Polycyclic heterocyclic groups include spiro, fused and bridged heterocyclic groups; wherein the spiro, fused and bridged heterocyclic groups are optionally connected to other groups by single bonds, or further connected to other cycloalkyl, heterocyclic, aryl and heteroaryl groups by any two or more atoms on the ring.
[0181] The heterocyclyl group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.
[0182] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (ie, rings sharing adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably 6- to 12-membered, such as phenyl and naphthyl. More preferably, phenyl.
[0183] The aryl group may be substituted or unsubstituted. When substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0184] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. The heteroaryl group is preferably 5 to 12-membered, more preferably 5-membered or 6-membered, such as imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazinyl and the like, preferably pyridyl, pyrazinyl, oxadiazolyl, triazolyl, tetrazolyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, pyrimidinyl or thiazolyl; more preferably pyridyl, oxadiazolyl, pyrazolyl, pyrazinyl, isoxazolyl, triazolyl, tetrazolyl, pyrrolyl, thiazolyl and oxazolyl.
[0185] The heteroaryl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0186] The term "alkoxy" refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl is as defined above. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, or cyclohexyloxy; alkoxy groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl, or carboxylate.
[0187] "Haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
[0188] "Haloalkoxy" refers to an alkoxy group substituted with one or more halogens, wherein alkoxy is as defined above.
[0189] "Hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above.
[0190] "Hydroxy" refers to an -OH group.
[0191] "Halogen" refers to fluorine, chlorine, bromine or iodine.
[0192] "Amino" refers to -NH2.
[0193] "Cyano" refers to -CN.
[0194] "Nitro" refers to -NO2.
[0195] "Carbonyl" refers to -C(O)-.
[0196] "Carboxyl" refers to -C(O)OH.
[0197] "THF" refers to tetrahydrofuran.
[0198] "Ethyl acetate" means ethyl acetate.
[0199] "MeOH" refers to methanol.
[0200] "DMF" refers to N,N-dimethylformamide.
[0201] "DIPEA" refers to diisopropylethylamine.
[0202] "TFA" refers to trifluoroacetic acid.
[0203] "TEA" refers to triethylamine.
[0204] "MeCN" refers to acetylene glycol.
[0205] "DMA" refers to N,N-dimethylacetamide.
[0206] "Et2O" refers to diethyl ether.
[0207] "DCM" refers to dichloromethane.
[0208] "DMAP" refers to 4-dimethylaminopyridine.
[0209] "DCC" refers to dicyclohexylcarbodiimide.
[0210] "DCE" refers to 1,2-dichloroethane.
[0211] "DIPEA" refers to N,N-diisopropylethylamine.
[0212] "NBS" refers to N-bromosuccinimide.
[0213] "NIS" refers to N-iodosuccinimide.
[0214] "Cbz-Cl" refers to benzyl chloroformate.
[0215] "Pd2(dba)3" refers to tris(dibenzylideneacetone)dipalladium.
[0216] "Dppf" refers to 1,1'-bis(diphenylphosphino)ferrocene.
[0217] "HATU" refers to 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethyluronium hexafluorophosphate.
[0218] "KHMDS" refers to potassium hexamethyldisilazide.
[0219] "LiHMDS" refers to lithium bis(trimethylsilylamide).
[0220] "MeLi" refers to methyllithium.
[0221] "n-BuLi" refers to n-butyllithium.
[0222] "NaBH(OAc)3" refers to sodium triacetoxyborohydride.
[0223] "SEM" refers to (trimethylsilyl)ethoxymethyl.
[0224] "MOM" refers to methoxymethyl ether.
[0225] "OMs" means methanesulfonyloxy.
[0226] Different expressions such as “X is selected from A, B, or C”, “X is selected from A, B and C”, “X is A, B or C”, and “X is A, B and C” all express the same meaning, that is, X can be any one or more of A, B, and C.
[0227] The hydrogen atoms described in the present invention can all be replaced by their isotope deuterium, and any hydrogen atom in the example compounds of the present invention can also be replaced by a deuterium atom.
[0228] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. For example, "a heterocyclic group optionally substituted with an alkyl group" means that the alkyl group may but need not be present, and that the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.
[0229] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms, in a group are replaced independently of one another by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and a person skilled in the art can determine (by experiment or theory) which substitutions are possible or impossible without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (e.g., olefinic) bond.
[0230] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.
[0231] "Pharmaceutically acceptable salts" refer to salts of the compounds of the present invention that are safe and effective when used in mammals and have the desired biological activity. DETAILED DESCRIPTION
[0232] The present invention is further described below with reference to the following examples, but these examples are not intended to limit the scope of the present invention.
[0233] Example
[0234] The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts (δ) are given in parts per million (ppm). NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer, using deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD), and deuterated chloroform (CDCl3) as the solvents, with tetramethylsilane (TMS) as the internal standard.
[0235] Liquid chromatography-mass spectrometry (LC-MS) was performed on an Agilent 1200 Infinity Series mass spectrometer. HPLC was performed on an Agilent 1200DAD high-pressure liquid chromatograph (Sunfire C18 150 × 4.6 mm column) and a Waters 2695-2996 high-pressure liquid chromatograph (Gimini C 18 150×4.6mm chromatographic column).
[0236] Thin layer chromatography silica gel plates use Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates. The specifications used for TLC are 0.15mm-0.20mm, and the specifications used for thin layer chromatography separation and purification products are 0.4mm-0.5mm. Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
[0237] The starting materials in the examples of the present invention are known and can be purchased commercially, or can be synthesized using or according to methods known in the art.
[0238] Unless otherwise specified, all reactions of the present invention are carried out under continuous magnetic stirring in a dry nitrogen or argon atmosphere, with dry solvents and reaction temperatures in degrees Celsius.
[0239] Intermediate 1
[0240] 2-Bromo-N-(4-chloro-5-methylisoxazol-3-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide
[0241]
[0242] first step
[0243] Preparation of 2-bromo-N-(4-chloro-5-methylisoxazol-3-yl)benzenesulfonamide
[0244] 4-Chloro-5-methylisoxazol-3-amine (5.0 g, 37.8 mmol) was dissolved in tetrahydrofuran (50 mL). The reaction mixture was cooled to -78°C and potassium tert-butoxide (8.43 g, 75.3 mmol) was added. The reaction mixture was stirred at -78°C for 0.5 h. Intermediate 1a (10.0 g, 39.4 mmol) was added to the reaction mixture, and the reaction mixture was stirred at room temperature for 1 h. Water and dichloromethane (3 x 20 mL) were then added for extraction. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to afford the desired product, Intermediate 1b (12.5 g, 88.5% yield).
[0245] MS m / z(ESI):351.2[M+1] + .
[0246] Step 2
[0247] Preparation of 2-bromo-N-(4-chloro-5-methylisoxazol-3-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide
[0248] Intermediate 1b (12.5 g, 35.7 mmol) and potassium carbonate (9.8 g, 71.4 mmol) were dissolved in N,N-dimethylformamide (20 mL). 2-(Trimethylsilyl)ethoxymethyl chloride (8.9 g, 53.6 mmol) was then added to the reaction mixture and stirred at room temperature for 16 hours. Water and dichloromethane (3 x 20 mL) were then added for extraction. The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford the desired product, Intermediate 1 (17.2 g, 98.5% yield).
[0249] Example 1
[0250] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl-d2)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0251]
[0252] first step
[0253] Preparation of N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-4'-((hydroxy-d)-methyl-d2)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0254] Example 1-1 (80 mg, 0.17 mmol) (prepared according to WO2010114801A1) and lithium aluminum tetrahydride deuterate (11 mg, 0.26 mmol) were dissolved in tetrahydrofuran (5 mL). The reaction solution was cooled to 0°C and stirred for 2 h. Saturated brine (10 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (2 x 10 mL). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (petroleum ether / ethyl acetate) to afford Example 1-2 (50 mg, 70%).
[0255] MS m / z(ESI):464.2[M+1] + .
[0256] Step 2
[0257] Preparation of (2'-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl-d2 methanesulfonic acid
[0258] To a solution of Example 1-2 (50 mg, 0.11 mmol) in dichloromethane (4 mL) was added methylsulfonyl chloride (14.8 mg, 0.13 mmol) and diisopropylethylamine (41.8 mg, 0.32 mmol) under ice-cooling conditions. The reaction mixture was warmed to room temperature and stirred for 1 h. The reaction mixture was concentrated to afford crude Example 1-3 (60 mg, 98%), which was used directly in the next step.
[0259] MS m / z(ESI):541.2[M+1] + .
[0260] Step 3
[0261] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl-d2)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0262] Example 1-3 (60 mg, 0.11 mmol) was dissolved in DMF (4 mL). Potassium carbonate (30.7 mg, 0.24 mmol) and 2-butyl-1,3-diazaspiro[4,4]non-1-en-4-one (25.8 mg, 0.13 mmol) were added under ice-cooling conditions. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated, and the crude product was purified by HPLC to afford Example 1-4 (42 mg, 72%).
[0263] MS m / z(ESI):639.3[M+1]+ .
[0264] Step 4
[0265] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl-d2)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0266] Example 1-4 (42 mg, 0.07 mmol) was dissolved in ethanol (2 mL), and 6N hydrochloric acid was added. The mixture was heated at reflux for 1 h, adjusted to pH 8 with sodium carbonate, and then to pH 5. The mixture was extracted with ethyl acetate (2 x 10 mL). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and purified by reverse-phase HPLC to afford Example 1 (10 mg, 26%).
[0267] MS m / z(ESI):595.3[M+1] + .
[0268] Example 2
[0269] 4'-((((2-Butyl-1,3-diazaspiro[4.4]nona-1,3-dien-4-yl)oxy]methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0270]
[0271] first step
[0272] Preparation of 4'-((((2-butyl-1,3-diazaspiro[4.4]nona-1,3-dien-4-yl]oxy)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0273] Example 2-1 (100 mg, 0.19 mmol) (prepared according to WO2010114801A1) was dissolved in chloroform (4 mL). Silver oxide (47.3 mg, 0.38 mmol) and 2-butyl-1,3-diazaspiro[4,4]non-1-en-4-one (44.5 mg, 0.23 mmol) were added, and the mixture was heated under reflux for 12 h. The reaction mixture was concentrated, and the crude product was purified by reverse-phase HPLC to yield Example 2-2 (56 mg, 46%).
[0274] MS m / z(ESI):637.3[M+1] + .
[0275] Step 2
[0276] Preparation of 4'-((((2-butyl-1,3-diazaspiro[4.4]nona-1,3-dien-4-yl]oxy)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0277] The synthesis method of Example 2 was referred to the synthesis method of Example 1, and Example 2 (30 mg, 57%) was obtained using Example 2-1 as a raw material.
[0278] MS m / z(ESI):593.3[M+1] + .
[0279] Example 4
[0280] 1-((2'-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid
[0281]
[0282] first step
[0283] Preparation of methyl 1-((2'-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate
[0284] Example 2-1 (100 mg, 0.19 mmol) (prepared according to WO2010114801A1) was dissolved in acetonitrile (4 mL). Methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate (51.9 mg, 0.23 mmol) and potassium carbonate (52.8 mg, 0.38 mmol) were added. The reaction mixture was heated under reflux for 6 h. The reaction mixture was concentrated, and the crude product was purified by reverse-phase HPLC to afford Example 4-1 (86 mg, 67%).
[0285] MS m / z(ESI):655.3[M+1] + .
[0286] Step 2
[0287] Preparation of 1-((2'-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid
[0288] The synthesis method of Example 4 was referred to the synthesis method of Example 1, and Example 4 (31 mg, 40%) was obtained using Example 4-1 as a raw material.
[0289] MS m / z(ESI):611.2[M+1] + .
[0290] Example 5
[0291] 2-(2-butyl-1-((2'-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethylthioamide
[0292]
[0293] The synthesis method of Example 5 was similar to that of Example 4. 2-(2-butyl-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethylthioamide was used instead of 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid methyl ester to obtain Example 5 (21 mg, 56%).
[0294] MS m / z(ESI):666.3[M+1] + .
[0295] Example 6
[0296] 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)phenyl)-N-(4,5-dimethylisoxazol-3-yl)pyridine-3-sulfonamide
[0297]
[0298] first step
[0299] 3-(4-Borate-3-(ethoxymethyl)benzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-ene-4-
[0300] Preparation of ketones
[0301] To a solution of Example 6-1 (4.8 g, 11.6 mmol) (synthesis method reference WO2010135350A2) and bis(pinacolato)diboron (4.4 g, 17.5 mmol) in dioxane (100 mL) were added potassium acetate (3.4 g, 35 mmol) and Pd(dppf)2Cl2 (0.95 g, 1.1 mmol). The mixture was replaced with nitrogen and heated at 85 ° C overnight. The reaction mixture was concentrated under reduced pressure to obtain a crude product, which was purified by column chromatography (petroleum ether / ethyl acetate, 15% v / v) to give Example 6-2 (4.3 g, 80%).
[0302] MS m / z(ESI):469.3[M+1] + .
[0303] Step 2
[0304] Preparation of 2-bromo-N-(4,5-dimethylisoxazol-3-yl)pyridine-3-sulfonamide
[0305] 3-Amino-4,5-dimethylisoxazole (264 mg, 2.35 mmol) was dissolved in 10 mL of dichloromethane, and triethylamine (594 mg, 5.88 mmol) and 2-bromopyridine-3-sulfonyl chloride (500 mg, 1.96 mmol) were added. The mixture was allowed to react at room temperature for 2 hours. 50 mL of water was added, and the mixture was extracted with dichloromethane (40 mL x 2). The organic phases were combined, washed sequentially with water (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate system) to obtain Example 6-3 (350 mg, 53.8%).
[0306] MS m / z(ESI):332.0[M+1] + .
[0307] Step 3
[0308] Preparation of 2-bromo-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)pyridine-3-sulfonamide
[0309] Example 6-3 (350 mg, 1.05 mmol) was dissolved in dichloromethane (10 mL), and triethylamine (319 mg, 3.16 mmol), 4-dimethylaminopyridine (129 mg, 1.05 mmol), and bromomethyl methyl ether (158 mg, 1.26 mmol) were added sequentially. The mixture was stirred at room temperature for 2 h. 50 mL of water was added, and the mixture was extracted with dichloromethane (40 mL x 2). The organic phases were combined, washed sequentially with water (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain Example 6-4 (280 mg, 71.1%).
[0310] MS m / z(ESI):376.0[M+1] + .
[0311] Step 4
[0312] Preparation of 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)phenyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)pyridine-3-sulfonamide
[0313] Example 6-4 (50 mg, 0.133 mmol) was dissolved in 1,4-dioxane (2 mL) and water (0.5 mL). Example 6-2 (63 mg, 0.133 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (10 mg, 0.0133 mmol), and cesium carbonate (65 mg, 0.200 mmol) were added. The atmosphere was purged with nitrogen three times and microwaved at 100°C for 1 hour. The reaction mixture was cooled to room temperature, 30 mL of water was added, and extraction was performed with ethyl acetate (30 mL x 2). The organic phases were combined, washed sequentially with water (30 mL) and saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title product, Example 6-5 (75 mg), which was used directly in the next step.
[0314] MS m / z(ESI):638.3[M+1] + .
[0315] Step 5
[0316] Preparation of 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)phenyl)-N-(4,5-dimethylisoxazol-3-yl)pyridine-3-sulfonamide
[0317] Example 6-5 (75 mg, 0.118 mmol) was dissolved in ethanol (3 mL), and hydrochloric acid (6 M, 1 mL) was added, followed by reaction at 80°C for 3 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The residue was purified by reverse-phase HPLC to obtain the title product, 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)phenyl)-N-(4,5-dimethylisoxazol-3-yl)pyridine-3-sulfonamide 6 (30 mg, 42.8%).
[0318] MS m / z(ESI):594.3[M+1] + .
[0319] Example 7
[0320] 2-(6-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)pyridin-3-yl)-N-(4,5-dimethylisoxazol-3-yl)benzenesulfonamide
[0321]
[0322] first step
[0323] Preparation of methyl 5-bromo-6-(bromomethyl)picolinate
[0324] Methyl 5-bromo-6-methylpicolinate (1.0 g, 4.35 mmol) was dissolved in carbon tetrachloride (30 mL), and N-bromosuccinimide (851 mg, 4.78 mmol) and azobisisobutyronitrile (71 mg, 0.435 mmol) were added. The atmosphere was replaced with nitrogen three times and the mixture was refluxed for 5 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and then 50 mL of water was added. Extraction was performed with ethyl acetate (50 mL x 2). The organic phases were combined, washed sequentially with water (50 mL) and saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield Example 7-1 (600 mg, 44.9%).
[0325] MS m / z(ESI):308.9[M+1] + .
[0326] Step 2
[0327] Preparation of ethyl 5-bromo-6-(ethoxymethyl)picolinate
[0328] Example 7-1 (600 mg, 1.95 mmol) was dissolved in ethanol (20 mL), and sodium ethoxide (399 mg, 5.86 mmol) was added. The mixture was heated under reflux for 2 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and 50 mL of water was added. The mixture was extracted with ethyl acetate (50 mL x 2). The organic phases were combined, washed sequentially with water (50 mL) and saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford Example 7-2 (520 mg, 92.7%).
[0329] MS m / z(ESI):288.0[M+1] + .
[0330] Step 3
[0331] Preparation of (5-bromo-6-(ethoxymethyl)pyridin-2-yl)methanol
[0332] Example 7-2 (520 mg, 1.80 mmol) was dissolved in tetrahydrofuran (15 mL), replaced with nitrogen three times, and cooled to -78°C. A toluene solution of diisobutylaluminum hydride (1.5 M, 3.6 mL, 5.42 mmol) was added dropwise, and then the mixture was allowed to warm to room temperature for 5 hours. The reaction solution was poured into 100 mL of ice water and extracted with ethyl acetate (80 mL x 2). The organic phases were combined, washed sequentially with water (80 mL) and saturated sodium chloride solution (80 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain Example 7-3 (260 mg, 58.7%).
[0333] MS m / z(ESI):246.0[M+1] + .
[0334] Step 4
[0335] Preparation of methyl (5-bromo-6-(ethoxymethyl)pyridin-2-yl)methanesulfonate
[0336] Example 7-3 (260 mg, 1.06 mmol) was dissolved in dichloromethane (10 mL), and triethylamine (320 mg, 3.17 mmol) and methanesulfonyl chloride (242 mg, 2.11 mmol) were added. The mixture was allowed to react at room temperature for 2 hours. The reaction solution was poured into 50 mL of ice water and extracted with ethyl acetate (50 mL x 2). The organic phases were combined, washed sequentially with water (50 mL) and saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title product, Example 7-4 (330 mg), which was used directly in the next step.
[0337] MS m / z(ESI):324.0[M+1]+ .
[0338] Step 5
[0339] Preparation of 3-((5-bromo-6-(ethoxymethyl)pyridin-2-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[0340] Example 7-4 (330 mg, 1.02 mmol) was dissolved in N,N-dimethylformamide (10 mL), and 2-butyl-1,3-diazaspiro[4,4]non-1-en-4-one (237 mg, 1.22 mmol) and potassium carbonate (422 mg, 3.05 mmol) were added. The mixture was heated to 80°C and reacted for 5 hours. The reaction solution was cooled to room temperature, 50 mL of water was added, and extraction was performed with ethyl acetate (50 mL x 2). The organic phases were combined, washed sequentially with water (50 mL) and saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain Example 7-5 (180 mg, 41.9%).
[0341] MS m / z(ESI):422.1[M+1] + .
[0342] Step 6
[0343] Preparation of 2-(6-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)pyridin-3-yl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)benzenesulfonamide
[0344] Example 7-5 (50 mg, 0.118 mmol) was dissolved in 1,4-dioxane (2 mL) and 0.5 mL of water, and (2-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)phenyl)boronic acid (48 mg, 0.142 mmol) (preparation method, see WO2010135350A2), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (8.6 mg, 0.0118 mmol), and cesium carbonate (58 mg, 0.177 mmol) were added. The atmosphere was purged with nitrogen three times and microwaved at 100°C for 1 hour. The reaction solution was cooled to room temperature, 30 mL of water was added, and extraction was performed with ethyl acetate (30 mL x 2). The organic phases were combined, washed sequentially with water (30 mL) and saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give Example 7-6 (35 mg), which was used directly in the next step.
[0345] MS m / z(ESI):638.3[M+1] + .
[0346] Step 7
[0347] Preparation of 2-(6-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)pyridin-3-yl)-N-(4,5-dimethylisoxazol-3-yl)benzenesulfonamide
[0348] The protecting group of Example 7-6 was removed by referring to the synthetic method of Example 6 to obtain Example 7 (19 mg, 58.3%).
[0349] MS m / z(ESI):594.3[M+1] + .
[0350] Example 8
[0351] 2-(6-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-4-(ethoxymethyl)pyridin-3-yl)-N-(4,5-dimethylisoxazol-3-yl)benzenesulfonamide
[0352]
[0353] With reference to the route and method of Example 7, 5-bromo-4-methylpicolinic acid ethyl ester was used instead of 5-bromo-6-methylpicolinic acid methyl ester as the starting material to obtain Example 8 (11 mg, 39.4%).
[0354] MS m / z(ESI):594.3[M+1] + .
[0355] Example 9
[0356] 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)phenyl)-N-(3-methoxy-5-methylpyrazin-2-yl)pyridine-3-sulfonamide
[0357]
[0358] first step
[0359] Preparation of 2-bromo-N-(3-methoxy-5-methylpyrazin-2-yl)pyridine-3-sulfonamide
[0360] 3-Methoxy-5-methylpyrazin-2-amine (130 mg, 0.938 mmol) was dissolved in dichloromethane (5 mL), and triethylamine (237 mg, 2.34 mmol) and 2-bromopyridine-3-sulfonyl chloride (200 mg, 0.781 mmol) were added. The mixture was reacted at room temperature for 2 hours. 50 mL of water was added, and the mixture was extracted with dichloromethane (40 mL x 2). The organic phases were combined, washed sequentially with water (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford Example 9-1 (110 mg, 32.7%).
[0361] MS m / z(ESI):359.0[M+1] + .
[0362] Step 2
[0363] Preparation of 2-bromo-N-(3-methoxy-5-methylpyrazin-2-yl)-N-(methoxymethyl)pyridine-3-sulfonamide
[0364] Example 9-1 (110 mg, 0.306 mmol) was dissolved in dichloromethane (5 mL), and triethylamine (93 mg, 0.919 mmol), 4-dimethylaminopyridine (37 mg, 0.306 mmol), and bromomethyl methyl ether (46 mg, 0.368 mmol) were added sequentially. The mixture was allowed to react at room temperature for 2 hours. 50 mL of water was added, and the mixture was extracted with dichloromethane (40 mL x 2). The organic phases were combined, washed sequentially with water (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford Example 9-2 (80 mg, 64.9%).
[0365] MS m / z(ESI):403.0[M+1] + .
[0366] Step 3
[0367] Preparation of 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)phenyl)-N-(3-methoxy-5-methylpyrazin-2-yl-N-(methoxymethyl)pyridine-3-sulfonamide
[0368] Using Example 9-2 as the raw material and referring to the route and method of Example 6-3, Example 9-3 (81 mg, 61%) was obtained.
[0369] MS m / z(ESI):665.3[M+1] + .
[0370] Step 4
[0371] Preparation of 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)phenyl)-N-(3-methoxy-5-methylpyrazin-2-yl)pyridine-3-sulfonamide
[0372] Using Example 9-3 as the raw material and referring to the route and method of Example 6, Example 9 (30 mg, 40%) was obtained.
[0373] MS m / z(ESI):620.3[M+1] + .
[0374] Example 10
[0375] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-6-fluoro-[1,1'-biphenyl]-2-sulfonamide
[0376]
[0377] first step
[0378] Preparation of 2-bromo-N-(4,5-dimethylisoxazol-3-yl)-3-fluorobenzenesulfonamide
[0379] 3-Amino-4,5-dimethylisoxazole (123 mg, 1.10 mmol) was dissolved in dichloromethane (10 mL), and triethylamine (222 mg, 2.19 mmol) and 2-bromo-3-fluorobenzenesulfonyl chloride (200 mg, 0.731 mmol) were added. The mixture was reacted at room temperature for 2 hours. 50 mL of water was added, and the mixture was extracted with dichloromethane (40 mL x 2). The organic phases were combined, washed sequentially with water (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford Example 10-1 (120 mg, 31.3%).
[0380] MS m / z(ESI):349.0[M+1] + .
[0381] Step 2
[0382] Preparation of 2-bromo-N-(4,5-dimethylisoxazol-3-yl)-3-fluoro-N-(methoxymethyl)benzenesulfonamide
[0383] Example 10-1 (120 mg, 0.344 mmol) was dissolved in dichloromethane (10 mL), and triethylamine (104 mg, 1.03 mmol), 4-dimethylaminopyridine (42 mg, 0.344 mmol), and bromomethyl methyl ether (86 mg, 0.688 mmol) were added sequentially. The mixture was allowed to react at room temperature for 2 hours. 50 mL of water was added, and the mixture was extracted with dichloromethane (40 mL x 2). The organic phases were combined, washed sequentially with water (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford Example 10-2 (90 mg, 66.6%).
[0384] MS m / z(ESI):393.0[M+1] + .
[0385] Step 3
[0386] Preparation of 4'-(((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-6-fluoro-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0387] Using Example 10-2 as the raw material and referring to the route and method of Example 6-3, Example 10-3 (51 mg, 56%) was obtained.
[0388] MS m / z(ESI):655.3[M+1] + .
[0389] Step 4
[0390] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-6-fluoro-[1,1'-biphenyl]-2-sulfonamide
[0391] Using Example 10-3 as the raw material, refer to the route and method of the third and fourth steps of Example 6 to obtain Example 10 (18 mg, 55.2%).
[0392] MS m / z(ESI):611.3[M+1] + .
[0393] Example 11
[0394] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-6-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0395]
[0396]
[0397] first step
[0398] Preparation of 2-bromo-1-(bromomethyl)-3-nitrobenzene
[0399] 2-Bromo-3-nitrotoluene (1.0 g, 4.63 mmol) was dissolved in carbon tetrachloride (30 mL), and N-bromosuccinimide (988 mg, 5.56 mmol) and azobisisobutyronitrile (76 mg, 0.463 mmol) were added. The atmosphere was replaced with nitrogen three times and the mixture was refluxed for 5 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and then 50 mL of water was added. Extraction was performed with ethyl acetate (50 mL x 2). The organic phases were combined, washed sequentially with water (50 mL) and saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain Example 11-1 (630 mg, 46.4%).
[0400] MS m / z(ESI):293.9[M+1] + .
[0401] Step 2
[0402] Preparation of 2-bromo-1-(ethoxymethyl)-3-nitrobenzene
[0403] Example 11-1 (630 mg, 2.15 mmol) was dissolved in ethanol (20 mL), and sodium ethoxide (419 mg, 6.45 mmol) was added. The mixture was reacted at 40°C for 2 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and 50 mL of water was added. Extraction was performed with ethyl acetate (50 mL x 2). The organic phases were combined, washed sequentially with water (50 mL) and saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product Example 11-2 (410 mg), which was used directly in the next step.
[0404] MS m / z(ESI):260.0[M+1] + .
[0405] Step 3
[0406] Preparation of 2-bromo-3-(ethoxymethyl)aniline
[0407] Heat 20 mL of acetic acid to 80°C, add iron powder (880 mg, 15.8 mmol), and slowly add Example 11-2 (410 mg, 1.58 mmol) in batches. Continue reacting at 80°C for 30 minutes. The reaction solution is cooled to room temperature, filtered, and the filtrate is concentrated under reduced pressure. 50 mL of water is added, and extraction is performed with ethyl acetate (50 mL x 2). The organic phases are combined, washed sequentially with saturated sodium carbonate solution (50 mL) and saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain Example 11-3 (300 mg), which is used directly in the next step.
[0408] MS m / z(ESI):230.0[M+1] + .
[0409] Step 4
[0410] Preparation of 2-bromo-3-(ethoxymethyl)benzenesulfonyl chloride
[0411] Example 11-3 (300 mg, 1.30 mmol) was dissolved in a 6 M hydrochloric acid solution (5 mL), cooled to 0°C, and 1 mL of sodium nitrite (108 mg, 1.57 mmol) was slowly added dropwise. The reaction was continued at 0°C for 1 hour. 3 mL of acetic acid, cuprous chloride (6.4 mg, 0.0650 mmol), and cupric chloride dihydrate (22 mg, 0.130 mmol) were added in sequence, followed by the slow dropwise addition of thionyl chloride (774 mg, 6.50 mmol). The mixed solution was allowed to react at 0°C for 1 hour. 50 mL of water was added, and the mixture was extracted with ethyl acetate (40 mL x 2). The organic phases were combined, washed with saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product Example 11-4 (330 mg), which was used directly in the next step.
[0412] MS m / z(ESI):312.9[M+1] + .
[0413] Step 5
[0414] Preparation of 2-bromo-N-(4,5-dimethylisoxazol-3-yl)-3-(ethoxymethyl)benzenesulfonamide
[0415] 3-Amino-4,5-dimethylisoxazole (177 mg, 1.58 mmol) was dissolved in 5 mL of dichloromethane, and triethylamine (319 mg, 3.16 mmol) and Example 11-4 (330 mg, 1.05 mmol) were added. The mixture was then reacted at room temperature for 2 hours. 40 mL of water was added, and the mixture was extracted with dichloromethane (40 mL x 2). The organic phases were combined, washed sequentially with water (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford Example 11-5 (350 mg).
[0416] MS m / z(ESI):389.0[M+1] + .
[0417] Step 6
[0418] Preparation of 2-bromo-N-(4,5-dimethylisoxazol-3-yl)-3-(ethoxymethyl)benzenesulfonamide
[0419] Example 11-5 (350 mg, 0.900 mmol) was dissolved in dichloromethane (10 mL), and triethylamine (273 mg, 2.70 mmol), 4-dimethylaminopyridine (110 mg, 0.900 mmol), and bromomethyl methyl ether (169 mg, 1.35 mmol) were added sequentially. The mixture was reacted at room temperature for 2 hours. 50 mL of water was added, and the mixture was extracted with dichloromethane (40 mL x 2). The organic phases were combined, washed sequentially with water (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford Example 11-6 (130 mg, 33.4%).
[0420] MS m / z(ESI):433.0[M+1] + .
[0421] Step 7
[0422] Preparation of 3-(4-bromobenzoyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[0423] Dissolve p-Bromobenzyl bromide (200 mg, 0.800 mmol) in N,N-dimethylformamide (5 mL), add potassium carbonate (221 mg, 1.60 mmol) and 2-butyl-1,3-diazaspiro[4,4]non-1-en-4-one (155 mg, 0.800 mmol), and heat to 80°C for 4 hours. The reaction mixture was cooled to room temperature, 50 mL of water was added, and extraction was performed with ethyl acetate (40 mL x 2). The organic phases were combined, washed sequentially with water (40 mL x 2) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Purification by silica gel column chromatography afforded Example 11-7 (130 mg, 44.8%).
[0424] MS m / z(ESI):363.1[M+1] + .
[0425] Step 8
[0426] Preparation of 2-butyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaphthalen-2-yl)benzyl)-1,3-diazaspiro[4.4]non-1-en-4-one
[0427] Example 11-7 (130 mg, 0.358 mmol) was dissolved in 1,4-dioxane (5 mL), and boronic acid naphthalene (182 mg, 0.716 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (26 mg, 0.0358 mmol), and potassium acetate (70 mg, 0.358 mmol) were added. The atmosphere was purged with nitrogen three times and heated to 100°C for 4 hours. The reaction solution was cooled to room temperature, 40 mL of water was added, and extraction was performed with ethyl acetate (40 mL x 2). The organic phases were combined, washed sequentially with water (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain Example 11-8 (90 mg, 61.1%).
[0428] MS m / z(ESI):411.3[M+1] + .
[0429] Step 9
[0430] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-6-(ethoxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0431] Example 11-7 (50 mg, 0.122 mmol) was dissolved in 1,4-dioxane (2 mL) and 0.5 mL of water. Example 11-8 (53 mg, 0.122 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (8.9 mg, 0.0122 mmol), and cesium carbonate (79 mg, 0.243 mmol) were added. The atmosphere was purged with nitrogen three times and the mixture was microwaved at 100°C for 1 hour. The reaction mixture was cooled to room temperature, 30 mL of water was added, and the mixture was extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed sequentially with water (30 mL) and saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford Example 11-9 (40 mg, 51.5%).
[0432] MS m / z(ESI):637.3[M+1] + .
[0433] Step 10
[0434] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-6-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0435] Example 11-9 (40 mg, 0.0628 mmol) was dissolved in 3 mL of ethanol, and hydrochloric acid (6 M, 1 mL) was added. The mixture was heated to 80°C for 3 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The residue was purified by reverse-phase HPLC to afford Example 11 (25 mg, 67.1%).
[0436] MS m / z(ESI):593.3[M+1] + .
[0437] Intermediate 2
[0438] 3-(3-(Bromomethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[0439]
[0440] first step
[0441] Preparation of 4-bromo-3-methylbenzyl methanesulfonate
[0442] Intermediate 2a (2.0 g, 10.0 mmol) and triethylamine (1.4 g, 11.0 mmol) were dissolved in dichloromethane (5 mL). Methanesulfonyl chloride (1.24 g, 11.0 mmol) was added to the reaction mixture under ice-cooling, and the mixture was stirred at room temperature for 1 hour. Water and dichloromethane (20 mL x 3) were then added for extraction. The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford the desired product, 4-bromo-3-methylbenzyl methanesulfonate (2.6 g, 93.8% yield).
[0443] MS m / z(ESI):278.9[M+1] + .
[0444] Step 2
[0445] Preparation of 3-(4-bromo-3-methylbenzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[0446] Intermediate 2b (2.0 g, 7.2 mmol) was dissolved in N,N-dimethylformamide (5 mL). Sodium hydride (0.34 g, 8.6 mmol) was added to the reaction mixture under ice-cooling, and the reaction was stirred for 1 hour. 2-Butyl-1,3-diazaspiro[4.4]non-1-en-4-one (1.63 g, 8.6 mmol) was added to the reaction mixture, and the reaction was stirred at room temperature for 1 hour. Water and dichloromethane (20 mL x 3) were added for extraction. The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford the desired product, 4-bromo-3-methylbenzyl methanesulfonate (2.3 g, 87.8% yield).
[0447] MS m / z(ESI):377.1[M+1] + .
[0448] Step 3
[0449] Preparation of 2-butyl-3-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,3-diazaspiro[4.4]non-1-en-4-one
[0450] Intermediate 2c (2.0 g, 5.3 mmol), pinacol diboronate (1.6 g, 6.4 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (42 mg, 0.05 mmol), and potassium acetate (1.1 g, 10.6 mmol) were dissolved in dioxane (5 mL). The reaction mixture was stirred at 80°C under nitrogen for 16 hours. Water and dichloromethane (20 mL x 3) were then added for extraction. The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford the desired product, 2-butyl-3-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,3-diazaspiro[4.4]non-1-en-4-one (1.8 g, 52.4% yield).
[0451] MS m / z(ESI):425.3[M+1] + .
[0452] Step 4
[0453] Preparation of 3-(3-(bromomethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[0454] Intermediate 2d (1.5 g, 3.5 mmol) was dissolved in acetonitrile (5 mL). N-bromosuccinimide (0.75 g, 4.2 mmol) was added to the reaction mixture under ice-cooling, and the reaction was stirred at room temperature for 1 hour. Water and dichloromethane (3 x 20 mL) were then added for extraction. The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford the desired product, 3-(3-(bromomethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one (1.62 g, 91.8% yield).
[0455] MS m / z(ESI):503.2[M+1] + .
[0456] Example 12
[0457] 4'-(((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-((trifluoromethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[0458]
[0459] first step
[0460] Preparation of 2'-(bromomethyl)-4'-(((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0461] Intermediate 2 (100 mg, 0.2 mmol), (2-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)phenyl)boronic acid (75 mg, 0.2 mmol) (prepared by reference to WO2010135350A2), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (16 mg, 0.02 mmol), and cesium carbonate (291 mg, 0.9 mmol) were stirred in dioxane (4 mL) and water (1 mL) at 100°C under microwave stirring for 1 hour. The mixture was then extracted with water and dichloromethane (20 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford Example 12-1 (110 mg, 82.5% yield).
[0462] MS m / z(ESI):671.2[M+1] + .
[0463] Step 2
[0464] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-2'-((trifluoromethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[0465] Trifluoromethyl trifluoromethanesulfonate (72 mg, 0.33 mmol) and silver fluoride (48 mg, 0.33 mmol) were dissolved in acetonitrile (5 mL). The reaction mixture was cooled to -30°C and stirred for 2 h. Example 12-1 (110 mg, 0.16 mmol) dissolved in 5 mL of acetonitrile was then added to the reaction mixture, which was stirred at room temperature for 24 h. Saturated brine (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford Example 12-2 (85 mg, 77.6%).
[0466] MS m / z(ESI):676.3[M+1] + .
[0467] Step 3
[0468] Preparation of 4'-(((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-((trifluoromethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[0469] Example 12-2 (85 mg, 0.13 mmol) was dissolved in dioxane (2 mL). 6 mol / L hydrochloric acid in dioxane (2 mL) was added to the reaction mixture under ice-cooling conditions. The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated to obtain Example 12 (32 mg, 40.4%).
[0470] MS m / z(ESI):633.2[M+1] + .
[0471] Example 13
[0472] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(cyclopropyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[0473]
[0474] first step
[0475] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(cyclopropyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0476] Example 12-1 (100 mg, 0.15 mmol) and potassium carbonate (42 mg, 0.3 mmol) were dissolved in dichloromethane (5 mL). Cyclopropanol (18 mg, 0.3 mmol) was then added to the reaction mixture, which was stirred at room temperature for 2 h. Saturated brine (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford Example 13-1 (62 mg, 78.6%).
[0477] MS m / z(ESI):649.3[M+1] + .
[0478] Step 2
[0479] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(cyclopropyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[0480] The synthesis method of Example 13 was based on the synthesis method of Example 12. Example 13-1 was used as the starting material to obtain the title compound Example 13 (22 mg, 52.7%).
[0481] MS m / z(ESI):605.3[M+1] + .
[0482] Example 14
[0483] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-((cyclopropylmethoxy)methyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[0484]
[0485] first step
[0486] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-((cyclopropylmethoxy)methyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0487] Example 12-1 (100 mg, 0.15 mmol) and potassium carbonate (42 mg, 0.3 mmol) were dissolved in dichloromethane (5 mL). Cyclopropylmethanol (22 mg, 0.3 mmol) was then added to the reaction mixture, which was stirred at room temperature for 2 h. Saturated brine (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford Example 14-1 (66 mg, 77.5%).
[0488] MS m / z(ESI):663.3[M+1] + .
[0489] Step 2
[0490] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-((cyclopropylmethoxy)methyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[0491] The synthesis method of Example 14 was based on the synthesis method of Example 12. Example 14-1 was used as the starting material to obtain the title compound Example 14 (28 mg, 48.8%).
[0492] MS m / z(ESI):619.3[M+1] + .
[0493] Example 15
[0494] 4'-(((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(((3,3-difluoroazetidin-1-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[0495]
[0496] first step
[0497] Preparation of 4'-(((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(((3,3-difluoroazetidin-1-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0498] Example 12-1 (100 mg, 0.15 mmol) and potassium carbonate (63 mg, 0.45 mmol) were dissolved in dichloromethane (5 mL). 3,3-Difluorotrimethyleneimine hydrochloride (39 mg, 0.3 mmol) was then added to the reaction mixture, which was stirred at room temperature for 2 h. Saturated brine (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford Example 15-1 (66 mg, 77.5%).
[0499] MS m / z(ESI):684.3[M+1] + .
[0500] Step 2
[0501] Preparation of 4'-(((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(((3,3-difluoroazetidin-1-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[0502] The synthesis method of Example 15 was based on the synthesis method of Example 12, and Example 15-1 was used as the raw material to obtain the title compound Example 15 (33 mg, 62.8%).
[0503] MS m / z(ESI):640.3[M+1] + .
[0504] Example 16
[0505] Methyl ((4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)-[1,1'-biphenyl]-2-yl)methyl)carbamate
[0506]
[0507] first step
[0508] Preparation of methyl ((4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-[1,1'-biphenyl]-2-yl)methyl)carbamate
[0509] Example 12-1 (100 mg, 0.15 mmol) and potassium carbonate (63 mg, 0.45 mmol) were dissolved in dichloromethane (5 mL). Methyl carbamate (22 mg, 0.3 mmol) was then added to the reaction mixture, which was stirred at room temperature for 2 h. Saturated brine (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford Example 16-1 (58 mg, 56.5%).
[0510] MS m / z(ESI):666.3[M+1] + .
[0511] Step 2
[0512] Preparation of methyl ((4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)-[1,1'-biphenyl]-2-yl)methyl)carbamate
[0513] The synthesis method of Example 16 was similar to that of Example 12. Example 16-1 was used as the starting material to obtain the title compound Example 16 (26 mg, 55.8%).
[0514] MS m / z(ESI):622.3[M+1] + .
[0515] Example 17
[0516] (4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)-[1,1'-biphenyl]-2-yl)methylcarbamate
[0517]
[0518] first step
[0519] Preparation of 4'-(((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(hydroxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0520] Example 12-1 (100 mg, 0.15 mmol) was dissolved in a mixture of 5 mL of ethanol and 5 mL of water, followed by the addition of sodium hydroxide (18 mg, 0.45 mmol). The reaction mixture was stirred overnight at room temperature. Saturated brine (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford Example 17-1 (70 mg, 78.4%).
[0521] MS m / z(ESI):609.3[M+1] + .
[0522] Step 2
[0523] Preparation of (4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-[1,1'-biphenyl]-2-yl)methylcarbamate
[0524] Example 17-1 (100 mg, 0.16 mmol) was dissolved in 5 mL of dimethyl disulfide, followed by the addition of methyl isocyanate (28 mg, 0.48 mmol). The reaction mixture was stirred at 55°C for 2 h. Saturated brine (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL). The organic phases were combined, dried, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford Example 17-2 (110 mg, 62.8%).
[0525] MS m / z(ESI):666.3[M+1] + .
[0526] Step 3
[0527] Preparation of (4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)-[1,1'-biphenyl]-2-yl)methylcarbamate
[0528] The synthesis method of Example 17 was based on the synthesis method of Example 12, and Example 17-2 was used as the raw material to obtain the title compound Example 17 (42 mg, 68.9%).
[0529] MS m / z(ESI):622.3[M+1] + .
[0530] Example 18
[0531] 2'-(azetidine-1-carbonyl)-4'-(((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[0532]
[0533] first step
[0534] Preparation of 2'-(azetidine-1-carbonyl)-4'-(((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0535] Example 12-1 (100 mg, 0.15 mmol) and potassium carbonate (63 mg, 0.45 mmol) were dissolved in dichloromethane (5 mL). Cyclobutylamine (15 mg, 0.2 mmol) was then added to the reaction mixture, which was stirred at room temperature for 2 h. Saturated brine (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford Example 18-1 (65 mg, 72.6%).
[0536] MS m / z(ESI):648.3[M+1] + .
[0537] Step 2
[0538] Preparation of 2'-(azetidine-1-carbonyl)-4'-(((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0539] Example 18-1 (65 mg, 0.1 mmol) was dissolved in dichloromethane (10 mL), and hexadecyltrimethylammonium bromide (51 mg, 0.14 mmol) and KMnO4 (22 mg, 0.14 mmol) were added to the reaction mixture. The reaction mixture was stirred at reflux for 2 h. The reaction mixture was cooled to room temperature, and then saturated aqueous sodium sulfite solution (5 mL) was added with vigorous stirring. Saturated brine (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford Example 18-2 (45 mg, 73.4%).
[0540] MS m / z(ESI):662.3[M+1] + .
[0541] Step 3
[0542] Preparation of 2'-(azetidine-1-carbonyl)-4'-(((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[0543] The synthesis method of Example 18 was based on the synthesis method of Example 12. Example 18-2 was used as the raw material to obtain the title compound Example 18 (22 mg, 48.5%).
[0544] MS m / z(ESI):618.3[M+1] + .
[0545] Example 19
[0546] N-((4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)-[1,1'-biphenyl-2-yl)methyl)-N,3,3-trimethylbutanamide
[0547]
[0548] first step
[0549] Preparation of 4'-(((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-cyclopropyl-5-methylisoxazol-3-yl)-N-(methoxymethyl)-2'-((methylamino)methyl)-[1,1'-biphenyl]-2-sulfonamide
[0550] Example 19-1 (104 mg, 0.15 mmol) (synthesis method refers to Example 12-1) was prepared by dissolving potassium carbonate (63 mg, 0.45 mmol) in dichloromethane (5 mL). Methylamine hydrochloride (30 mg, 0.45 mmol) was then added to the reaction solution, which was stirred at room temperature for 2 h. Saturated brine (10 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford Example 19-2 (65 mg, 67.0%).
[0551] MS m / z(ESI):648.3[M+1] + .
[0552] Step 2
[0553] Preparation of N-((4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4-cyclopropyl-5-methylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-[1,1'-biphenyl-2-yl)methyl)-N,3,3-trimethylbutanamide
[0554] Example 19-2 (65 mg, 0.10 mmol), 3,3-dimethylbutanoic acid (23 mg, 0.20 mmol), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (114 mg, 0.30 mmol) were dissolved in dichloromethane (5 mL). Triethylamine (38 mg, 0.30 mmol) was then added to the reaction solution, which was stirred at room temperature for 2 h. Saturated brine (10 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford Example 19-3 (55 mg, 73.7%).
[0555] MS m / z(ESI):746.4[M+1] + .
[0556] Step 3
[0557] Preparation of N-((4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4-cyclopropyl-5-methylisoxazol-3-yl)sulfamoyl)-[1,1'-biphenyl]-2-yl)methyl)-N,3,3-trimethylbutanamide
[0558] The synthesis method of Example 19 was based on the synthesis method of Example 12. Example 19-2 was used as the starting material to obtain the title compound Example 19 (36 mg, 58.5%).
[0559] MS m / z(ESI):702.4[M+1] + .
[0560] Example 20
[0561] N-((4'-((2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-yl)sulfonyl)cyclopropanecarboxamide
[0562]
[0563] first step
[0564] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0565] Ammonia gas was bubbled into a solution of Example 20-1 (2.35 g, 5 mmol) (prepared by reference to WO2010135350A2) in THF (30 mL) until saturated. The mixture was stirred at 25°C for 12 hours. The organic phases were combined, dried, and concentrated, and the residue was purified by silica gel column chromatography (dichloromethane / methanol) to afford Example 20-2 (2.05 g, 91%).
[0566] MS m / z(ESI):498.2[M+1] + .
[0567] Step 2
[0568] Preparation of N-((4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-yl)sulfonyl)cyclopropanecarboxamide
[0569] To a solution of Example 20-2 (100 mg, 0.2 mmol) in DCM (5 mL) were added cyclopropylcarbonyl chloride (88.2 mg, 0.84 mmol) and 1,8-diazabicycloundec-7-ene (756 mg, 3.01 mmol) at 25°C, and the mixture was stirred at 50°C for 2 hours. The reaction mixture was quenched with 5 mL of water and extracted with DCM (10 mL x 3). The organic phases were combined, dried, concentrated, and purified by preparative HPLC to afford Example 20 (56 mg, 49.1%).
[0570] MS m / z(ESI):566.3[M+1] + .
[0571] Example 21
[0572] N-((4'-((2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-yl)sulfonyl)picolinamide
[0573]
[0574] The synthesis method of Example 21 was similar to that of Example 20, except that cyclopropylcarbonyl chloride was replaced with pyridylcarbonyl chloride to obtain Example 21 (65 mg, 60.4%).
[0575] MS m / z(ESI):603.3[M+1] + .
[0576] Example 22
[0577] N-((4'-((2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-yl)sulfonyl)benzamide
[0578]
[0579] The synthesis method of Example 22 was similar to that of Example 20, except that cyclopropanecarboxylic acid chloride was replaced with benzoyl chloride to obtain Example 22 (57 mg, 43.2%).
[0580] MS m / z(ESI):602.3[M+1] + .
[0581] Example 23
[0582] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[0583]
[0584] The synthesis method of Example 23 was similar to that of Example 20-2, except that 4-cyclopropyl-5-methylisoxazol-3-amine was used instead of ammonia to obtain Example 23 (45 mg, 39.5%).
[0585] MS m / z(ESI):619.3[M+1] + .
[0586] Example 24
[0587] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(5,6-dihydro-4H-cyclopenta[d]isoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0588]
[0589] The synthesis method of Example 24 was similar to that of Example 20-2, except that 5,6-dihydro-4H-cyclopenta[d]isoxazol-3-amine was used instead of ammonia to obtain Example 24 (36 mg, 40.1%).
[0590] MS m / z(ESI):605.3[M+1] + .
[0591] Example 25
[0592] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-2-sulfonamide
[0593]
[0594] To a solution of 1H-tetrazol-5-amine (16.5 mg, 0.19 mmol) and NaOH (15.5 mg, 0.38 mmol) in water (2 mL) was added dropwise Example 20-1 (100 mg, 0.19 mmol) at 70°C. The mixture was stirred for 3 hours. The mixture was acidified with concentrated hydrochloric acid under ice-cooling and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, dried, and concentrated. The residue was purified by HPLC to afford Example 25 (26 mg, 23.8%).
[0595] MS m / z(ESI):566.7[M+1] + .
[0596] Example 26
[0597] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[0598]
[0599] The synthesis method of Example 26 was similar to that of Example 25, except that 1H-tetrazol-5-amine was replaced with 3-amino-1,2,4-oxadiazol-5(2H)-one to obtain Example 26 (36 mg, 33.1%).
[0600] MS m / z(ESI):582.2[M+1] + .
[0601] Example 27
[0602] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(cyclopropylsulfonyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-carboxamide
[0603]
[0604] first step
[0605] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-carboxylic acid
[0606] To a round-bottom flask were added Example 6-2 (2.35 g, 5 mmol), 2-bromobenzoic acid (0.99 g, 5 mmol), Pd(dppf)Cl2*DCM (200 mg, 0.25 mmol), Cs2CO3 (3.26 g, 10 mmol), 1'4-Dioxane (25 mL), and H2O (5 mL). The mixture was stirred at 80°C under N2 protection for 12 hours. The reaction mixture was quenched with 20 mL of dilute hydrochloric acid (1 M) and extracted with ethyl acetate (30 mL x 3). The organic phases were combined, dried, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to afford Example 27-1 (1.69 g, 73.3%).
[0607] MS m / z(ESI):463.3[M+1] + .
[0608] Step 2
[0609] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(cyclopropylsulfonyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-carboxamide
[0610] To a solution of Example 27-1 (100 mg, 0.22 mmol), EDCI (58 mg, 0.3 mmol), and DMAP (37 mg, 0.3 mmol) in DCM (5 mL) was added cyclopropylmethanesulfonamide (36 mg, 0.3 mmol) at 25°C, and the mixture was stirred overnight at 25°C for 12 hours. The reaction solution was quenched with 5 mL of water and extracted with DCM (10 mL x 3). The organic phases were combined, dried, concentrated, and purified by preparative HPLC to afford the title product, Example 27 (48 mg, 39.2%).
[0611] MS m / z(ESI):566.3[M+1] + .
[0612] Example 28
[0613] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-2-carboxamide
[0614]
[0615] The synthesis method of Example 28 was similar to that of Example 27, except that 2H-tetrazol-5-amine was used instead of cyclopropanesulfonamide to obtain Example 28 (62 mg, 58.2%).
[0616] MS m / z(ESI):530.3[M+1] + .
[0617] Example 29
[0618] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(phenylsulfonyl)-[1,1'-biphenyl]-2-carboxamide
[0619]
[0620] The synthesis method of Example 29 was similar to that of Example 27, except that benzenesulfonamide was used instead of cyclopropanesulfonamide to obtain Example 29 (62 mg, 58.2%).
[0621] MS m / z(ESI):602.3[M+1] + .
[0622] Example 30
[0623] Methyl ((4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate
[0624]
[0625] The synthesis method of Example 30 was similar to that of Example 20, except that methyl chloroformate was used instead of cyclopropanecarboxylic acid chloride to obtain Example 30 (66 mg, 52.2%).
[0626] MS m / z(ESI):556.2[M+1] + .
[0627] Example 31
[0628] Cyclopropyl ((4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate
[0629]
[0630] The synthesis method of Example 31 was similar to that of Example 20, except that cyclopropyl chloroformate was used instead of cyclopropanecarboxylic acid chloride to obtain Example 31 (45 mg, 41.3%).
[0631] MS m / z(ESI):582.3[M+1] + .
[0632] Example 32
[0633] Benzyl ((4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate
[0634]
[0635] The synthesis method of Example 32 was similar to that of Example 20, except that benzyl chloroformate was used instead of cyclopropanecarboxylic acid chloride to obtain Example 32 (65 mg, 60.5%).
[0636] MS m / z(ESI):632.3[M+1] + .
[0637] Example 33
[0638] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(isopropylcarbamoyl)-[1,1'-biphenyl]-2-sulfonamide
[0639]
[0640] Pyridine (32 μL, 0.39 mmol) and Example 20-1 (0.1 g, 0.19 mmol) were stirred for 5 minutes and then added to a solution of sodium cyanate (18.9 mg, 0.29 mmol) in acetonitrile (5 mL). The mixture was stirred at room temperature for 4 hours, and isopropylamine (17.2 mg, 0.29 mmol) was added and stirred at room temperature for approximately 1 hour. The reaction solution was acidified with dilute hydrochloric acid (pH 5-6) under ice-cooling. The aqueous layer was extracted three times with ethyl acetate. The organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The residue was concentrated under reduced pressure and purified by HPLC to afford Example 33 (59 mg, 52%).
[0641] MS m / z(ESI):583.8[M+1] + .
[0642] Example 34
[0643] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(propylcarbamoyl)-[1,1'-biphenyl]-2-sulfonamide
[0644]
[0645] The synthesis method of Example 34 was similar to that of Example 33, except that n-propylamine was used instead of isopropylamine to obtain Example 34 (68 mg, 63.1%).
[0646] MS m / z(ESI):583.3[M+1] + .
[0647] Example 35
[0648] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(phenylcarbamoyl)-[1,1'-biphenyl]-2-sulfonamide
[0649]
[0650] The synthesis method of Example 35 was similar to that of Example 33, except that aniline was used instead of isopropylamine to obtain Example 35 (58 mg, 45.2%).
[0651] MS m / z(ESI):617.3[M+1] + .
[0652] Example 36
[0653] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(cyclopropylcarbamoyl)-[1,1'-biphenyl]-2-sulfonamide
[0654]
[0655] The synthesis method of Example 36 was similar to that of Example 33, except that cyclopropylamine was substituted for cycloisopropylamine to obtain Example 36 (53 mg, 48.3%).
[0656] MS m / z(ESI):581.3[M+1] + .
[0657] Example 37
[0658] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(ethylcarbamoyl)-[1,1'-biphenyl]-2-sulfonamide
[0659]
[0660] The synthesis method of Example 37 was similar to that of Example 33, except that cyclopropanecarboxylic acid chloride was replaced with ethyl isocyanate to obtain Example 37 (64 mg, 60.5%).
[0661] MS m / z(ESI):569.3[M+1] + .
[0662] Example 38
[0663] N-(N-(4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-yl)sulfonamido)benzamide
[0664]
[0665] first step
[0666] Preparation of 3-((2'-amino-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[0667] To a round-bottom flask were added Example 6-2 (2.35 g, 5 mmol), 2-bromoaniline (0.86 g, 5 mmol), Pd(dppf)Cl2*DCM (200 mg, 0.25 mmol), Cs2CO3 (3.26 g, 10 mmol), 1'4-Dioxane (25 mL), and H2O (5 mL). The mixture was stirred at 80°C under N2 protection for 12 hours. The reaction mixture was quenched with 30 mL of water and extracted three times with 30 mL of ethyl acetate. The organic phases were combined, dried, and concentrated. The residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether) to afford Example 38-1 (1.61 g, 75.2%).
[0668] MS m / z(ESI):434.3[M+1] + .
[0669] Step 2
[0670] Preparation of 3-((2'-sulfonylurea-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[0671] At 0°C, tert-butyl alcohol (0.85 g, 11.48 mmol) in anhydrous dichloromethane (10 mL) was added to a stirred solution of chlorosulfonyl isocyanate (1.62 g, 11.48 mmol) in anhydrous dichloromethane (10 mL). After 30 minutes, the resulting solution (1.75 mL, 0.91 mmol) was slowly added to a solution of Example 38-1 (0.36 g, 0.83 mmol) in anhydrous dichloromethane (5 mL) at 0°C. The reaction solution was warmed to room temperature and stirred for 2 hours. The reaction mixture was diluted with dichloromethane (30 mL). The mixture was washed with 0.1N dilute hydrochloric acid (20 mL) and water (25 mL) in sequence. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was refluxed in distilled water (30 mL) for 15-30 minutes. The reaction mixture was extracted with ethyl acetate (3×30 mL), and the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography (ethyl acetate / petroleum ether system) to obtain Example 38-2 (0.31 g, 72.9%).
[0672] MS m / z(ESI):513.3[M+1] + .
[0673] Step 3
[0674] Preparation of N-(N-(4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-yl)sulfamoylbenzamide
[0675] The synthesis method of Example 38 was similar to that of Example 20, except that cyclopropylcarbonyl chloride was replaced with benzoyl chloride to obtain Example 38 (180 mg, 48.4%).
[0676] MS m / z(ESI):617.3[M+1] + .
[0677] Example 39
[0678] N-(4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-yl)-5-methylpyridine-2-sulfonamide
[0679]
[0680] The synthesis method of Example 39 was similar to that of Example 20. Example 38-1 was used as the starting material, and cyclopropylcarbonyl chloride was replaced with 5-methylpyridine-2-sulfonyl chloride to obtain Example 39 (80 mg, 56.2%).
[0681] MS m / z(ESI):589.3[M+1] + .
[0682] Example 40
[0683] N-(4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-yl)-4,5-dimethylisoxazole-3-sulfonamide
[0684]
[0685] The synthesis method of Example 40 was similar to that of Example 20. Example 38-1 was used as the starting material, and 4,5-dimethylisoxazole-3-sulfonyl chloride was used instead of cyclopropylcarbonyl chloride to obtain Example 40 (53 mg, 62.1%).
[0686] MS m / z(ESI):593.3[M+1] + .
[0687] Example 41
[0688] 2'-(Benzyloxy)-4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[0689]
[0690] first step
[0691] Preparation of ethyl 3-(benzyloxy)-4-bromobenzoate
[0692] To a solution of Example 41-1 (5 g, 20.40 mmol) in DMF (50 mL) were slowly added benzyl bromide (3.5 g, 20.40 mmol) and potassium carbonate (5.63 g, 40.80 mmol). The mixture was stirred at 80°C for 2 hours. After cooling, the reaction solution was diluted with 100 mL of ethyl acetate and washed with water (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography with eluent System B to obtain the title product, Example 41-2 (6.50 g, colorless liquid), in a yield of 95.1%.
[0693] 1 H NMR (400MHz, Chloroform-d) δ7.63(d,J=8.1Hz,2H),7.51(dd,J=9.3,7.5Hz,3H),7.44–7.37(m,2H),7.37–7.31(m,1H),5.21(s,2H),3.91(s,3H).
[0694] Step 2
[0695] Preparation of (3-(Benzyloxy)-4-bromophenyl)methanol
[0696] To a solution of Example 41-2 (6.5 g, 20.24 mmol) in DCM (60 mL) was slowly added DIBAL-H (1 M, 50.60 mL) under nitrogen at 0°C, and the mixture was stirred at 25°C for 1 hour. The reaction mixture was quenched by adding icy 5% NaOH (60 mL) and extracted with dichloromethane (50 mL x 3). The organic phases were combined, dried, and concentrated to afford the title product, Example 41-3 (6.50 g, colorless liquid), which was used directly in the next step.
[0697] Step 3
[0698] Preparation of 3-(3-(Benzyloxy)-4-bromophenyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[0699] To a solution of Example 41-3 (5.8 g, 19.78 mmol) in DCM (30 mL) was added methylsulfonyl chloride (4.53 g, 39.57 mmol) and diisopropylethylamine (7.67 g, 59.35 mmol, 10.34 mL) under nitrogen at 0°C. The mixture was stirred at room temperature for 1 hour, and then 10 mL of ice water was added to quench the reaction. The lower organic phase solution was added to a mixture of tributylmethylammonium chloride (0.4 mL, 75% purity), 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride (4.57 g, 19.78 mmol), aqueous sodium hydroxide solution (10 M, 13.16 mL) and DCM (30 mL) at room temperature and reacted for 2 hours. The reaction mixture was quenched with water (30 mL) and extracted with dichloromethane (30 mL*3). The organic phases were combined, dried, and concentrated. The residue was purified by silica gel column chromatography using eluent System B to give the title product Example 41-4 (8.60 g, light yellow oil) in a yield of 92.6%.
[0700] MS m / z(ESI):469.0[M+1] + .
[0701] 1H NMR(400MHz,Chloroform-d)δ7.51(d,J=8.0Hz,1H),7.45–7.41(m,2H),7.38(dd, J=8.3,6.5Hz,2H),7.34–7.29(m,1H),6.72(d,J=1.9Hz,1H),6.64(dd,J=8.0,1.9 Hz,1H),5.12(s,2H),4.60(s,2H),2.26(t,J=8.1Hz,2H),2.02–1.93(m,6H),1.82 (d,J=9.7Hz,2H),1.58–1.51(m,2H),1.31(t,J=7.5Hz,2H),0.87(t,J=7.3Hz,3H).
[0702] Step 4
[0703] Preparation of 3-(3-(benzyloxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-2-yl)benzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[0704] To a reactor, Example 41-4 (1 g, 2.13 mmol), Pd(dppf)Cl2*DCM (174 mg, 213.03 μmol), potassium acetate (626 mg, 6.39 mmol), pinacol borate (650 mg, 2.56 mmol), and 1'4-Dioxane (10 mL) were added. The mixture was stirred at 90°C under nitrogen for 12 hours. After cooling, the reaction mixture was quenched with 10 mL of water and extracted with ethyl acetate (15 mL*3). The organic phases were combined, dried, and concentrated to afford the title product, Example 41-5 (600 mg, a reddish-brown oil), which was used directly in the next step.
[0705] Step 5
[0706] 2'-(Benzyloxy)-4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-
[0707] Preparation of (4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0708] To a reactor were added Example 41-5 (0.6 g, 1.16 mmol), 2-bromo-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)benzenesulfonamide (436 mg, 1.16 mmol), Pd(dppf)Cl2*DCM (94.80 mg, 116.17 μmol), potassium carbonate (320.63 mg, 2.32 mmol), 1'4-Dioxane (10 mL), and H2O (2 mL). The mixture was stirred at 100°C under nitrogen for 12 hours. After cooling, the reaction mixture was quenched with 8 mL of water and extracted with ethyl acetate (10 mL*3). The organic phases were combined, dried, and concentrated. The residue was purified by silica gel column chromatography using eluent System B to afford the title product, Example 41-6 (650 mg, light brown solid) in an 81.7% yield.
[0709] MS m / z(ESI):685.1[M+1] + .
[0710] 1 H NMR(400MHz,Chloroform-d)δ8.02(d,J=8.0Hz,1H),7.56(td,J=7.6,1.3Hz,1H),7.47–7.43(m,1H),7.2 5–7.21(m,4H),7.19–7.16(m,2H),7.15–7.10(m,1H),6.77–6.73(m,2H),5.01(d,J=6.0Hz,2H),4.70(d,J =6.4Hz,2H),4.58(d,J=10.9Hz,1H),4.42(d,J=10.8Hz,1H),3.31(s,3H),2.34(s,2H),2.28(s,3H),1.9 6(d,J=10.5Hz,6H),1.89(s,3H),1.83(s,2H),1.58(d,J=7.8Hz,2H),1.36(d,J=8.3Hz,2H),0.90(s,3H).
[0711] Step 6
[0712] Preparation of 2'-(benzyloxy)-4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[0713] To a round-bottom flask was added Example 41-6 (50 mg, 73.01 μmol) and HCl / Dioxane (4 M, 5.00 mL), and the mixture was stirred at 70°C for 1 hour. The reaction mixture was cooled, concentrated, and purified by preparative HPLC to afford the title product, Example 41 (14 mg, white solid) in a 29.6% yield.
[0714] MS m / z(ESI):641.0[M+1] + .
[0715] 1 H NMR (400MHz, DMSO-d6) δ10.40(s,1H),8.13–8.04(m,1H),7.56(d,J=11.9Hz,2H),7.22(q,J=4.8,4.4H z,4H),7.15–7.06(m,2H),6.98(d,J=7.7Hz,1H),6.82(s,1H),6.65(d,J=7.7Hz,1H),4.96(d,J=12.7H z,1H),4.86(d,J=12.6Hz,1H),4.68(s,2H),2.31(t,J=7.5Hz,2H),2.10(s,3H),1.83(d,J=8.6Hz,6H) ,1.66(d,J=7.1Hz,2H),1.61(s,3H),1.48(q,J=7.6Hz,2H),1.31–1.26(m,2H),0.82(t,J=7.3Hz,3H).
[0716] Example 42
[0717] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(2,2,2-trifluoroethoxy)-[1,1'-biphenyl]-2-sulfonamide
[0718]
[0719] first step
[0720] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-hydroxy-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0721] To a round-bottom flask, add Example 41-6 (600 mg, 876.11 μmol), wet palladium on carbon (150 mg), and MeOH (10 mL). The mixture is stirred at 20°C under a hydrogen atmosphere for 24 hours. The reaction mixture is filtered and concentrated to afford the title product, Example 42-1 (600 mg, light yellow solid) in a 96.0% yield.
[0722] MS m / z(ESI):595.0[M+1] + .
[0723] Step 2
[0724] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-2'-(2,2,2-trifluoroethoxy)-[1,1'-biphenyl]-2-sulfonamide
[0725] To a solution of Example 42-1 (30 mg, 50.44 μmol) in DMF (1 mL) were added potassium carbonate (13.92 mg, 100.89 μmol) and trifluoroethyl trifluoromethanesulfonate (58.51 mg, 252.22 μmol), and the mixture was stirred at 80°C for 1 hour. After cooling, the reaction solution was quenched with 5 mL of water and extracted with ethyl acetate (6 mL x 3). The organic phases were combined, dried, and concentrated. The residue was purified by silica gel column chromatography with eluent System B to afford the title product, Example 42-2 (26 mg, light brown solid) in a yield of 73.2%.
[0726] MS m / z(ESI):677.2[M+1] + .
[0727] Step 3
[0728] Preparation of 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(2,2,2-trifluoroethoxy)-[1,1'-biphenyl]-2-sulfonamide
[0729] To a round-bottom flask was added Example 42-2 (26 mg, 38.53 μmol) and HCl / Dioxane (4 M, 5 mL), and the mixture was stirred at 70°C for 1 hour. The reaction mixture was cooled, concentrated, and purified by preparative HPLC to afford the title product Example 42 (14 mg, white solid) in a 39.8% yield.
[0730] MS m / z(ESI):633.1[M+1] + .
[0731] 1 H NMR (400MHz, DMSO-d6) δ10.44(s,1H),8.04(dd,J=7.7,1.6Hz,1H),7.57(d,J=11.1Hz,2H),7.21 –7.16(m,1H),6.99(s,2H),6.71(d,J=7.5Hz,1H),4.71(s,2H),4.57(d,J=11.3Hz,1H),4.38(t,J =10.4Hz,1H),2.36(t,J=7.5Hz,2H),2.18(s,3H),2.00(d,J=7.7Hz,1H),1.91–1.81(m,5H),1.6 9(d,J=8.5Hz,2H),1.63(s,3H),1.53(p,J=7.5Hz,2H),1.33–1.28(m,2H),0.83(t,J=7.5Hz,3H).
[0732] Example 43
[0733] 2-(2-butyl-1-((2'-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl-d2)-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanesulfamide
[0734]
[0735] first step
[0736] Preparation of 4'-(bromomethyl-d2)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0737] To a solution of Example 1-2 (900 mg, 1.95 mmol) in DCM (20 mL) was added carbon tetrabromide (1.60 g, 4.86 mmol) and triphenylphosphine (1.02 g, 3.89 mmol) under nitrogen at 0°C. The mixture was stirred at 20°C for 1 hour. The reaction mixture was quenched with water (30 mL) and extracted with dichloromethane (30 mL x 3). The organic phases were combined, dried, and concentrated. The residue was purified by silica gel column chromatography with eluent System B to afford the title product, Example 43-1 (1 g, white solid), in a 97.8% yield.
[0738] MS m / z(ESI):525.1[M+1] + .
[0739] Step 2
[0740] Preparation of 2-(2-butyl-1-((2'-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl-d2)-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylacetamide
[0741] To a solution of Example 43-1 (180 mg, 342.56 μmol) in MeCN (6 mL) were added potassium carbonate (94.55 mg, 685.13 μmol) and 2-(2-butyl-4-methyl-6-oxo-1H-pyrimidin-5-yl)-N,N-dimethylacetamide (86.09 mg, 342.56 μmol), and the mixture was stirred at 70°C for 1 hour. The reaction mixture was quenched with water (20 mL) and extracted with dichloromethane (20 mL x 3). The organic phases were combined, dried, and concentrated. The residue was purified by silica gel column chromatography with eluent System B to afford the title product, Example 43-2 (80 mg, light yellow solid) in a 33.6% yield.
[0742] MS m / z(ESI):696.3[M+1] + .
[0743] Step 3
[0744] Preparation of 2-(2-butyl-1-((2'-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl-d2)-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanesulfamide
[0745] To a solution of Example 43-2 (80 mg, 114.97 μmol) in toluene (5 mL) was added Lawesson's reagent (139.34 mg, 344.90 μmol), and the mixture was stirred at 70°C under nitrogen for 1 hour. The reaction mixture was cooled and quenched with water (10 mL). The mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated. The residue was purified by silica gel column chromatography with eluent System B to afford the title product, Example 43-3 (50 mg, light yellow solid), in a yield of 61.1%.
[0746] MS m / z(ESI):712.0[M+1] + .
[0747] Step 4
[0748] Preparation of 2-(2-butyl-1-((2'-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl-d2)-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanesulfamide
[0749] To a round-bottom flask was added Example 43-3 (50 mg, 70.23 μmol) and HCl / Dioxane (4 M, 5 mL), and the mixture was stirred at 70°C for 1 hour. The reaction mixture was cooled, concentrated, and purified by preparative HPLC to afford the title product Example 43 (9 mg, white solid) in an 18.8% yield.
[0750] MS m / z(ESI):668.1[M+1] + .
[0751] 1 H NMR (400MHz, DMSO-d6) δ10.51(s,1H),8.04(dd,J=7.5,1.8Hz,1H),7.60(d,J=7.9Hz,2H),7.25(s,1H ),7.17(d,J=7.1Hz,1H),6.97(dd,J=8.3,1.7Hz,1H),6.89(d,J=7.8Hz,1H),4.02–3.93(m,2H),3.80( s,2H),3.47(s,3H),3.42(s,3H),3.23–3.12(m,2H),2.65(d,J=8.1Hz,2H),2.18(d,J=5.1Hz,6H),1. 64(s,3H),1.58(q,J=7.7Hz,2H),1.30(d,J=7.5Hz,2H),0.98(t,J=7.0Hz,3H),0.84(t,J=7.4Hz,3H).
[0752] Example 44
[0753] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl-d2)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0754]
[0755] Method 1:
[0756] The synthesis method of Example 44 was similar to that of Example 1, except that 4-chloro-5-methylisoxazolamine was used instead of 4,5-dimethylisoxazolamine to obtain Example 44 (51 mg, white solid) with a yield of 50.3%.
[0757] Method 2:
[0758]
[0759] first step
[0760] Preparation of (4-bromo-3-(ethoxymethyl)phenyl)-d2methanol
[0761] Example 44-1 (1.0 g, 3.48 mmol) (prepared according to WO2010114801A1) and lithium aluminum tetrahydride-d (219.3 mg, 5.22 mmol) were dissolved in tetrahydrofuran (20 mL). The reaction mixture was cooled to 0°C and stirred for 2 hours. Saturated brine (50 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (2 x 100 mL). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (petroleum ether / ethyl acetate) to afford Example 44-2 (850 mg, 98%).
[0762] MS m / z(ESI):248.1[M+1] + .
[0763] Step 2
[0764] Preparation of 4-bromo-3-(ethoxymethyl)benzyl-d2 methanesulfonate
[0765] To a solution of Example 44-2 (50 mg, 3.44 mmol) in dichloromethane (20 mL) was added methylsulfonyl chloride (433.4 mg, 3.78 mmol) and diisopropylethylamine (1.33 g, 10.32 mmol) in an ice bath. The reaction mixture was warmed to room temperature and stirred for 1 hour. The reaction mixture was concentrated to afford crude Example 44-3 (1.1 g, 98%), which was used directly in the next step.
[0766] MS m / z(ESI):326.2[M+1] + .
[0767] Step 3
[0768] Preparation of 3-(4-bromo-3-(ethoxymethyl)phenyl)methyl-d2)-2-butyl-1,3-diazaaspirino[4.4]non-1-en-4-one
[0769] Example 44-3 (1.1 g, 3.38 mmol) was dissolved in DMF (15 mL). Potassium carbonate (1.03 g, 7.44 mmol) and 2-butyl-1,3-diazaspiro[4,4]non-1-en-4-one (858.4 mg, 3.72 mmol) were added under ice-cooling conditions. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated, and the crude product was purified by HPLC to afford Example 44-4 (1.2 g, 86%).
[0770] MS m / z(ESI):424.4[M+1] + .
[0771] Step 4
[0772] Preparation of 2-butyl-3-((3-(ethoxymethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methyl-d2)-1,3-diazaspiro[4.4]non-1-en-4-one
[0773] Compound 44-4 (1.2 g, 2.86 mmol) was dissolved in 15 mL of 1,4-dioxane, and bis-pinacol boronate (0.87 g, 3.4 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (102.9 mg, 0.14 mmol), and potassium acetate (0.84 g, 8.56 mmol) were added. The mixture was heated to 80°C under nitrogen and stirred for 3 hours. The reaction mixture was cooled to room temperature, and saturated sodium chloride solution (50 mL) was added. The organic phases were extracted with ethyl acetate (100 mL x 3), the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography using an eluent system (ethyl acetate / petroleum ether = 10-50%) to obtain Example 44-5 (1.0 g, 80.0%).
[0774] MS m / z(ESI):471.5[M+1] + .
[0775] Step 5
[0776] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-ylmethyl-d2)-n-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl)-n-(2-trimethylsilylethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[0777] preparation
[0778] Example 44-5 (0.5 g, 1.07 mmol) was dissolved in 20 mL of 1,4-dioxane and water (2 mL). Intermediate 1 (0.4 g, 1.07 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (0.039 g, 0.053 mmol), and potassium carbonate (0.3 g, 3.2 mmol) were added. The mixture was heated to 90°C under nitrogen and stirred for 16 hours. The reaction mixture was cooled to room temperature, extracted with saturated sodium chloride solution (50 mL) and ethyl acetate (100 mL x 3), and the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography using an eluent system (ethyl acetate / petroleum ether = 10-50%) to obtain Example 44-6 (0.45 g, gray solid) in a 66.0% yield.
[0779] MS m / z(ESI):746.4[M+1] + .
[0780] Step 6
[0781] Preparation of 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-ylmethyl-d2)-n-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0782] Example 44-6 (0.45 g, 0.7 mmol) was dissolved in 10 mL of 4 M HCl / dioxane. The mixture was heated to 70°C and stirred for 2 hours. The reaction mixture was cooled to room temperature, and saturated sodium chloride solution (50 mL) was added. The organic phases were extracted with ethyl acetate (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography using p-HPLC (FA) as the eluent to afford Example 44 (0.2 g, 50.0%).
[0783] MS m / z(ESI):615.2[M+1] + .
[0784] 1H NMR(400MHz,DMSO-d6)δ8.05–7.97(m,1H),7.54(s,2H),7.22–7.12(m,2H),6.99(s,2 H),4.08(d,J=13.1Hz,1H),3.99(d,J=13.1Hz,1H),3.21(ddd,J=9.4,7.0,3.6Hz,2H), 2.35(t,J=7.5Hz,2H),2.25(s,3H),1.85(d,J=8.5Hz,6H),1.69(d,J=8.8Hz,2H),1.50 (q,J=7.7Hz,2H),1.28(d,J=7.6Hz,2H),1.01(t,J=6.9Hz,3H),0.82(t,J=7.3Hz,3H).
[0785] Example 45
[0786] 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4-chloro-5-methyl-isoxazol-3-yl)benzenesulfonamide
[0787]
[0788] Method 1:
[0789] The synthesis method of Example 45 was similar to that of Example 1, except that 4-chloro-5-methylisoxazolamine was used instead of 4,5-dimethylisoxazolamine to obtain Example 45 (56.6 mg, white solid) in a yield of 45.8%.
[0790] Method 2:
[0791]
[0792] first step
[0793] Preparation of 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-ylmethyl)-n-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl)-n-(2-trimethylsilylethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[0794] Example 45-1 (0.3 g, 0.64 mmol) (prepared according to WO2010114801A1) was dissolved in 10 mL of 1,4-dioxane and water (1 ml). Intermediate 1 (0.24 g, 0.64 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (0.023 g, 0.032 mmol), and potassium carbonate (0.18 g, 1.9 mmol) were added. The mixture was heated to 90°C under nitrogen and stirred for 16 hours. The reaction mixture was cooled to room temperature, added with saturated sodium chloride solution (50 mL), and extracted with ethyl acetate (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography using an eluent system (ethyl acetate / petroleum ether = 10-50%) to obtain Example 45-2 (0.27 g, gray solid) in a 66.0% yield.
[0795] MS m / z(ESI):744.4[M+1] + .
[0796] Step 2
[0797] Preparation of 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-ylmethyl)-n-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0798] Example 45-2 (0.27 g, 0.7 mmol) was dissolved in 10 mL of 4 M HCl / dioxane. The mixture was heated to 70°C and stirred for 2 hours. The reaction solution was cooled to room temperature, and saturated sodium chloride solution (50 mL) was added. The organic phases were extracted with ethyl acetate (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography using p-HPLC (FA) as the eluent to afford Example 45 (0.12 g, 54.5%).
[0799] MS m / z(ESI):612.8[M+1] + .
[0800] 1H NMR (400MHz, DMSO-d6) δ7.97-7.95(m,1H),7.37-7.31(m,2H),7.09(s,1H),6.97(d,J=7. 6Hz,1H),6.93-6.88(m,2H),4.70(s,2H),4.08(d,J=13.2Hz,1H),3.93(d,J=13.2Hz,1H) ,3.24-3.15(m,2H),2.36(t,J=7.6Hz,2H),2.12(s,3H),1.88-1.81(m,6H),1.72-1.65(m ,2H),1.57-1.49(m,2H),1.33-1.27(m,2H),1.01(t,J=6.8Hz,3H),0.83(t,J=7.2Hz,3H).
[0801] Example 46
[0802] 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4-bromo-5-methyl-isoxazol-3-yl)benzenesulfonamide
[0803]
[0804] The synthesis method of Example 46 was similar to that of Example 1, except that 4-bromo-5-methylisoxazolamine was used instead of 4,5-dimethylisoxazolamine to obtain Example 46 (40.8 mg, white solid) with a yield of 31.1%.
[0805] MS m / z(ESI):656.8[M+1] + .
[0806] 1 H NMR (400MHz, DMSO-d6) δ7.98-7.95(m,1H),7.36-7.31(m,2H),7.09(s,1H),6.98(d,J=8. 0Hz,1H),6.92-6.89(m,2H),4.70(s,2H),4.08(d,J=13.2Hz,1H),3.93(d,J=13.2Hz,1H) ,3.22-3.17(m,2H),2.37(t,J=7.2Hz,2H),2.12(s,3H),1.90-1.81(m,6H),1.73-1.65(m ,2H),1.57-1.49(m,2H),1.33-1.27(m,2H),1.01(t,J=7.2Hz,3H),0.83(t,J=7.2Hz,3H).
[0807] Example 47
[0808] 4'-(2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0809]
[0810] The synthesis method of Example 47-1 was based on the synthesis method of Example 43-5, except that 2-bromo-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)benzenesulfonamide was replaced with 2-bromo-N-(4-chloro-5-methylisoxazol-3-yl)-N-(methoxymethyl)benzenesulfonamide, and 2-butyl-4-chloro-1H-imidazole-5-carboxaldehyde was replaced with 2-(2-butyl-4-methyl-6-oxo-1H-pyrimidin-5-yl)-N,N-dimethylacetamide to obtain Example 47-1 (50 mg, white solid) with a yield of 44.1%.
[0811] MS m / z(ESI):615.2[M+1] + .
[0812] first step
[0813] 4'-(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl)-N-(4-chloro-5-methylisoxazole-3-yl)
[0814] Preparation of 2-(ethoxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0815] To a solution of Example 47-1 (50 mg, 76.97 μmol) in MeOH (6 mL) was added sodium borohydride (6 mg, 153.94 μmol), and the mixture was stirred at 20°C for 1 hour. The organic phases were combined, dried, and concentrated, and the residue was purified by silica gel column chromatography using eluent System B to afford the title product 47-2 (45 mg, light yellow solid) in a 90.3% yield.
[0816] MS m / z(ESI):651.1[M+1] + .
[0817] Step 2
[0818] Preparation of 4'-(2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0819] To a round-bottom flask were added 47-2 (50 mg, 76.73 μmol) and a 4 M solution of hydrogen chloride in dioxane (5 mL), and the mixture was stirred at 70°C for 1 hour. The reaction mixture was cooled, concentrated, and purified by preparative HPLC to afford the title compound 47 (19 mg, white solid) in a 40.8% yield.
[0820] MS m / z(ESI):607.1[M+1] + .
[0821] 1 H NMR (400MHz, DMSO-d6) δ11.14(s,1H),8.02(dd,J=7.5,1.9Hz,1H),7.58(s,2H),7.21(s,1H) ,7.14(s,1H),6.97(d,J=7.9Hz,1H),6.88(d,J=7.9Hz,1H),5.29(s,2H),5.27(s,1H),4.34( d,J=4.0Hz,2H),4.09–3.97(m,2H),3.25–3.15(m,2H),2.54(dd,J=8.8,6.4Hz,2H),2.27(s, 3H),1.51(q,J=7.6Hz,2H),1.30–1.25(m,2H),0.98(t,J=7.0Hz,3H),0.83(t,J=7.4Hz,3H).
[0822] Example 48
[0823] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl-d2)-N-(4-fluoro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0824]
[0825] The synthesis method of Example 48 was similar to that of Example 1, except that 4-fluoro-5-methylisoxazolamine was used instead of 4,5-dimethylisoxazolamine to obtain Example 48 (11 mg, white solid) with a yield of 40.3%.
[0826] MS m / z(ESI):599.3[M+1] + .
[0827] 1H NMR(400MHz,DMSO-d6)δ8.05–7.97(m,1H),7.54(s,2H),7.22–7.12(m,2H),6.99(s,2 H),4.08(d,J=13.1Hz,1H),3.99(d,J=13.1Hz,1H),3.21(ddd,J=9.4,7.0,3.6Hz,2H), 2.35(t,J=7.5Hz,2H),2.25(s,3H),1.85(d,J=8.5Hz,6H),1.69(d,J=8.8Hz,2H),1.50 (q,J=7.7Hz,2H),1.28(d,J=7.6Hz,2H),1.01(t,J=6.9Hz,3H),0.82(t,J=7.3Hz,3H).
[0828] Example 49
[0829] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxydeuteriomethyl)-[1,1'-biphenyl]-2-sulfonamide
[0830]
[0831] first step
[0832] Preparation of methyl 2-bromo-5-(bromomethyl)benzoate
[0833] N-Bromosuccinimide (854.68 mg, 4.80 mmol) and Example 49-1 (1.0 g, 4.37 mmol) were dissolved in carbon tetrachloride (5 mL). Benzoyl peroxide (105.74 mg, 436.55 μmol) was then added to the reaction solution. The reaction solution was stirred at 80°C for 16 h. Saturated sodium chloride (10 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product, which was then purified by column chromatography (petroleum ether / ethyl acetate system) to obtain the target molecule Example 49-2 (1.1 g, 3.57 mmol, 81.82% yield).
[0834] Step 2
[0835] Preparation of (2-bromo-5-(bromomethyl)phenyl)deuterium-methane-ol
[0836] Deuterated lithium aluminum tetrahydride (104.72 mg, 2.44 mmol) was dissolved in tetrahydrofuran (3 mL), followed by the addition of Example 49-2 (500 mg, 1.62 mmol). The reaction mixture was stirred at room temperature for 1 h. Water (0.1 mL), 15% sodium hydroxide solution (0.1 mL), and water (0.3 mL) were added sequentially to the reaction mixture. After stirring for 0.5 h, the mixture was filtered. The filter cake was washed with dichloromethane (10 mL x 3), the filtrate was dried, and concentrated to obtain the target molecule Example 49-3 (310 mg, 1.10 mmol, 67.72% yield).
[0837] Step 3
[0838] Preparation of 3-(4-bromo-3-(hydroxymethyl-2-benzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[0839] 2-Butyl-1,3-diazaspiro[4.4]non-1-en-4-one (62.01 mg, 319.18 μmol) and Example 49-3 were dissolved in acetonitrile (2 mL), followed by the addition of potassium carbonate (29.36 mg, 212.79 μmol). The reaction mixture was stirred at 80° C. for 3 h. After the reaction was completed, a saturated sodium chloride solution (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product, which was then purified by column chromatography (petroleum ether / ethyl acetate system) to obtain the target molecule Example 49-4 (18 mg, 45.53 μmol, 21.40% yield).
[0840] MS m / z(ESI):395.2[M+1] + .
[0841] Step 4
[0842] Preparation of 3-(4-bromo-3-(ethoxymethyl D2)benzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[0843] Example 49-4 (500 mg, 1.26 mmol) was dissolved in tetrahydrofuran (2 mL), followed by the addition of sodium hydride (151.76 mg, 3.79 mmol, 60% purity). The reaction mixture was stirred at room temperature for 0.5 h, followed by the addition of iodoethane (986.30 mg, 6.32 mmol), and the reaction mixture was stirred at room temperature for 1.5 h. After the reaction, saturated sodium chloride solution (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product, which was then purified by column chromatography (petroleum ether / ethyl acetate) to afford Example 49-5 (210 mg, 496.01 μmol, 39.22% yield).
[0844] MS m / z(ESI):423.2[M+1] + .
[0845] Step 5
[0846] Preparation of 2-butyl-3-(3-(ethoxymethyl-d2)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,3-diazaspiro[4.4]non-1-en-4-one
[0847] Example 49-5 (100 mg, 236.19 μmol), pinacol diboronate (71.97 mg, 283.43 μmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (19.27 mg, 23.62 μmol), and potassium acetate (45.35 mg, 472.39 μmol) were dissolved in dioxane (5 mL). The reaction mixture was stirred at 90°C for 16 hours. Saturated aqueous sodium chloride (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to afford the crude target molecule, Example 49-6 (105 mg, 223.19 μmol, 94.50% yield). The crude product was used directly in the next step without purification.
[0848] MS m / z(ESI):471.2[M+1] + .
[0849] Step 6
[0850] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl-d2)-N-(((2-(trimethylsilyl)ethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[0851] Intermediate 1 (93 mg, 235.05 μmol), Example 49-6 (110.58 mg, 235.05 μmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (21.53 mg, 23.51 μmol), and cesium carbonate (229.88 mg, 705.16 μmol) were dissolved in dioxane and water (2.5 mL, 4:1). The reaction mixture was stirred at 100°C for 1 hour. Saturated aqueous sodium chloride (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product. The crude product was then purified by column chromatography (petroleum ether / ethyl acetate) to afford the target molecule, Example 49-7 (106 mg, 160.79 μmol, 68.41% yield).
[0852] MS m / z(ESI):745.3[M+1] + .
[0853] Step 7
[0854] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxydeuteriomethyl)-[1,1'-biphenyl]-2-sulfonamide
[0855] The synthesis method of Example 49 was based on the synthesis method of Example 33, and Example 49-7 was used as the raw material to obtain the title compound Example 40 (32 mg, 33.5%).
[0856] MS m / z(ESI):615.2[M+1] + .
[0857] 1 H NMR (400MHz, DMSO) δ8.01 (dd, J=16.0, 14.4Hz, 1H), 7.60 (t, J=29.2Hz, 2H), 7.15 (d,J=11.1Hz,2H),7.00(s,2H),4.83–4.66(m,2H),3.28–3.13(m,2H),2.36(t,J= 7.5Hz,2H),2.28(s,3H),1.86(d,J=6.4Hz,6H),1.71(d,J=8.0Hz,2H),1.52(dt, J=15.2,7.5Hz,2H),1.34–1.25(m,2H),1.01(t,J=7.0Hz,3H),0.88–0.75(m,3H).
[0858] Example 50
[0859] 2-(5-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-3-(ethoxymethyl)pyridin-2-yl)-N-(4,5-dimethylisoxazol-3-yl)benzenesulfonamide
[0860]
[0861] The synthesis method of Example 50 was carried out with reference to the synthesis method of Example 1 to obtain Example 50 (51 mg, white solid) with a yield of 50.3%.
[0862] MS m / z(ESI):594.1[M+1] + .
[0863] 1 H NMR(400MHz, DMSO-d6)δ8.25(s,1H),8.19(s,1H),8.01–7.97(m,1H),7.50(s,2H),7.16(d,J= 26.4Hz,2H),4.80(s,2H),4.30(d,J=14.9Hz,1H),4.05(d,J=14.4Hz,1H),3.25(d,J=7.1Hz,2H ),2.38(t,J=7.4Hz,2H),2.11(s,3H),1.86(t,J=5.2Hz,6H),1.69(d,J=8.6Hz,2H),1.60(s,3 H), 1.52 (t, J = 7.5Hz, 2H), 1.31 (d, J = 7.7Hz, 2H), 1.02 (t, J = 7.0Hz, 3H), 0.83 (t, J = 7.3Hz, 3H).
[0864] Example 51
[0865] 2-(5-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-3-methylpyridin-2-yl)-N-(4,5-dimethylisoxazol-3-yl)benzenesulfonamide
[0866]
[0867] The synthesis method of Example 51 was based on the synthesis method of Example 41, except that 6-bromo-5-methylnicotinate was used instead of 41b to obtain Example 51 (21 mg, white solid) with a yield of 50.3%.
[0868] MS m / z(ESI):550.2[M+1] + .
[0869] 1 H NMR (400MHz, DMSO-d6) δ8.16 (s, 1H), 8.00 (d, J = 7.8Hz, 1H), 7.58 (dt, J = 15.1 ,7.4Hz,2H),7.40(s,1H),7.21(d,J=7.6Hz,2H),4.74(s,2H),2.40(t,J=7.5 Hz,2H),2.16(s,3H),2.01(s,3H),1.86(q,J=6.6Hz,6H),1.68(t,J=5.5Hz,2 H),1.65(s,3H),1.56–1.50(m,2H),1.33–1.28(m,2H),0.83(t,J=7.3Hz,3H).
[0870] Example 52
[0871] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(cyclopropyloxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0872]
[0873] first step
[0874] Preparation of 2-butyl-3-(3-(cyclopropyloxymethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,3-diazaspiro[4.4]non-1-en-4-one
[0875] Example 52-1 (240 mg, 553.79 μmol) (synthesis method reference WO2010135350A2), pinacol diboronate (168.8 mg, 664.54 μmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (45.19 mg, 55.38 μmol), and potassium acetate (162.8 mg, 1.66 mmol) were dissolved in dioxane (5 mL). The reaction mixture was stirred at 90°C for 16 hours. Saturated aqueous sodium chloride (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain the crude target molecule, Example 52-2 (240 mg, 499.54 μmol, 90.2% yield). The crude product was used directly in the next step without purification.
[0876] MS m / z(ESI):481.2[M+1] + .
[0877] Step 2
[0878] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(cyclopropyloxymethyl)-N-(((2-(trimethylsilyl)ethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[0879] Intermediate 1 (240.71 mg, 499.54 μmol), Example 52-2 (240 mg, 499.54 μmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (40.76 mg, 49.95 μmol), and cesium carbonate (488.55 mg, 1.50 mmol) were dissolved in dioxane / water (2.5 mL, 4:1). The reaction mixture was stirred at 100°C under microwave conditions for 1 h. Saturated aqueous sodium chloride (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product. The crude product was then purified by column chromatography (petroleum ether / ethyl acetate) to afford the target molecule, Example 52-3 (210 mg, 277.99 μmol, 55.65% yield).
[0880] MS m / z(ESI):755.2[M+1] + .
[0881] Step 3
[0882] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(cyclopropyloxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0883] Example 52-3 was dissolved in tetrahydrofuran (2 mL), followed by the addition of tetrabutylammonium fluoride (1 M, 2 mL). The reaction mixture was stirred at 70°C for 2 h. A saturated aqueous solution of sodium chloride (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product. The crude product was purified (HCOOH) to obtain the target molecule Example 52 (78 mg, 124.76 μmol, 30.40% yield).
[0884] MS m / z(ESI):625.2[M+1] + .
[0885] 1H NMR (400MHz, DMSO) δ8.02(d,J=6.3Hz,1H),7.54(s,2H),7.11(s,2H),6.99(d,J=7.7H z,2H),4.72(s,2H),4.08(dd,J=44.2,12.4Hz,2H),3.09(s,1H),2.34(dd,J=20.3,12 .7Hz,2H),2.25(s,3H),1.85(d,J=7.4Hz,6H),1.69(d,J=6.6Hz,2H),1.52(dt,J=15. 2,7.7Hz,2H),1.29(dq,J=14.5,7.3Hz,2H),0.82(t,J=7.3Hz,3H),0.45–0.11(m,4H).
[0886] Example 53
[0887] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0888]
[0889]
[0890] first step
[0891] Preparation of ethyl 4-bromo-3-(bromomethyl)benzoate
[0892] N-Bromosuccinimide (854.68 mg, 4.80 mmol) and Example 53-1 (1.0 g, 4.37 mmol) were dissolved in carbon tetrachloride (5 mL), and benzoyl peroxide (105.74 mg, 436.55 μmol) was added. The reaction solution was stirred at 80°C for 16 h. A saturated aqueous solution of sodium chloride (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate system) to obtain the target molecule Example 53-2 (1.1 g, 3.57 mmol, 81.82% yield).
[0893] Step 2
[0894] Preparation of ethyl 4-bromo-3-(methoxymethyl)benzoate
[0895] Example 53-2 (1 g, 3.11 mmol) was dissolved in N,N-dimethylformamide (2 mL) and methanol (1 mL), and sodium methoxide (335.56 mg, 6.21 mmol) was added. The reaction solution was stirred at 50°C for 16 h. A saturated aqueous solution of sodium chloride (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate system) to obtain the target molecule Example 53-3 (610 mg, 2.35 mmol, 75.81% yield).
[0896] Step 3
[0897] Preparation of (4-bromo-3-(methoxymethyl)phenyl)methanol
[0898] Example 53-3 (610 mg, 2.35 mmol) was dissolved in toluene (4.76 mL) and cooled to -10°C. Diisobutylaluminum hydride (1 M, 4.71 mL) was added, and the reaction solution was stirred at -10°C for 0.5 h. 5% aqueous sodium hydroxide solution (5 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate system) to obtain the target molecule Example 53-4 (480 mg, 2.08 mmol, 88.23% yield).
[0899] Step 4
[0900] Preparation of 1-bromo-4-(bromomethyl)-2-(methoxymethyl)benzene
[0901] Example 53-4 (480 mg, 2.08 mmol) and triphenylphosphine (817.21 mg, 3.12 mmol) were dissolved in dichloromethane (3 mL), followed by the addition of carbon tetrabromide (1.02 g, 3.12 mmol). The reaction mixture was stirred at 30°C for 3 h. A saturated aqueous solution of sodium chloride (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product, which was then purified by column chromatography (petroleum ether / ethyl acetate) to afford the target molecule Example 53-5 (430 mg, 1.46 mmol, 70.42% yield).
[0902] Step 5
[0903] Preparation of 3-(4-bromo-3-(methoxymethyl)benzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[0904] Example 53-5 (430 mg, 1.46 mmol) and 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one (312.57 mg, 1.61 mmol) were dissolved in acetonitrile (5 mL), and potassium carbonate (605.55 mg, 4.39 mmol) was then added. The reaction solution was stirred at 80°C for 16 h. A saturated aqueous solution of sodium chloride (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate system) to obtain the target molecule Example 53-6 (570 mg, 1.40 mmol, 95.67% yield).
[0905] MS m / z(ESI):407.2[M+1] + .
[0906] Step 6
[0907] Preparation of 2-butyl-3-(3-(methoxymethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,3-diazaspiro[4.4]non-1-en-4-one
[0908] Example 53-6 (570 mg, 1.40 mmol), pinacol diboronate (426.41 mg, 1.68 mmol), potassium acetate (411.40 mg, 4.20 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (114.18 mg, 139.93 μmol) were dissolved in dioxane (5 mL). The reaction mixture was stirred at 100°C for 16 hours. Saturated sodium chloride solution (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to afford the crude target molecule, Example 53-7 (610 mg, 1.34 mmol, 95.93% yield). The crude product was used directly in the next step without purification.
[0909] MS m / z(ESI):455.2[M+1] + .
[0910] Step 7
[0911] Preparation of 4'-((2-butyl-4-oxo-1,3-diazospiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(methoxymethyl)-N-(((2-(trimethylsilyl)ethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[0912] Intermediate 1 (1.23 g, 2.55 mmol), Example 53-7 (610 mg, 1.34 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (109.54 mg, 134.24 μmol), and cesium carbonate (1.31 g, 4.03 mmol) were dissolved in dioxane / water (2.5 mL, 4:1). The reaction mixture was stirred at 100°C under microwave conditions for 1 h. Saturated aqueous sodium chloride (10 mL) was added, and the organic phases were extracted with dichloromethane (10 mL x 3). The combined organic phases were dried and concentrated to obtain a crude product, which was then purified by column chromatography (petroleum ether / ethyl acetate) to afford the target molecule, Example 53-8 (550 mg, 754.05 μmol, 56.17% yield).
[0913] MS m / z(ESI):729.2[M+1] + .
[0914] Step 8
[0915] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0916] The synthesis method of Example 53 was based on the synthesis method of Example 33. Example 53-8 was used as the raw material to obtain the title compound Example 53 (22 mg, 48.5%).
[0917] MS: m / z (ESI): 599.3 [M+1] + .
[0918] 1 H NMR(400MHz,DMSO)δ8.24(s,1H),8.05–7.89(m,1H),7.49–7.23(m,2H),7.10(s,1H) ),7.00–6.78(m,3H),4.70(s,2H),4.04(d,J=12.9Hz,1H),3.90(d,J=13.0Hz,1H), 3.06(s,3H),2.37(t,J=7.5Hz,2H),2.12(s,3H),1.85(d,J=7.3Hz,6H),1.68(d,J= 7.0Hz,2H),1.53(dt,J=15.0,7.4Hz,2H),1.36–1.17(m,2H),0.83(t,J=7.3Hz,3H).
[0919] Example 54
[0920] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-methyl-[1,1'-biphenyl]-2-sulfonamide
[0921]
[0922] first step
[0923] Preparation of 3-(4-bromo-3-methylbenzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[0924] Example 54-1 (0.5 g, 1.89 mmol) and 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one (404.80 mg, 2.08 mmol) were dissolved in acetonitrile (5 mL), and potassium carbonate (784.22 mg, 5.68 mmol) was added. The reaction solution was stirred at 80°C for 16 h. Saturated aqueous sodium chloride (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate system) to obtain the target molecule Example 54-2 (0.59 g, 1.56 mmol, 82.55% yield).
[0925] MS m / z(ESI):377.3[M+1] + .
[0926] Step 2
[0927] Preparation of 2-butyl-3-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,3-diazaspiro[4.4]non-1-en-4-one
[0928] Example 54-2 (590 mg, 1.56 mmol), pinacol diboronate (476.49 mg, 1.88 mmol), potassium acetate (459.72 mg, 4.69 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (127.60 mg, 156.37 μmol) were dissolved in dioxane (5 mL). The reaction mixture was stirred at 100°C for 16 hours. Saturated aqueous sodium chloride (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to afford the crude target molecule, Example 54-3 (580 mg, 1.37 mmol, 87.40% yield). The crude product was used directly in the next step without purification.
[0929] MS m / z(ESI):425.3[M+1]+ .
[0930] Step 3
[0931] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-methyl-N-(((2-(trimethylsilyl)ethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[0932] Intermediate 1 (613.14 mg, 1.27 mmol), Example 54-3 (540 mg, 1.27 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (103.83 mg, 127.24 μmol), and cesium carbonate (1.24 g, 3.82 mmol) were dissolved in dioxane and water (2.5 mL, 4:1). The reaction mixture was stirred at 100°C under microwave conditions for 1 h. Saturated aqueous sodium chloride (10 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product. The crude product was then purified by column chromatography (petroleum ether / ethyl acetate) to afford the target molecule, Example 54-4 (550 mg, 754.05 μmol, 56.17% yield).
[0933] MS m / z(ESI):699.2[M+1] + .
[0934] Step 4
[0935] Preparation of 4'-((2-butyl-4-oxo-1,3-diazospiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-methyl-[1,1'-biphenyl]-2-sulfonamide
[0936] The synthesis method of Example 54 was based on the synthesis method of Example 33, and Example 54-4 was used as the raw material to obtain the title compound Example 54 (27 mg, 33.5%).
[0937] MS m / z(ESI):569.2[M+1] + .
[0938] 1H NMR (400MHz, DMSO) δ7.97 (dd, J=6.0, 3.3Hz, 1H), 7.50–7.19 (m, 2H), 6.96 (d, J= 7.8Hz,1H),6.92–6.83(m,2H),6.76(d,J=7.7Hz,1H),4.65(s,2H),2.37(t,J=7. 5Hz,2H),2.09(d,J=15.8Hz,3H),1.84(d,J=6.0Hz,9H),1.68(d,J=6.8Hz,2H),1 .53(dt,J=15.1,7.4Hz,2H), 1.31(dt,J=7.1,6.0Hz,2H), 0.84(t,J=7.3Hz,3H).
[0939] Example 55
[0940] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-propoxy-[1,1'-biphenyl]-2-sulfonamide
[0941]
[0942] The synthesis method of Example 55 was similar to that of Example 41, except that benzyl bromide was replaced by iodopropane and 2-bromo-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)benzenesulfonamide was replaced by 2-bromo-N-(4-chloro-5-methylisoxazol-3-yl)-N-(methoxymethyl)benzenesulfonamide to give Example 55 (27 mg, white solid) in a yield of 40.9%.
[0943] MS m / z(ESI):613.1[M+1] + .
[0944] 1H NMR(400MHz, DMSO-d6)δ10.90(s,1H),8.04(dd,J=7.8,1.5Hz,1H),7.62–7.47(m,2H),7.16(d,J=7.5H z,1H),7.04(d,J=7.7Hz,1H),6.73(s,1H),6.66–6.60(m,1H),4.70(s,2H),3.70(dt,J=12.9,6.8Hz,2H ),2.38(t,J=7.5Hz,2H),2.27(s,3H),1.86(q,J=7.7,6.8Hz,6H),1.73–1.65(m,2H),1.52(p,J=7.5Hz ,2H),1.39(tt,J=9.6,4.7Hz,2H),1.29(q,J=7.4Hz,2H),0.83(t,J=7.3Hz,3H),0.68(t,J=7.4Hz,3H).
[0945] Example 56
[0946] 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4-chloro-5-cyclopropyl-isoxazol-3-yl)benzenesulfonamide
[0947]
[0948] The synthesis method of Example 56 was similar to that of Example 1, except that 4-chloro-5-cyclopropylisoxazolamine was used instead of 4,5-dimethylisoxazolamine to obtain Example 56 (29.5 mg, white solid) in a yield of 22.4%.
[0949] MS m / z(ESI):638.8[M+1] + .
[0950] 1H NMR (400MHz, DMSO-d6) δ7.96-7.94(m,1H),7.36-7.31(m,2H),7.08(s,1H),6.97(d,J=7. 6Hz,1H),6.93-6.89(m,2H),4.70(s,2H),4.05(d,J=13.2Hz,1H),3.91(d,J=13.2Hz,1H), 3.23-3.15(m,2H),2.37(t,J=7.6Hz,2H),1.91-1.81(m,7H),1.73-1.64(m,2H),1.57-1.4 9(m,2H),1.33-1.27(m,2H),1.01(t,J=7.2Hz,3H),0.95-0.90(m,2H),0.85-0.82(m,5H).
[0951] Example 57
[0952] 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4-chloro-3-ethyl-isoxazol-5-yl)benzenesulfonamide
[0953]
[0954] The synthesis method of Example 57 was similar to that of Example 1, except that 4-chloro-3-ethylisoxazolamine was used instead of 4,5-dimethylisoxazolamine to obtain Example 57 (3.3 mg, white solid) in a yield of 2.5%.
[0955] MS m / z(ESI):627.0[M+1] + .
[0956] 1 H NMR(400MHz,DMSO-d6)δ8.01-7.99(m,1H),7.43-7.38(m,2H),7.10(s,1H),7.00-6.96(m ,2H),6.93-6.91(m,1H),4.71(s,2H),4.04(d,J=12.8Hz,1H),3.92(d,J=13.2Hz,1H),3.2 4-3.16(m,2H),2.38-3.31(m,4H),1.91-1.81(m,6H),1.72-1.65(m,2H),1.55-1.49(m,2H ),1.32-1.27(m,2H),1.07(d,J=7.6Hz,3H),1.00(t,J=7.2Hz,3H),0.83(t,J=7.2Hz,3H).
[0957] Example 58
[0958] 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(3-ethyl-4-methyl-isoxazol-5-yl)benzenesulfonamide
[0959]
[0960] The synthesis method of Example 58 was similar to that of Example 1, except that 4-chloro-3-ethylisoxazolamine was used instead of 4,5-dimethylisoxazolamine to obtain Example 58 (14.1 mg, white solid) in a yield of 11.1%.
[0961] MS m / z(ESI):607.0[M+1] + .
[0962] 1 H NMR (400MHz, DMSO-d6) δ8.00-7.98(m,1H),7.39-7.33(m,2H),7.08(s,1H),6.99(d,J=8.0Hz, 1H),6.96-6.90(m,2H),4.71(s,2H),4.01(d,J=13.2Hz,1H),3.92(d,J=13.2Hz,1H),3.22-3. 15(m,2H),2.36(t,J=7.2Hz,2H),2.28(q,J=7.6Hz,2H),1.93-1.80(m,6H),1.73-1.65(m,2H) ,1.55-1.51(m,2H),1.43(s,3H),1.32-1.27(m,2H),1.06-0.99(m,6H),0.83(t,J=7.2Hz,3H).
[0963] Example 59
[0964] N-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl)-4'-(((4-ethyl-5-(hydroxymethyl)-2-propyl-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-sulfonamide
[0965]
[0966]
[0967] first step
[0968] Preparation of methyl 1-((2'-(N-(4-chloro-5-methylisoxazol-3-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-ethyl-2-propyl-1H-imidazole-5-carboxylate
[0969] Example 59-1 (500 mg, 0.8 mmol) (prepared according to WO2010114801A1) was dissolved in MeCN (15 mL). Potassium carbonate (220 mg, 1.6 mmol) and methyl 4-ethyl-2-propyl-1H-imidazole-5-carboxylate (156 mg, 0.8 mmol) were added at room temperature. The reaction mixture was stirred at 70°C for 3 h. The reaction mixture was concentrated to afford the crude product 59-2 (500 mg, white solid) in an 85.0% yield.
[0970] MS m / z(ESI):745.2[M+1] + .
[0971] Step 2
[0972] Preparation of methyl 1-((2'-(N-(4-chloro-5-methylisoxazol-3-yl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-ethyl-2-propyl-1H-imidazole-5-carboxylate
[0973] 59-2 (500 mg, 0.67 mmol) was dissolved in HCl / dioxane (10 mL), and the reaction solution was stirred at 70°C for 3 h. The reaction solution was concentrated to afford 59-3 (400 mg, white solid) in a yield of 97.0%.
[0974] MS m / z(ESI):615.2[M+1] + .
[0975] Step 3
[0976] Preparation of 4-fluoro-5-methylisoxazol-3-amine-2-bromo-N-(4-fluoro-5-methylisoxazol-3-yl)benzenesulfonamide
[0977] Compound 59-3 (0.1 g, 0.16 mmol) was dissolved in 10 mL of THF, and lithium borohydride (10 mg, 0.48 mmol) was added. The reaction mixture was stirred at 25°C for 4 hours. The reaction solution was extracted with ethyl acetate, and the organic phase was concentrated. The crude product was used to obtain 59 (50 mg, white solid) in a 52.0% yield.
[0978] MS m / z(ESI):587.2[M+1]+ .
[0979] Example 60
[0980] 1-((2'-(N-(4-chloro-5-methylisoxazol-3-yl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-ethyl-2-propyl-1H-imidazole-5-carboxamide
[0981]
[0982]
[0983] first step
[0984] Preparation of 1-((2'-(N-(4-chloro-5-methylisoxazol-3-yl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-ethyl-2-propyl-1H-imidazole-5-carboxylic acid
[0985] Example 59-3 (200 mg, 0.33 mmol) and sodium hydroxide (26 mg, 0.65 mmol) were dissolved in a mixture of THF (8 mL) and H₂O (8 mL) and stirred at 30°C for 4 hours. Aqueous hydrochloric acid (1 M, 14 mL) was added, and the mixture was extracted with dichloromethane (2 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to afford the desired product 60-1 (120 mg, white solid) in a 61.0% yield.
[0986] MS m / z(ESI):601.1[M+1] + .
[0987] Step 2
[0988] Preparation of 1-((2'-(N-(4-chloro-5-methylisoxazol-3-yl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-ethyl-2-propyl-1H-imidazole-5-carboxamide
[0989] Example 60-1 (100 mg, 0.17 mmol) and ammonium chloride (18 mg, 0.34 mmol) were dissolved in DMF (5 mL). 2-(7-Azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (129 mg, 0.34 mmol) and diisopropylethylamine (44 mg, 0.34 mmol) were added. The reaction solution was stirred at 25°C for 1 h. Saturated brine (10 mL) was added, and the mixture was extracted with ethyl acetate (2 x 10 mL). The organic phases were combined, dried, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to obtain the desired product 60 (50 mg, white solid) in a 50.0% yield.
[0990] MS m / z(ESI):600.2[M+1] + .
[0991] Example 61
[0992] 1-((2'-(N-(4-chloro-5-methylisoxazol-3-yl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-ethyl-N-methyl-2-propyl-1H-imidazole-5-carboxamide
[0993]
[0994] The synthesis method of Example 61 was similar to that of Example 60, except that methylamine was substituted for ammonium chloride to obtain Example 61 (15 mg, 46.2% yield). MS m / z (ESI): 614.2 [M+1] + .
[0995] Example 62
[0996] N-(4-chloro-5-methylisoxazol-3-yl)-4'-((4-ethyl-5-(hydroxymethyl)-2-propyl-1H-imidazol-1-yl)methyl)-2'-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[0997]
[0998] The synthesis method of Example 62 can refer to the synthesis method of Example 59.
[0999] MS m / z(ESI):573.2[M+1] + .
[1000] Example 63
[1001] 1-((2'-(N-(4-chloro-5-methylisoxazol-3-yl)sulfamoyl)-2-(methoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-ethyl-2-propyl-1H-imidazole-5-carboxamide
[1002]
[1003] The synthesis method of Example 63 refers to the synthesis method of Example 60.
[1004] MS m / z(ESI):586.2[M+1] + .
[1005] Example 64
[1006] 1-((2'-(N-(4-chloro-5-methylisoxazol-3-yl)sulfamoyl)-2-(methoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-ethyl-N-methyl-2-propyl-1H-imidazole-5-carboxamide
[1007]
[1008] The synthesis method of Example 64 can refer to the synthesis method of Example 60.
[1009] MS m / z(ESI):600.2[M+1] + .
[1010] Example 65
[1011] 4'-((2'-butyl-5'-oxaspiro[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1012]
[1013] The synthesis method of Example 65 refers to the synthesis method of Example 2, except that 2-butyl-1,3-diazaspiro-[4,4]non-1-ene-4-one is replaced by 2'-butylspiro[bicyclo[3.1.0]hexane-3,4'-imidazole]-5'(1'H)-one to synthesize Example 65 (14 mg, yield 46%).
[1014] MS m / z(ESI):625.22[M+1] + .
[1015] Example 66
[1016] N-(4-chloro-5-methylisoxazol-3-yl)-4'-((2-(3-chloropropyl)-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1017]
[1018] The synthesis method of Example 66 refers to the synthesis method of Example 2, and 2-chlorobutyl-1,3-diazaspiro-[4,4]non-1-en-4-one is replaced by 2-butyl-1,3-diazaspiro-[4,4]non-1-en-4-one to synthesize Example 66 (6 mg, yield 15%).
[1019] MS m / z(ESI):633.2[M+1] + .
[1020] Example 67
[1021] N-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl)-4'-(((2-(2-(methylthio)ethyl)-4-oxo-1,3-diazaspiro][4.4]non-1-en-3-yl)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1022]
[1023] The synthesis method of Example 67 refers to the synthesis method of Example 59, and 2-(2-(methylthio)ethyl)-1,3-diazaspiro-[4,4]non-1-en-4-one is used instead of 2-butyl-1,3-diazaspiro-[4,4]non-1-en-4-one to synthesize Example 67 (16 mg, yield 21%).
[1024] MS m / z(ESI):631.2[M+1] + .
[1025] Example 68
[1026] 4'-((2-2--4--4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1027]
[1028] The synthesis method of Example 68 was similar to that of Example 59, except that 2-butyl-1,3-diazaspiro[4.5]dec-1-en-4-one was substituted for 2-butyl-1,3-diazaspiro[4,4]non-1-en-4-one to synthesize Example 68 (21 mg, yield 52%).
[1029] MS m / z(ESI):627.2[M+1] + .
[1030] 1 H NMR (400MHz, DMSO-d6) δ8.03(dd,J=7.5,1.8Hz,1H),7.59(t,J=7.7Hz,2H),7.16(d,J=9 .5Hz,2H),7.00(s,2H),4.73(s,2H),4.04(q,J=13.1Hz,2H),3.26–3.16(m,2H),2.35(d, J=7.6Hz,2H),2.29(s,3H),1.68(dq,J=16.3,8.3,6.4Hz,7H),1.52(q,J=7.5Hz,2H),1.4 0(d,J=12.1Hz,3H),1.29(q,J=7.4Hz,2H),1.00(t,J=7.0Hz,3H),0.82(t,J=7.3Hz,3H).
[1031] Example 69
[1032] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-((trifluoromethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1033]
[1034]
[1035] first step
[1036] Preparation of methyl 2-bromo-5-(bromomethyl)benzoate
[1037] To a solution of Example 69-1 (10 g, 43.65 mmol) in MeCN (80 mL) was added bromosuccinimide (8.16 g, 45.84 mmol) under nitrogen, and the mixture was stirred overnight at 25°C for 12 hours. The reaction solution was concentrated, diluted with 100 mL of ethyl acetate, and washed three times with 50 mL of water. The organic phases were combined, dried, and concentrated. The residue was purified by silica gel column chromatography with eluent System B to afford Example 69-2 (10 g, colorless liquid) in a yield of 74.3%.
[1038] 1 H NMR (400MHz, Chloroform-d) δ7.82(d,J=2.3Hz,1H),7.64(d,J=8.3Hz,1H),7.36(dd,J=8.3,2.4Hz,1H),4.44(s,2H),3.94(s,3H).
[1039] Step 2
[1040] Preparation of (2-bromo-5-(bromomethyl)phenyl)methanol
[1041] To a solution of Example 69-2 (10 g, 31.06 mmol) in DCM was added diisobutylaluminum hydride (1 M, 62.11 mL) under nitrogen at 0°C, and the mixture was stirred at 20°C for 1 hour. The reaction mixture was quenched with ice water (200 mL) and extracted with dichloromethane (100 mL x 3). The organic phases were combined, dried, and concentrated to afford Example 69-3 (6.0 g, white solid), which was used directly in the next step.
[1042] Step 3
[1043] Preparation of 3-(4-bromo-3-(hydroxymethyl)benzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[1044] To a solution of Example 69-3 (1.25 g, 4.46 mmol) and 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride (1.03 g, 4.46 mmol) in MeCN (15 mL) was added potassium carbonate (1.23 g, 8.93 mmol), and the mixture was stirred at 80°C for 12 hours. The reaction solution was quenched with water (10 mL) and extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated. The residue was purified by silica gel column chromatography with eluent System B to afford Example 69-4 (1.0 g, white solid) in a 56.9% yield.
[1045] MS m / z(ESI):493.0[M+1] + .
[1046] Step 4
[1047] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(hydroxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1048] preparation
[1049] Example 69-4 (400 mg, 1.05 mmol), (2-(N-(4-chloro-5-methylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)phenyl)boronic acid (380 mg, 1.06 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (85 mg, 105.1 μmol), K2CO3 (285 mg, 2.10 mmol), 1'4-Dioxane (5 mL) and H2O (1 mL) were added to the reactor. The mixture was stirred at 100°C under nitrogen for 12 hours. After the reaction solution was cooled, quenched with 8 mL of water and extracted with ethyl acetate (10 mL*3). The organic phases were combined, dried, and concentrated. The residue was purified by silica gel column chromatography with eluent System B to give Example 69-5 (500 mg, light brown solid) in a yield of 75.3%.
[1050] MS m / z(ESI):715.3[M+1] + .
[1051] Step 5
[1052] 2'-(Bromomethyl)-4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-
[1053] Preparation of (4-chloro-5-methylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1054] To a solution of Example 69-5 (500 mg, 0.79 mmol) in DCM (10 mL) was added carbon tetrabromide (525 mg, 1.58 mmol) and triphenylphosphine (310 mg, 1.18 mmol) under nitrogen at 0°C, and the mixture was stirred at 20°C for 1 hour. The reaction mixture was quenched with water (10 mL) and extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated. The residue was purified by silica gel column chromatography with eluent System B to afford Example 69-6 (520 mg, light yellow solid) in a 95.3% yield.
[1055] MS m / z(ESI):778.2[M+1] + .
[1056] Step 6
[1057] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(((trifluoromethoxy)methyl)-N-((2-(trimethylsilyl)ethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1058] Trifluoromethyl trifluoromethanesulfonate (72 mg, 0.33 mmol) and silver fluoride (48 mg, 0.33 mmol) were dissolved in acetonitrile (5 mL). The reaction mixture was cooled to -30°C and stirred for 2 h. Example 69-6 (125 mg, 0.16 mmol) dissolved in 5 mL of acetonitrile was then added to the reaction mixture, which was stirred at room temperature for 24 h. Saturated brine (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (3 x 10 mL). The organic phases were combined, dried, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford Example 69-7 (85 mg, 69.1%).
[1059] MS m / z(ESI):783.2[M+1] + .
[1060] Step 7
[1061] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-((trifluoromethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1062] The synthesis method of Example 69 was based on the synthesis method of Example 33. Example 69-7 was used as the starting material to obtain the title compound Example 69 (27 mg, 28.5%).
[1063] MS m / z(ESI):653.2[M+1] + .
[1064] Example 70
[1065] 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(cyclobutyloxymethyl)phenyl]-N-(4-chloro-5-methyl-isoxazol-3-yl)benzenesulfonamide
[1066]
[1067] first step
[1068] 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(cyclobutyloxymethyl)phenyl]-N-(4-chloro-5-methyl-isoxazol-3-yl)-N-(2-trimethylsilyloxymethyl)benzenesulfonamide
[1069] Preparation
[1070] Dissolve cyclobutanol (46 mg, 0.642 mmol) in N,N-dimethylformamide (5 mL), add sodium hydride (25 mg, 60% wt, 0.642 mmol), and react at room temperature for 30 minutes. Add Example 69-6 (100 mg, 0.128 mmol), and react at room temperature for 1 hour. Pour the reaction mixture into 30 mL of ice water and extract with ethyl acetate (30 mL x 2). The combined organic phases are washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to afford Example 70-1 (90 mg, yellow solid) in a 91.0% yield, which is used directly in the next step.
[1071] MS m / z(ESI):769.3[M+1] + .
[1072] Step 2
[1073] Preparation of 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(cyclobutyloxymethyl)phenyl]-N-(4-chloro-5-methyl-isoxazol-3-yl)benzenesulfonamide
[1074] Example 70-1 (90 mg, 0.117 mmol) was dissolved in 4 M hydrochloric acid in dioxane (4 mL) and heated to 60°C for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by reverse-phase HPLC to afford Example 70 (35.5 mg, white solid) in a 48.6% yield.
[1075] MS m / z(ESI):639.2[M+1] + .
[1076] Example 71
[1077] 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(oxoalkane-3-oxymethyl)phenyl]-N-(4-chloro-5-methyl-isoxazol-3-yl)benzenesulfonamide
[1078]
[1079] first step
[1080] 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(oxoalkane-3-oxymethyl)phenyl]-N-(4-chloro-5-methyl-isoxazol-3-yl)-N-(2-trimethylsilyloxymethyl)benzenesulfonamide
[1081] Dissolve oxetan-3-ol (48 mg, 0.642 mmol) in N,N-dimethylformamide (5 mL), add sodium hydride (26 mg, 60% wt, 0.642 mmol), and react at room temperature for 30 minutes. Add Example 69-6 (100 mg, 0.128 mmol), and react at room temperature for 1 hour. Pour the reaction mixture into 30 mL of ice water and extract with ethyl acetate (30 mL x 2). The combined organic phases are washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to afford Example 71-1 (75 mg, yellow solid) in a 75.7% yield, which is used directly in the next step.
[1082] MS m / z(ESI):771.3[M+1] + .
[1083] Step 2
[1084] 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(oxoalkane-3-oxymethyl)phenyl]-N-(4-chloro-5-methyl-isoxazol-3-yl)benzenesulfonamide
[1085] Example 71-1 (75 mg, 0.097 mmol) was dissolved in 1 M tetrabutylammonium fluoride in tetrahydrofuran (4 mL) and heated to 60°C for 2 hours. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and 40 mL of ethyl acetate was added. The mixture was washed sequentially with water (40 mL x 2) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting crude product was subjected to reverse-phase HPLC analysis to afford Example 71 (12.6 mg, white solid) in a 20.3% yield.
[1086] MS m / z(ESI):641.2[M+1] + .
[1087] Example 72
[1088] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(isopropoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1089]
[1090] first step
[1091] Preparation of 4'-((2-butyl-4-oxo-1,3-diazospiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(isopropoxymethyl)-N-(((2-(trimethylsilyl)ethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1092] Sodium hydroxide (13 mg, 0.32 mmol) was added to isopropanol (2 mL), and the reaction solution was stirred at room temperature for 1 h. Subsequently, Example 69-6 (125 mg, 0.16 mmol) dissolved in N,N-dimethylformamide (2 mL) was added to the reaction solution, and the reaction solution was stirred at 50°C for 16 h. Saturated sodium chloride (10 mL) was added to the reaction solution, and the solution was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate system) to obtain Example 72-1 (610 mg, 75.81% yield).
[1093] MS m / z(ESI):757.3[M+1] + .
[1094] Step 2
[1095] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-
[1096] Preparation of methylisoxazol-3-yl)-2'-(isopropoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1097] The synthesis method of Example 72 was based on the synthesis method of Example 71, and Example 72-1 was used as the raw material to obtain the title compound Example 72 (31 mg, 36.5%).
[1098] MS m / z(ESI):627.2[M+1] + .
[1099] Example 73
[1100] N-(4-chloro-5-methylisoxazol-3-yl)-4'-((4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-((pyridin-2-oxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1101]
[1102] first step
[1103] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-N-(methoxymethyl)-2'-((pyridin-2-oxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1104] To a solution of Example 69-6 (100 mg, 144.51 μmol) in DMF (2 mL) were added potassium carbonate (40 mg, 289.02 μmol) and 2-hydroxypyridine (27 mg, 289.02 μmol), and the mixture was stirred at 80°C for 5 hours. The reaction mixture was quenched with water (10 mL) and extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated. The residue was purified by silica gel column chromatography with eluent System B to afford the title product 73-1 (52 mg, light yellow solid) in a 50.8% yield.
[1105] MS m / z(ESI):706.2[M+1] + .
[1106] Step 2
[1107] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-((pyridin-2-oxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1108] The synthesis method of Example 73 was based on the synthesis method of Example 71. Example 73-1 was used as the raw material to obtain the title compound Example 73 (18 mg, white solid) with a yield of 36.9%.
[1109] MS m / z(ESI):662.1[M+1] + .
[1110] Example 74
[1111] 2'-((1H-imidazol-1-yl)methyl)-4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1112]
[1113] The synthesis method of Example 74 was based on the synthesis method of Example 73-1, except that imidazole was used instead of 2-hydroxypyridine to obtain Example 74 (26 mg, white solid) with a yield of 56.3%.
[1114] MS m / z(ESI):635.2[M+1] + .
[1115] Example 75
[1116] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-((4-oxo-5-azaspiro[2.4]hept-5-yl)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1117]
[1118] The synthesis method of Example 75 was based on the synthesis method of Example 73-1, except that imidazole was used instead of 2-hydroxypyridine to obtain Example 75 (35 mg, white solid) with a yield of 45.2%.
[1119] MS m / z(ESI):678.2[M+1] + .
[1120] Example 76
[1121] N-[[5-[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-[(4-chloro-5-methyl-isoxazol-3-yl)sulfamoyl]phenyl]phenyl]methyl]-N,1-dimethyl-cyclopropanecarboxamide
[1122]
[1123]
[1124] first step
[1125] Preparation of N,1-dimethylcyclopropanecarboxamide
[1126] 1-Methylcyclopropane-1-carboxylic acid (1.0 g, 10.0 mmol) was dissolved in anhydrous dichloromethane (20 mL), and N,N-dimethylformamide (74 mg, 1.0 mmol) was added. Oxalyl chloride (1.91 g, 15.0 mmol) was added dropwise and allowed to react at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure and redissolved in anhydrous dichloromethane (20 mL). Triethylamine (3.03 g, 30.0 mmol) and methylamine hydrochloride (1.35 g, 20.0 mmol) were added and allowed to react at room temperature for 2 hours. The reaction solution was diluted with 50 mL of dichloromethane, washed sequentially with water (50 mL) and saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography (methanol / dichloromethane = 0-10%) to obtain Example 76-1 (730 mg, white solid) in a yield of 64.6%.
[1127] MS m / z(ESI):114.1[M+1] + .
[1128] Step 2
[1129] Preparation of N-[[5-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-[(4-chloro-5-methyl-isoxazol-3-yl)-(2-trimethylsilyloxymethyl)sulfamoyl]phenyl]phenyl]methyl]-N,1-dimethyl-cyclopropanecarboxamide
[1130] Example 76-1 (73 mg, 0.642 mmol) was dissolved in N,N-dimethylformamide (5 mL), and sodium hydride (26 mg, 60% wt, 0.642 mmol) was added. The mixture was allowed to react at room temperature for 30 minutes. Example 69-6 (100 mg, 0.128 mmol) was added and allowed to react at room temperature for 1 hour. The reaction mixture was poured into 30 mL of ice water and extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain Example 76-2 (105 mg, yellow solid). The crude product was used directly in the next step.
[1131] MS m / z(ESI):810.3[M+1] + .
[1132] Step 3
[1133] N-[[5-[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-[(4-chloro-5-methyl-isoxazol-3-yl)sulfamoyl]phenyl]phenyl]methyl]-N,1-dimethyl-cyclopropanecarboxamide
[1134] Example 76-2 (105 mg, 0.130 mmol) was dissolved in 4 M hydrochloric acid in dioxane (4 mL) and heated to 60°C for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by reverse-phase HPLC to afford Example 76 (21.6 mg, white solid) in a 24.4% yield.
[1135] MS m / z(ESI):680.3[M+1] + .
[1136] Example 77
[1137] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(cyanomethyl)-[1,1'-biphenyl]-2-sulfonamide
[1138]
[1139] first step
[1140] Preparation of 4'-((2-butyl-4-oxo-1,3-diazospiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(cyanomethyl)-N-(((2-(trimethylsilyl)ethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1141] Trimethylsilyl cyanide (48 mg, 0.48 mmol) and Example 69-6 (125 mg, 0.16 mmol) were dissolved in CH3CN (5 mL), and then tetrabutylammonium fluoride (1 M, 0.48 mL) was added to the reaction solution. The reaction solution was stirred at room temperature for 2 h. Saturated sodium chloride (10 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate system) to obtain the target molecule Example 77-1 (95 mg, 81.9% yield).
[1142] MS m / z(ESI):724.2[M+1] + .
[1143] Step 2
[1144] Preparation of 4'-((2-butyl-4-oxo-1,3-diazospiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(cyanomethyl)-[1,1'-biphenyl]-2-sulfonamide
[1145] The synthesis method of Example 77 was based on the synthesis method of Example 52, and Example 77-1 was used as the raw material to obtain the title compound Example 77 (22 mg, 28.5%).
[1146] MS m / z(ESI):594.2[M+1] + .
[1147] Example 78
[1148] 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4-chloro-5-methylisoxazol-3-yl)sulfamoyl)-[1,1'-biphenyl]-2-yl)-N,N-dimethylacetamide
[1149]
[1150] first step
[1151] Preparation of 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4-chloro-5-methylisoxazol-3-yl)sulfamoyl)-[1,1'-biphenyl]-2-yl)acetic acid
[1152] Water (4 mL), concentrated sulfuric acid (4 mL) and glacial acetic acid (4 mL) were added to Example 77-1 (200 mg, 0.28 mmol), and the reaction solution was stirred at 100°C for 1 h. Water (10 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate system) to obtain the target molecule Example 78-1 (82 mg, 48.5% yield).
[1153] MS m / z(ESI):613.2[M+1] + .
[1154] Step 2
[1155] Preparation of 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4-chloro-5-methylisoxazol-3-yl)sulfamoyl)-[1,1'-biphenyl]-2-yl)-N,N-dimethylacetamide
[1156] Example 78-1 (100 mg, 0.16 mmol), dimethylamine hydrochloride (26 mg, 0.32 mmol), and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (122 mg, 0.32 mmol) were dissolved in dichloromethane (5 mL). Triethylamine (33 mg, 0.32 mmol) was then added to the reaction solution, and the reaction solution was stirred at room temperature for 1 h. Water (10 mL) was added to the reaction solution, and the solution was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product, which was then purified by column chromatography (petroleum ether / ethyl acetate system) to obtain the target molecule Example 78 (32 mg, 33.5% yield).
[1157] MS m / z(ESI):640.2[M+1] + .
[1158] Example 79
[1159] 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4-chloro-5-methylisoxazol-3-yl)sulfamoyl)-[1,1'-biphenyl]-2-yl)-N,N-diethylacetamide
[1160]
[1161] first step
[1162] Preparation of 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4-chloro-5-methylisoxazol-3-yl)sulfamoyl)-[1,1'-biphenyl]-2-yl)-N,N-diethylacetamide
[1163] Example 78-1 (100 mg, 0.16 mmol), diethylamine hydrochloride (35 mg, 0.32 mmol), and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (122 mg, 0.32 mmol) were dissolved in dichloromethane (5 mL). Triethylamine (33 mg, 0.32 mmol) was then added to the reaction solution, and the reaction solution was stirred at room temperature for 1 h. Water (10 mL) was added to the reaction solution, and the solution was extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and concentrated to obtain a crude product, which was then purified by column chromatography (petroleum ether / ethyl acetate system) to obtain the target molecule Example 79 (32 mg, 33.5% yield).
[1164] MS m / z(ESI):668.2[M+1] + .
[1165] Example 82
[1166] N-[[5-[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-[(4-chloro-5-methyl-isoxazol-3-yl)sulfamoyl]phenyl]phenyl]methyl]-N,1-dimethyl-cyclopropanecarboxamide
[1167]
[1168]
[1169] first step
[1170] Preparation of 2-(2-bromo-5-methylphenyl)propanol
[1171] Methyl 2-bromo-5-methylbenzoate (3.0 g, 13.1 mmol) was dissolved in anhydrous tetrahydrofuran (50 mL). The mixture was cooled to -78°C under nitrogen. A 3M solution of methylmagnesium bromide in tetrahydrofuran (17.5 mL, 52.4 mmol) was added dropwise and the temperature was slowly warmed to room temperature for 3 hours. The reaction mixture was cooled to 0°C and quenched by the addition of saturated ammonium chloride. The mixture was then extracted with ethyl acetate (100 mL x 2). The organic phases were combined, washed sequentially with water (100 mL) and saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The mixture was then purified by silica gel column chromatography (ethyl acetate / petroleum ether = 0-30%) to afford Example 82-1 (2.2 g, white solid) in a yield of 73.3%.
[1172] 1 H NMR (400MHz, CDCl3) δ7.51-7.48(m,2H),6.96-6.91(m,1H),2.63(s,1H),2.33(s,3H),1.76(s,6H).
[1173] Step 2
[1174] Preparation of 1-bromo-2-(2-ethoxypropan-2-yl)-4-toluene
[1175] Example 82-1 (2.2 g, 9.61 mmol) was dissolved in anhydrous tetrahydrofuran (30 mL), and sodium hydride (576 mg, 60% wt, 14.4 mmol) was added. The mixture was allowed to react at room temperature for 1 hour. Ethyl iodide (2.25 g, 14.4 mmol) was added, and the mixture was heated to 80°C for 4 hours. The reaction mixture was cooled to room temperature, poured into 100 mL of ice water, and extracted with ethyl acetate (80 mL x 2). The organic phases were combined, washed sequentially with water (80 mL) and saturated sodium chloride solution (80 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The mixture was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 0-20%) to afford Example 82-2 (1.4 g, white solid) in a yield of 54.9%.
[1176] MS m / z(ESI):257.1[M+1] + .
[1177] Step 3
[1178] Preparation of 1-bromo-4-(bromomethyl)-2-(2-ethoxypropan-2-yl)benzene
[1179] Example 82-2 (1.4 g, 5.47 mmol) was dissolved in carbon tetrachloride (30 mL), and azobisisobutyronitrile (90 mg, 0.547 mmol) and N-bromosuccinimide (1.07 g, 6.02 mmol) were added. The mixture was refluxed under nitrogen for 4 hours. The reaction solution was cooled to room temperature, washed sequentially with water (30 mL) and saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 0-30%) to obtain Example 82-3 (850 mg, yellow solid) in a yield of 46.5%.
[1180] MS m / z(ESI):335.0[M+1] + .
[1181] Step 4
[1182] Preparation of 3-(4-bromo-3-(2-ethoxypropan-2-yl)benzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[1183] Dissolve 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one (739 mg, 3.81 mmol) in N,N-dimethylformamide (10 mL), cool to 0°C, add sodium hydride (152 mg, 60% wt, 3.81 mmol), and warm to room temperature for 30 minutes. Add Example 82-3 (850 mg, 2.54 mmol) and react at room temperature for 2 hours. The reaction mixture was cooled to 0°C, and water was slowly added dropwise to quench the reaction. The pH was adjusted to approximately 6 with dilute hydrochloric acid, and extracted with ethyl acetate (50 mL x 2). The organic phases were combined, washed sequentially with water (50 mL) and saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (methanol / dichloromethane = 0-10%) to afford Example 82-4 (680 mg, yellow solid) in a 59.7% yield.
[1184] MS m / z(ESI):449.2[M+1] + .
[1185] Step 5
[1186] 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(1-ethoxy-1-methyl-ethyl)phenyl]-N-(4-chloro-5-methyl-isoxazol-3-yl)-N-(2-trimethylsilyloxymethyl)benzene
[1187] Preparation of sulfonamide
[1188] Example 82-4 (100 mg, 0.223 mmol) was dissolved in 1,4-dioxane (2 mL) and water (0.5 mL). (2-(N-(4-chloro-5-methylisoxazol-3-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)sulfamoyl)phenyl)boronic acid (149 mg, 0.334 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (16 mg, 0.0223 mmol), and sodium carbonate (35 mg, 0.334 mmol) were added. The atmosphere was purged with nitrogen three times and microwaved at 100°C for 1 hour. The reaction solution was poured into 30 mL of water and extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (methanol / dichloromethane = 0-10%) to obtain Example 82-5 (90 mg, yellow solid) with a yield of 52.4%.
[1189] MS m / z(ESI):771.3[M+1] + .
[1190] Step 6
[1191] Preparation of N-[[5-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-[(4-chloro-5-methyl-isoxazol-3-yl)sulfamoyl]phenyl]phenyl]methyl]-N,1-dimethyl-cyclopropanecarboxamide
[1192] Example 82-5 (90 mg, 0.117 mmol) was dissolved in 4 M hydrochloric acid in dioxane (4 mL) and heated to 60°C for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by reverse-phase HPLC to afford Example 82 (39.5 mg, white solid) in a 52.7% yield.
[1193] MS: m / z(ESI):641.3[M+1] + .
[1194] Example 83
[1195] 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(1-ethoxycyclopropyl)phenyl]-N-(4-chloro-5-methyl-isoxazol-3-yl)benzenesulfonamide
[1196]
[1197] first step
[1198] Preparation of 2-bromo-N-methoxy-N,5-dimethylbenzamide
[1199] Dissolve 2-bromo-5-methylbenzoic acid (3.0 g, 14.0 mmol) in anhydrous dichloromethane (50 mL). Add N,N-dimethylformamide (103 mg, 1.40 mmol). Cool to 0°C, then add oxalyl chloride (3.54 g, 27.9 mmol) dropwise. Allow to react at room temperature for 3 hours. Concentrate the reaction mixture under reduced pressure and redissolve in anhydrous dichloromethane (50 mL). Add triethylamine (4.23 g, 41.9 mmol) and dimethylhydroxylamine hydrochloride (2.72 g, 27.9 mmol). Allow to react at room temperature for 2 hours. Pour the reaction mixture into 100 mL of water and extract with dichloromethane (100 mL x 2). The organic phases were combined, washed with saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 0-60%) to obtain Example 83-1 (3.2 g, white solid) with a yield of 88.6%.
[1200] MS m / z(ESI):258.0[M+1] + .
[1201] Step 2
[1202] Preparation of 1-(2-bromo-5-methylphenyl)ethan-1-one
[1203] Example 83-1 (3.2 g, 12.4 mmol) was dissolved in anhydrous tetrahydrofuran (50 mL), cooled to -78°C under nitrogen, and 3M methylmagnesium bromide solution in tetrahydrofuran (6.2 mL, 18.6 mmol) was added dropwise. The mixture was allowed to warm to room temperature and allowed to react for 3 hours. The reaction mixture was cooled to 0°C, quenched by the dropwise addition of saturated ammonium chloride solution, and extracted with ethyl acetate (60 mL x 2). The organic phases were combined, washed sequentially with water (60 mL) and saturated sodium chloride solution (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The mixture was then chromatographed on a silica gel column (ethyl acetate / petroleum ether = 0-60%) to afford Example 83-2 (2.1 g, white solid) in a yield of 79.5%.
[1204] MS m / z(ESI):213.0[M+1] + .
[1205] Step 3
[1206] Preparation of 1-bromo-2-(1-ethoxyvinyl)-4-toluene
[1207] Example 83-2 (2.1 g, 9.86 mmol) was dissolved in anhydrous tetrahydrofuran (30 mL), and potassium tert-butoxide (1.66 g, 14.8 mmol) was added. The mixture was allowed to react at room temperature for 1 hour. A 1M solution of triethyloxonium tetrafluoroborate in dichloromethane (14.8 mL, 14.8 mmol) was added, and the mixture was allowed to react at room temperature for 2 hours. The reaction mixture was poured into 100 mL of water and extracted with ethyl acetate (60 mL x 2). The organic phases were combined, washed sequentially with water (60 mL) and saturated sodium chloride solution (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 0-60%) to afford Example 83-3 (1.7 g, white solid) in a yield of 71.5%.
[1208] MS m / z(ESI):242.1[M+1] + .
[1209] Step 4
[1210] Preparation of 1-bromo-2-(1-ethoxycyclopropyl)-4-toluene
[1211] Example 83-3 (1.7 g, 7.05 mmol) and diiodomethane (2.83 g, 10.6 mmol) were dissolved in dichloromethane (30 mL). The mixture was cooled to -78°C under nitrogen. A 1M solution of diethylzinc in n-hexane (10.6 mL, 10.6 mmol) was added dropwise. The mixture was allowed to react at -78°C for 1 hour, then slowly warmed to room temperature for 4 hours. The reaction solution was slowly poured into 100 mL of ice water and extracted with dichloromethane (100 mL x 2). The organic phases were combined, washed sequentially with water (100 mL) and saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 0-30%) to afford Example 83-4 (800 mg, white solid) in a yield of 44.5%.
[1212] MS m / z(ESI):255.0[M+1] + .
[1213] Step 5
[1214] Preparation of 1-bromo-4-(bromomethyl)-2-(1-ethoxycyclopropyl)benzene
[1215] Example 83-4 (800 mg, 3.14 mmol) was dissolved in carbon tetrachloride (15 mL), and azobisisobutyronitrile (51 mg, 0.314 mmol) and N-bromosuccinimide (670 mg, 3.76 mmol) were added. The mixture was refluxed under nitrogen for 4 hours. The reaction solution was cooled to room temperature, washed sequentially with water (30 mL) and saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 0-30%) to obtain Example 83-5 (620 mg, yellow solid) in a yield of 59.5%.
[1216] MS m / z(ESI):332.9[M+1] + .
[1217] Step 6
[1218] Preparation of 3-(4-bromo-3-(1-ethoxycyclopropyl)benzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[1219] Dissolve 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one (542 mg, 2.79 mmol) in N,N-dimethylformamide (10 mL), cool to 0°C, add sodium hydride (112 mg, 60% wt, 2.79 mmol), and warm to room temperature for 30 minutes. Add Example 83-5 (620 mg, 1.86 mmol) and react at room temperature for 2 hours. The reaction mixture was cooled to 0°C, and water was slowly added dropwise to quench the reaction. The pH was adjusted to approximately 6 with dilute hydrochloric acid, and extracted with ethyl acetate (50 mL x 2). The organic phases were combined, washed sequentially with water (50 mL) and saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (methanol / dichloromethane = 0-10%) to afford Example 83-6 (430 mg, yellow solid) in a 51.7% yield.
[1220] MS m / z(ESI):447.2[M+1] + .
[1221] Step 7
[1222] Preparation of 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(1-ethoxycyclopropyl)phenyl]-N-(4-chloro-5-methyl-isoxazol-3-yl)-N-(2-trimethylsilyloxymethyl)benzenesulfonamide
[1223] Example 83-6 (100 mg, 0.224 mmol) was dissolved in 1,4-dioxane (2 mL) and water (0.5 mL). (2-(N-(4-chloro-5-methylisoxazol-3-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)sulfamoyl)phenyl)boronic acid (150 mg, 0.336 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (16 mg, 0.0224 mmol), and sodium carbonate (36 mg, 0.336 mmol) were added. The atmosphere was purged with nitrogen three times and microwaved at 100°C for 1 hour. The reaction solution was poured into 30 mL of water and extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (methanol / dichloromethane = 0-10%) to obtain Example 83-7 (70 mg, yellow solid) with a yield of 40.6%.
[1224] MS m / z(ESI):769.3[M+1] + .
[1225] Step 8
[1226] Preparation of 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(1-ethoxycyclopropyl)phenyl]-N-(4-chloro-5-methyl-isoxazol-3-yl)benzenesulfonamide
[1227] Example 83-7 (70 mg, 0.091 mmol) was dissolved in 4 M hydrochloric acid in dioxane (4 mL) and heated to 60°C for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was subjected to reverse-phase HPLC to afford Example 83 (15.0 mg, 25.8% yield).
[1228] MS m / z(ESI):639.3[M+1] + .
[1229] Example 84
[1230] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(((methoxy-d3)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1231]
[1232] The synthesis method of Example 84 was similar to that of Example 69, and deuterated methanol was used as the starting material to obtain Example 84 (26 mg, yield: 56.3%).
[1233] MS m / z(ESI):602.2[M+1] + .
[1234] 1 H NMR (400MHz, DMSO) δ8.09–7.93 (m, 1H), 7.53 (s, 2H), 7.14 (d, J= 21.2Hz,2H),6.98(dd,J=16.8,7.7Hz,2H),4.73(s,2H),4.00(dd,J=31.4,13.0Hz,2H),2.36(t,J=7.5Hz,2H),2.25(s,3H),1. 85(d,J=7.1Hz,6H),1.69(d,J=7.5Hz,2H),1.52(dt,J=15.2,7.6Hz,2H),1.29(dt,J=22.4,7.5Hz,2H),0.82(t,J=7.3Hz,3H).
[1235] Example 85
[1236] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-((cyclopropylmethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1237]
[1238] The synthesis method of Example 85 was based on the synthesis method of Example 69, and cyclopropylmethanol was used as the raw material to obtain Example 85 (14 mg, yield: 43%).
[1239] MS m / z(ESI):639.2[M+1] + .
[1240] Example 86
[1241] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(((2,2,2-trifluoroethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1242]
[1243] The synthesis method of Example 86 was based on the synthesis method of Example 69, and trifluoroethanol was used as the raw material to obtain Example 86 (21 mg, yield: 46%).
[1244] MS m / z(ESI):667.2[M+1] + .
[1245] Example 87
[1246] 4'-((2'-butyl-5'-oxospiro[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1247]
[1248] The synthesis method of Example 87 refers to the synthesis method of Example 2, except that 2-butyl-1,3-diazaspiro-[4,4]non-1-ene-4-one is replaced by 2'-butylspiro[bicyclo[3.1.0]hexane-3,4'-imidazole]-5'(1'H)-one to synthesize Example 87 (11 mg, yield 36%).
[1249] MS m / z(ESI):605.2[M+1] +.
[1250] 1 H NMR (400MHz, DMSO) δ8.06 (dd, J=7.4, 1.9Hz, 1H), 7.66–7.57 (m, 2H), 7.21–7.14 (m, 2H ),7.03–6.92(m,2H),4.68(s,2H),4.00(s,2H),3.21(d,J=6.8Hz,2H),2.32(d,J=7.5 Hz,2H),2.20(s,4H),1.86(d,J=13.5Hz,2H),1.66(s,3H),1.50(dq,J=9.2,5.5Hz,5H ),1.33–1.26(m,2H),1.08–0.98(m,4H),0.82(t,J=7.3Hz,3H),0.56(q,J=4.0Hz,1H).
[1251] Example 88
[1252] 4'-((2-2--4--4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-N-(4,-5-dimethylisoxazol-3-yl)-2'-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1253]
[1254] The synthesis method of Example 88 was similar to that of Example 54, except that 2-butyl-1,3-diazaspiro[4.5]dec-1-en-4-one was substituted for 2-butyl-1,3-diazaspiro[4,4]non-1-en-4-one to synthesize Example 88 (29 mg, yield 52%).
[1255] MS m / z(ESI):593.3[M+1] + .
[1256] Example 89
[1257] 4'-((2-2--4--4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(deuterated methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1258]
[1259] The synthesis method of Example 89 was similar to that of Example 69, except that 2-butyl-1,3-diazaspiro[4.5]dec-1-en-4-one was substituted for 2-butyl-1,3-diazaspiro[4,4]non-1-en-4-one to synthesize Example 88 (31 mg, yield 42%).
[1260] MS m / z(ESI):596.3[M+1] + .
[1261] Example 91
[1262] 1-((2'-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid ethyl ester
[1263]
[1264] first step
[1265] Preparation of ethyl 1-((2'-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate
[1266] Example 2-1 (100 mg, 0.19 mmol) (prepared according to WO2010114801A1) was dissolved in acetonitrile (4 mL), and ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate (53 mg, 0.23 mmol) and potassium carbonate (52.8 mg, 0.38 mmol) were added. The reaction mixture was heated under reflux for 6 h. The reaction mixture was concentrated, and the crude product was purified by reverse-phase HPLC to obtain Example 91-1 (86 mg, 66% yield).
[1267] MS m / z(ESI):683.3[M+1] + .
[1268] Step 2
[1269] Preparation of ethyl 1-((2'-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate
[1270] The synthesis method of Example 91 refers to the synthesis method of the fourth step in Example 1, and Example 91 (31 mg, yield: 40%) is obtained using Example 91-1 as the raw material.
[1271] MS m / z(ESI):639.3[M+1] + .
[1272] 1 H NMR (400MHz, DMSO-d6) δ8.99(s,1H),8.26(dd,J=7.4,1.4Hz,1H),7.65(dd,J=7.5,1.9Hz,1H),7.63(td,J=7.2,1.4Hz,1H ),7.46(td,J=7.3,2.0Hz,1H),7.30(dq,J=2.0,1.0Hz,1H),7.21(d,J=7.4Hz,1H),7.00(dq,J=7.5,1.1Hz,1H),5.43(t,J= 1.0Hz,2H),4.97(s,1H),4.70(d,J=1.1Hz,2H),4.31(q,J=8.0Hz,2H),3.58(q,J=8.0Hz,2H),2.59(t,J=7.1Hz,3H),2.28 (s,2H),1.81(s,2H),1.73(s,6H),1.76–1.65(m,2H),1.36(t,J=8.0Hz,3H),1.19(t,J=8.0Hz,4H),1.01(t,J=8.0Hz,3H).
[1273] Example 92
[1274] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(dimethylcarbamoyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1275]
[1276] The synthesis method of Example 92 was similar to that of Example 20, except that dimethylaminoformyl chloride was used instead of cyclopropanecarboxylic acid chloride to obtain Example 92 (18.8 mg, yield: 54.8%).
[1277] MS m / z(ESI):569.3[M+1] + .
[1278] 1H NMR(400MHz,DMSO-d6)δ10.16(s,1H),8.00(d,J=6.8Hz,1H),7.61-7.48(m,2H),7.20(s,1H) ,7.16-7.10(m,1H),7.06-7.00(m,2H),4.73(s,2H),4.10(d,J=13.2Hz,1H),4.03(d,J=13.2 Hz,1H),3.30-3.21(m,2H),2.61(s,6H),2.37(t,J=7.6Hz,2H),1.92-1.81(m,6H),1.72-1.6 6(m,2H),1.57-1.50(m,2H),1.32-1.27(m,2H),1.04(t,J=6.8Hz,3H),0.84(t,J=7.2Hz,3H).
[1279] Example 93
[1280] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(ethylcarbamoyl)-[1,1'-biphenyl]-2-sulfonamide
[1281]
[1282] Compound 20-2 (30 mg, 0.060 mmol) was dissolved in anhydrous tetrahydrofuran (2 mL), and ethyl isocyanate (86 mg, 1.21 mmol) and N,N-diisopropylethylamine (39 mg, 0.301 mmol) were added. The mixture was heated to 70°C for 16 hours. The mixture was concentrated under reduced pressure, and the resulting residue was purified by reverse-phase pre-HPLC chromatography to afford Example 93 (9.0 mg, 25.6% yield).
[1283] MS m / z(ESI):569.3[M+1] + .
[1284] 1H NMR(400MHz,DMSO-d6)δ8.00(d,J=8.0Hz,1H),7.56-7.46(m,2H),7.17(s,1H),7.11-7.00(m,3 H),5.94(s,1H),4.74(s,2H),4.15(d,J=13.2Hz,1H),4.00(d,J=13.2Hz,1H),3.30-3.21(m,2H ),2.91-2.87(m,2H),2.36(t,J=7.6Hz,2H),1.93-1.79(m,6H),1.72-1.65(m,2H),1.56-1.48( m,2H),1.33-1.24(m,2H),1.03(t,J=6.8Hz,3H),0.91(t,J=7.2Hz,3H),0.82(t,J=7.2Hz,3H).
[1285] Example 94
[1286] N-((4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-(1,1'-biphenyl)-2-yl)sulfonyl)pyrrolidine-1-carboxamide
[1287]
[1288] The synthesis method of Example 94 was similar to that of Example 20, except that 1-pyrrolidinecarbonyl chloride was used instead of cyclopropanecarboxylic acid chloride to obtain Example 94 (8.2 mg, yield: 22.3%).
[1289] MS m / z(ESI):595.3[M+1] + .
[1290] 1H NMR (400MHz, DMSO-d6) δ8.01-7.97(m,1H),7.47-7.41(m,2H),7.14(s,1H),7.07(d,J=7.6Hz,1 H),7.01-7.01(m,1H),6.98-6.93(m,1H),4.72(s,2H),4.10(d,J=13.2Hz,1H),4.02(d,J=13.2H z,1H),3.29-3.25(m,2H),3.11-2.78(m,4H),2.36(t,J=7.6Hz,2H),1.91-1.82(m,6H),1.72-1 .61(m,6H),1.58-1.50(m,2H),1.33-1.27(m,2H),1.04(t,J=6.8Hz,3H),0.84(t,J=7.2Hz,3H).
[1291] Example 95
[1292] tert-Butyl ((4"-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2"-(ethoxymethyl)-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate
[1293]
[1294] first step
[1295] Preparation of tert-butyl ((2-bromophenyl)sulfonyl)carbamate
[1296] Dissolve tert-butyl carbamate (26 mg, 2.35 mmol) in 5 mL of dichloromethane, add triethylamine (594 mg, 5.88 mmol) and 2-bromopyridine-3-sulfonyl chloride (500 mg, 1.96 mmol), and react at room temperature for 2 hours. Add 50 mL of water, and extract with dichloromethane (40 mL x 2). The organic phases are combined, washed sequentially with water (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by silica gel column chromatography (petroleum ether / ethyl acetate system) to obtain Example 95-1 (360 mg, yield: 45.8%).
[1297] MS m / z(ESI):336.0[M+1] + .
[1298] Step 2
[1299] Preparation of tert-butyl ((4"-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2"-(ethoxymethyl)-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate
[1300] Referring to the synthetic method of Example 6-5, Example 95-1 and Example 6-2 were used as raw materials to obtain Example 95 (18 mg, yield: 29.6%).
[1301] MS m / z(ESI):598.3[M+1] + .
[1302] Example 96
[1303] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-((cyclopropylmethoxy)methyl)-N-(3-methoxy)-5-methylpyrazin-2-yl)-[1,1'-biphenyl]-2-sulfonamide
[1304]
[1305]
[1306] first step
[1307] Preparation of 2-bromo-N-(3-methoxy-5-methylpyrazin-2-yl)pyridine-3-sulfonamide
[1308] Referring to the synthetic method of Example 6-3, Example 96-1 (562 mg, yield: 55.6%) was obtained using 2-bromopyridine-3-sulfonyl chloride and 3-methoxy-5-methylpyrazine-2-amine as starting materials.
[1309] MS m / z(ESI):359.0[M+1] + .
[1310] Step 2
[1311] Preparation of 2-bromo-N-(3-methoxy-5-methylpyrazin-2-yl)-N-(methoxymethyl)pyridine-3-sulfonamide
[1312] Referring to the synthetic method of Example 6-3, Example 96-1 and bromomethyl methyl ether were used as raw materials to obtain Example 96-2 (582 mg, yield: 85.6%).
[1313] MS m / z(ESI):403.0[M+1] + .
[1314] Step 3
[1315] Preparation of 2'-(bromomethyl)-4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(3-methoxy-5-methylpyrazin-2-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1316] Referring to the synthetic method of Example 12-1, Example 96-2 and Intermediate 2 were used as raw materials to obtain Example 96-3 (380 mg, yield: 65.4%).
[1317] MS m / z(ESI):698.2[M+1] + .
[1318] Step 4
[1319] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-((cyclopropylmethoxy)methyl)-N-(3-methoxy)-5-methylpyrazin-2-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1320] Preparation
[1321] Referring to the synthetic method of Example 12-2, Example 96-3 and cyclopropylmethanol were used as raw materials to obtain Example 96-4 (220 mg, yield: 45.4%).
[1322] MS m / z(ESI):690.4[M+1] + .
[1323] Step 5
[1324] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-((cyclopropylmethoxy)methyl)-N-(3-methoxy)-5-methylpyrazin-2-yl)-[1,1'-biphenyl]-2-sulfonamide
[1325] Referring to the synthetic method of Example 12, Example 96-4 was used as the raw material to obtain Example 96 (22 mg, yield: 15.4%).
[1326] MS m / z(ESI):646.3[M+1] + .
[1327] Example 97
[1328] Methyl 4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-[1,1'-biphenyl]-2-carboxylate
[1329]
[1330] first step
[1331] Preparation of methyl 2-bromo-5-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)benzoate
[1332] Referring to the synthesis method of intermediate 2c, Example 97-1 (652 mg, yield: 55.6%) was obtained using methyl 2-bromo-5-(bromomethyl)benzoate and 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one as starting materials.
[1333] MS m / z(ESI):421.0[M+1] + .
[1334] Step 2
[1335] Preparation of methyl 5-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(4,4,5,5-tetramethyl-1,3-,2-dioxaborolan-2-yl)benzoate
[1336] Referring to the synthesis method of intermediate 2d, Example 97-2 (550 mg, yield: 85.6%) was obtained using Example 97-1 and bipyraclostrobin as raw materials.
[1337] MS m / z(ESI):469.3[M+1] + .
[1338] Step 3
[1339] Preparation of methyl 4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-[1,1'-biphenyl]-2-carboxylate
[1340] Referring to the synthesis method of Example 12-1, Example 97-3 (220 mg, yield: 35.6%) was obtained using Example 97-2 as the raw material.
[1341] MS m / z(ESI):637.3[M+1] + .
[1342] Step 4
[1343] Preparation of methyl 4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-[1,1'-biphenyl]-2-carboxylate
[1344] Referring to the synthetic method of Example 12, Example 97 (28 mg, yield: 22.6%) was obtained using Example 97-3 as the raw material.
[1345] MS m / z(ESI):593.2[M+1] + .
[1346] 1 H NMR (400MHz, DMSO-d6) δ8.29(d,J=3.7Hz,1H),7.95(dd,J=6.7,2.8Hz,1H),7.63(d,J=2.1Hz,1H),7 .36(d,J=6.5Hz,2H),7.18(d,J=8.3Hz,1H),7.04(d,J=7.9Hz,1H),6.95(d,J=6.4Hz,1H),4.77(s,2H ),3.31(d,J=1.8Hz,3H),2.36(d,J=7.5Hz,2H),2.10–1.96(m,4H),1.87(q,J=7.2Hz,5H),1.70(d,J =8.5Hz,2H),1.52(q,J=7.5Hz,2H),1.43(d,J=2.9Hz,3H),1.33–1.27(m,2H),0.83(t,J=7.3Hz,3H).
[1347] Example 98
[1348] 1-(3-(ethoxymethyl)-4-(3-(N-(3-methoxy-5-methylpyrazin-2-yl)sulfamoyl)pyridin-2-yl)benzyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid ethyl ester
[1349]
[1350] first step
[1351] Preparation of 2-bromo-N-(3-methoxy-5-methylpyrazin-2-yl)pyridine-3-sulfonamide
[1352] Dissolve 2-bromopyridine-3-sulfonyl chloride (1.0 g, 3.9 mmol) in anhydrous dichloromethane (20 mL) and pyridine (5 mL), add 3-methoxy-5-methylpyrazin-2-amine (542 mg, 3.9 mmol), and react at room temperature for 3 hours. Pour the reaction mixture into 50 mL of water, adjust the pH to 6 with dilute hydrochloric acid, and extract with dichloromethane (50 mL x 2). The combined organic phases are washed sequentially with water (50 mL) and saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The residue is purified by silica gel column chromatography to yield the title product, Example 98-1 (1.0 g, 71.1% yield).
[1353] MS m / z(ESI):358.9[M+1] + .
[1354] Step 2
[1355] Preparation of 2-bromo-N-(3-methoxy-5-methylpyrazin-2-yl)-N-(methoxymethyl)pyridine-3-sulfonamide
[1356] Dissolve 98-1 (1 g, 2.78 mmol) in anhydrous dichloromethane (10 mL), add pyridine (1 ml), cool to 0°C, slowly add bromomethyl methyl ether (365 mg, 2.92 mmol) dropwise, and warm to room temperature for 2 hours. The reaction mixture is slowly poured into 50 mL of water and extracted with dichloromethane (40 mL x 2). The combined organic phases are washed sequentially with water (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The residue is purified by silica gel column chromatography to yield the title product, Example 98-2 (1 g, 89% yield).
[1357] MS m / z(ESI):403.0[M+1] + .
[1358] Step 3
[1359] Preparation of 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)phenyl)-N-(4-chloro-5-methylisoxazol-3-yl)-N-(methoxymethyl)pyridine-3-sulfonamide
[1360] The synthesis method of Example 98-3 was based on the synthesis method of Example 6-5, and 98-2 was used instead of 6-4 to obtain Example 98-3 (50 mg, yield: 39.7%).
[1361] MS m / z(ESI):711.3[M+1] + .
[1362] Step 4
[1363] Preparation of 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)phenyl)-N-(4-chloro-5-methylisoxazol-3-yl)pyridine-3-sulfonamide
[1364] The synthesis method of Example 98 was based on the synthesis method of Example 6, and 98-3 was used instead of 6-5 to obtain Example 98 (20 mg, yield: 55%).
[1365] MS m / z(ESI):667.3[M+1] +
[1366] 1 H NMR (400MHz, DMSO-d6) δ8.50(d,J=4.8Hz,1H),8.29(dd,J=7.9,1.7Hz,1H),7.38(dd,J=8.0,4.7Hz ,1H),7.11–7.02(m,2H),6.97(s,1H),6.76(d,J=7.9Hz,1H),5.49(s,2H),5.43(s,1H),4.20(q,J= 7.1Hz,2H),3.98(s,2H),3.67(s,3H),3.11(q,J=7.0Hz,2H),2.64(d,J=7.7Hz,2H),2.09(s,3H),1 .98(d,J=6.4Hz,1H),1.68(h,J=7.4Hz,2H),1.47(s,6H),1.19(d,J=7.1Hz,3H),0.98–0.92(m,5H).
[1367] Example 99
[1368] Ethyl 1-((2'-(N-(4,5-dimethylisoxazol-3-yl)sulfamoyl)-2-(ethoxymethyl)-(1,1'-biphenyl]-4-yl)methyl-d2)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate
[1369]
[1370] The synthesis method of compound 99 was similar to that of Example 1 to obtain 99 (30 mg, yield: 66%). MS m / z (ESI): 641.3 [M+1] +
[1371] 1H NMR (400MHz, DMSO-d6) δ8.99(s,1H),8.26(dd,J=7.4,1.4Hz,1H),7.65(dd,J=7.5,1.9Hz,1H),7.63(td,J=7.2 ,1.4Hz,1H),7.46(td,J=7.3,2.0Hz,1H),7.30(q,J=1.1Hz,1H),7.24–7.17(m,2H),4.97(s,1H),4.70(d,J=1. 1Hz,2H),4.31(q,J=8.0Hz,2H),3.58(q,J=8.0Hz,2H),2.59(t,J=7.1Hz,3H),2.28(s,3H),1.81(s,2H),1.73( s,6H),1.71(dtd,J=15.1,8.0,7.1Hz,2H),1.36(t,J=8.0Hz,3H),1.19(t,J=8.0Hz,3H),1.01(t,J=8.0Hz,3H).
[1372] Example 100
[1373] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(5-methyl-4-(methyl-d3)isoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1374]
[1375] The synthesis method of Example 100 was similar to that of Example 1, except that 4,5-dimethylisoxazolamine was replaced with 5-methyl-4-(deuterated methyl)isoxazol-3-amine to obtain Example 100 (6.8 mg, yield: 14.0%).
[1376] MS m / z(ESI):596.3[M+1] + .
[1377] Example 101
[1378] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1379]
[1380] The synthesis method of Example 101 was similar to that of Example 1, except that 4,5-dimethylisoxazolamine was replaced with 5-methyl-3-amino-4-azaisoxazole to obtain Example 101 (7.0 mg, yield: 15.0%).
[1381] MS m / z(ESI):580.3[M+1] + .
[1382] 1 H NMR (400MHz, DMSO-d6) δ7.96-7.94(m,1H),7.36-7.31(m,2H),7.08(s,1H),7.01(d,J=7. 6Hz,1H),6.94-6.91(m,2H),4.71(s,2H),4.14(d,J=13.2Hz,1H),3.95(d,J=13.2Hz,1H) ,3.23-3.19(m,2H),2.36(t,J=7.6Hz,2H),2.22(s,3H),1.92-1.79(m,6H),1.74-1.65(m ,2H),1.56-1.48(m,2H),1.32-1.26(m,2H),1.01(t,J=6.8Hz,3H),0.82(t,J=7.2Hz,3H).
[1383] Example 102
[1384] 1-(3-(ethoxymethyl)-4-(3-(N-(3-methoxy-5-methylpyrazin-2-yl)sulfamoyl)pyridin-2-yl)benzyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid
[1385]
[1386] Compound 98 (100 mg, 0.15 mmol) and NaOH (2 M, 1.5 mL) were added to tetrahydrofuran (10 mL). The reaction solution was stirred at 25°C for 4 hours, 1 M HCl (10 mL) was added, and the mixture was extracted with dichloromethane (30 mL x 2). The combined extracts were dried over Na2SO4 and spin-dried. The crude product was purified by silica gel column chromatography to afford the title compound 102 (60 mg, 63% yield).
[1387] MS m / z(ESI):639.3[M+1] +
[1388] 1H NMR (400MHz, DMSO-d6) δ8.94(s,1H),8.79(dd,J=7.5,1.5Hz,1H),8.29(dd,J=7.5,1.5Hz,1H),7.96(d, J=7.5Hz,1H),7.51–7.43(m,2H),7.36(dq,J=2.1,1.1Hz,1H),7.05(dq,J=7.5,1.1Hz,1H),5.42(t,J=1 .0Hz,2H),4.97(s,1H),4.77(d,J=1.1Hz,2H),4.09(s,2H),3.58(q,J=8.0Hz,2H),2.59(t,J=7.1Hz,2H ),2.51(d,J=0.7Hz,3H),1.73(s,6H),1.76–1.65(m,2H),1.19(t,J=8.0Hz,4H),1.01(t,J=8.0Hz,3H).
[1389] Example 103
[1390] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(5-methylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1391]
[1392] The synthesis method of Example 103 was similar to that of Example 1, except that 3-amino-5-methylisoxazole was used instead of 4,5-dimethylisoxazoleamine to obtain Example 103 (18.6 mg, yield: 15.2%).
[1393] MS m / z(ESI):579.3[M+1] + .
[1394] 1H NMR(400MHz,DMSO-d6)δ11.22(br s,1H),7.98(d,J=7.6Hz,1H),7.65-7.57(m,2H),7.24-7.17(m,2H),7.07-7.02(m,2 H),5.76(s,1H),4.76(s,2H),4.07(d,J=13.2Hz,1H),4.00(d,J=13.2Hz,1H),3.28-3 .16(m,2H),2.35(t,J=7.6Hz,2H),2.25(s,3H),1.92-1.79(m,6H),1.76-1.65(m,2H) ,1.54-1.47(m,2H),1.32-1.24(m,2H),1.01(t,J=6.8Hz,3H),0.81(t,J=7.2Hz,3H).
[1395] Example 104
[1396] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(3-cyclopropylisoxazol-5-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1397]
[1398] The synthesis method of Example 104 was similar to that of Example 1, except that (3-cyclopropylisoxazol-5-yl)amine was used instead of 4,5-dimethylisoxazolamine to obtain Example 104 (18.4 mg, yield: 15.2%).
[1399] MS m / z(ESI):605.3[M+1] + .
[1400] 1H NMR(400MHz, DMSO-d6)δ8.00(d,J=8.0Hz,1H),7.68-7.60(m,2H),7.22(d,J=7.6Hz,1H),7.20(s,1H),7.06(d, J=8.4Hz,1H),7.01(d,J=7.6Hz,1H),5.19(s,1H),4.77(s,2H),4.03(d,J=13.2Hz,1H),3.97(d,J=13.2Hz,1H), 3.27–3.21(m,2H),2.38(t,J=7.6Hz,2H),1.93-1.84(m,6H),1.83-1.79(m,1H),1.75-1.68(m,2H),1.55-1.47 (m,2H),1.31-1.24(m,2H),1.01(t,J=6.8Hz,3H),0.95-0.90(m,2H),0.81(t,J=7.2Hz,3H),0.66-0.60(m,2H).
[1401] Example 105
[1402] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(2-chloro-5-methoxypyrimidin-4-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1403]
[1404] The synthesis method of Example 105 was similar to that of Example 1, except that 2-chloro-4-amino-5-methoxypyrimidine was used instead of 4,5-dimethylisoxazolamine to obtain Example 105 (26.6 mg, yield: 21.4%).
[1405] MS m / z(ESI):640.2[M+1] + .
[1406] 1H NMR(400MHz,DMSO-d6)δ8.08(d,J=7.6Hz,1H),8.05-7.98(m,1H),7.66-7.56(m,2 H),7.23-7.13(m,2H),7.02(s,2H),4.75(s,2H),4.01-3.93(m,2H),3.78(s,3H), 3.24-3.16(m,3H),2.36(t,J=7.6Hz,2H),1.92-1.82(s,6H),1.76-1.66(m,2H),1 .55-1.47(m,2H),1.32-1.24(m,2H),1.00(t,J=6.8Hz,3H),0.81(t,J=7.2Hz,3H).
[1407] Example 106
[1408] N-(5-(tert-Butyl)isoxazol-3-yl)-4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-(1,1'-biphenyl)-2-sulfonamide
[1409]
[1410] The synthesis method of compound 106 was similar to that of Example 1 to obtain 106 (62 mg, yield: 66%).
[1411] MS m / z(ESI):621.3[M+1] +
[1412] 1 H NMR(400MHz,DMSO-d6)δ11.23(s,1H),8.02(dd,J=7.6,1.8Hz,1H),7.69–7.59(m,2H),7.3 3–7.11(m,3H),7.03(t,J=6.5Hz,2H),5.68(s,2H),4.76(s,2H),4.09–3.96(m,2H),3.25–3 .16(m,2H),2.34(t,J=7.5Hz,2H),1.85(d,J=7.6Hz,4H),1.70(d,J=8.9Hz,2H),1.50(p,J =7.5Hz,2H),1.31–1.25(m,2H),1.20(s,9H),1.00(t,J=7.0Hz,3H),0.80(t,J=7.3Hz,3H).
[1413] Example 107
[1414] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-hydroxy-[1,1'-biphenyl]-2-sulfonamide
[1415]
[1416] first step
[1417] Preparation of 3-(4-bromo-3-hydroxybenzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
[1418] Referring to the synthesis method of intermediate 2c, Example 107-1 (343 mg, yield: 45.3%) was obtained using 2-bromo-5-(bromomethyl)phenol and 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one as starting materials.
[1419] MS m / z(ESI):379.1[M+1] + .
[1420] Step 2
[1421] Preparation of 2-butyl-3-(3-hydroxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,3-diazaspiro[4.4]non-1-en-4-one
[1422] Referring to the synthesis method of intermediate 2d, Example 107-2 (252 mg, yield: 65.6%) was obtained using Example 107-1 and bipyraclostrobin as raw materials.
[1423] MS m / z(ESI):427.3[M+1] + .
[1424] Step 3
[1425] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-hydroxy-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1426] Referring to the synthesis method of Example 12-1, Example 107-2 was used as the raw material to obtain Example 107-3 (120 mg, yield: 45.6%).
[1427] MS m / z(ESI):595.3[M+1] + .
[1428] Step 4
[1429] Preparation of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-hydroxy-[1,1'-biphenyl]-2-sulfonamide
[1430] Referring to the synthesis method of Example 12, Example 107 (21 mg, yield: 24.6%) was obtained using Example 107-3 as the raw material.
[1431] MS m / z(ESI):551.2[M+1] + .
[1432] 1 H NMR (400MHz, DMSO) δ10.24(s,1H),9.37(s,1H),7.95(d,J=7.4Hz,1H),7.49(dt,J= 26.6,7.1Hz,2H),7.12(d,J=7.3Hz,1H),6.73(t,J=39.8Hz,1H),6.49(d,J=10.6Hz, 2H),4.56(s,2H),2.28(t,J=7.5Hz,2H),2.13(s,3H),1.79(d,J=6.9Hz,5H),1.71–1 .54(m,5H),1.46(dt,J=15.2,7.6Hz,2H),1.29–1.17(m,3H),0.77(t,J=7.4Hz,3H).
[1433] Example 108
[1434] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(4-isopropyl-5-methylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1435]
[1436] The synthesis method of Example 108 was similar to that of Example 1, except that 4-isopropyl-5-methylisoxazol-3-amine was used instead of 4,5-dimethylisoxazolamine to obtain Example 108 (3.5 mg, yield: 5.4%).
[1437] MS m / z(ESI):621.3[M+1] + .
[1438] 1H NMR(400MHz, DMSO-d6)δ8.00(d,J=8.8Hz,1H),7.38-7.30(m,2H),7.09(s,1H),6.98(d,J=8. 0Hz,1H),6.91-6.86(m,2H),4.70(s,2H),4.03(d,J=13.2Hz,1H),3.97(d,J=13.2Hz,1H),3.2 2-3.17(m,2H),2.37-2.33(m,2H),2.09(s,3H),2.03-1.97(m,1H),1.89-1.81(m,6H),1.72- 1.65(m,2H),1.55-1.49(m,2H),1.33-1.27(m,2H),1.07-1.00(m,9H),0.83(t,J=7.2Hz,3H).
[1439] Example 109
[1440] 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)phenyl)-N-(4-chloro-5-methylisoxazol-3-yl)pyridine-3-sulfonamide
[1441]
[1442] first step
[1443] Preparation of 2-bromo-N-(4-chloro-5-methylisoxazol-3-yl)pyridine-3-sulfonamide
[1444] Dissolve 2-bromopyridine-3-sulfonyl chloride (1.0 g, 4.72 mmol) in anhydrous dichloromethane (20 mL) and pyridine (5 mL), add 4-chloro-5-methylisoxazol-3-amine (625 mg, 4.72 mmol), and react at room temperature for 3 hours. Pour the reaction mixture into 50 mL of water, adjust the pH to 6 with dilute hydrochloric acid, and extract with dichloromethane (50 mL x 2). The combined organic phases are washed sequentially with water (50 mL) and saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The residue is purified by silica gel column chromatography using eluent System B to afford the title product, Example 109-1 (1.0 g, 55.1% yield).
[1445] MS m / z(ESI):351.9[M+1] + .
[1446] Step 2
[1447] Preparation of 2-bromo-N-(4-chloro-5-methylisoxazol-3-yl)-N-(methoxymethyl)pyridine-3-sulfonamide
[1448] Dissolve 2-bromo-N-(4-chloro-5-methylisoxazol-3-yl)pyridine-3-sulfonamide (600 mg, 1.95 mmol) in anhydrous dichloromethane (10 mL). Add pyridine (770 mg, 9.74 mmol). Cool to 0°C, then slowly add bromomethyl methyl ether (365 mg, 2.92 mmol) dropwise. Warm to room temperature and allow to react for 2 hours. The reaction mixture is slowly poured into 50 mL of water and extracted with dichloromethane (40 mL x 2). The combined organic phases are washed sequentially with water (40 mL) and saturated sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The residue is purified by silica gel column chromatography to afford the title product, Example 109-2 (500 mg, 72.9% yield).
[1449] MS m / z(ESI):395.9[M+1] + .
[1450] Step 3
[1451] Preparation of 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)phenyl)-N-(4-chloro-5-methylisoxazol-3-yl)-N-(methoxymethyl)pyridine-3-sulfonamide
[1452] The synthesis method of Example 109-3 was based on the synthesis method of Example 6-5, and 109-2 was used instead of 6-4 to obtain Example 109-3 (40 mg, yield: 35.7%).
[1453] MS m / z(ESI):658.2[M+1] + .
[1454] Step 4
[1455] Preparation of 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)phenyl)-N-(4-chloro-5-methylisoxazol-3-yl)pyridine-3-sulfonamide
[1456] The synthesis method of Example 109 was based on the synthesis method of Example 6, and 109-3 was used instead of 6-5 to obtain Example 109 (18.1 mg, yield: 48.2%).
[1457] MS m / z(ESI):614.2[M+1] + .
[1458] 1H NMR(400MHz,DMSO-d6)δ8.72-8.66(m,1H),8.37(d,J=8.0Hz,1H),7.58-7.55(m,1H),7 .19(s,1H),7.09(d,J=7.6Hz,1H),7.01(d,J=8.0Hz,1H),4.75(s,2H),4.07(s,2H),3.2 5-3.19(m,2H),2.37(t,J=7.6Hz,2H),2.24(s,3H),1.93-1.79(m,6H),1.74-1.67(m,2 H),1.57-1.50(m,2H),1.33-1.27(m,2H),1.00(t,J=6.8Hz,3H),0.84(t,J=7.2Hz,3H).
[1459] Example 110
[1460] 2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl-d2)-2-(ethoxymethyl)phenyl)-N-(4-fluoro-5-methylisoxazol-3-yl)pyridine-3-sulfonamide
[1461]
[1462] The synthesis method of Example 110 was similar to that of Example 1, except that 4-fluoro-5-methylisoxazolamine was used instead of 4,5-dimethylisoxazolamine to obtain Example 110 (19 mg, yield: 50.3%).
[1463] MS m / z(ESI):600.3[M+1]
[1464] 1 H NMR (400MHz, DMSO) δ8.79(t,J=9.8Hz,1H),8.41(d,J=8.1Hz,1H),7.64(dd,J=8.0,4.8H z,1H),7.22(s,1H),7.05(dt,J=42.2,21.0Hz,3H),4.09(s,2H),3.22(dd,J=13.9,7.0H z,2H),2.36(t,J=7.5Hz,2H),2.28(s,3H),1.87(s,6H),1.71(s,2H),1.52(dt,J=15.2, 7.5Hz, 2H), 1.30 (dt, J=14.7, 7.4Hz, 2H), 0.99 (t, J=7.0Hz, 3H), 0.83 (t, J=7.3Hz, 3H).
[1465] Example 111
[1466] (2-(4-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2-(ethoxymethyl)phenyl)-N-(4-fluoro-5-methylisoxazol-3-yl)pyridine-3-sulfonamide
[1467]
[1468] The synthesis method of Example 111 was similar to that of Example 1, except that 4-fluoro-5-methylisoxazolamine was used instead of 4,5-dimethylisoxazolamine to obtain Example 111 (29 mg, yield: 55.6%).
[1469] MS m / z(ESI):598.3[M+1]
[1470] 1 H NMR (400MHz, DMSO-d6) δ9.13(s,1H),8.79(dd,J=7.5,1.5Hz,1H),8.29(dd,J=7.5,1.5Hz,1H),8.03( d,J=7.4Hz,1H),7.54(q,J=1.1Hz,1H),7.50–7.43(m,2H),5.00(t,J=1.0Hz,2H),4.77(d,J=1.1Hz,2H ),3.58(q,J=8.0Hz,2H),2.55(t,J=7.1Hz,2H),2.30(s,2H),2.11–2.00(m,6H),1.99–1.89(m,2H),1. 60(p,J=7.1Hz,2H), 1.40(dtd,J=15.1,7.9,6.9Hz,2H), 1.19(t,J=8.0Hz,3H), 0.91(t,J=8.0Hz,3H).
[1471] Example 112
[1472] 4'-(2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl)-2'-(ethoxymethyl)-N-(4-fluoro-5-methylisoxazol-3-yl)-(1,1'-biphenyl)-2-sulfonamide
[1473]
[1474] The synthesis method of Example 112 was similar to that of Example 1, except that 4-fluoro-5-methylisoxazolamine was used instead of 4,5-dimethylisoxazolamine to obtain Example 112 (25 mg, yield: 52.6%).
[1475] MS m / z(ESI):591.2[M+1]
[1476] 1 H NMR(400MHz, DMSO-d6)δ9.10(s,1H),8.26(dd,J=7.4,1.4Hz,1H),7.65(dd,J=7.5,1.9Hz,1H),7.63(td,J=7.2,1.4H z,1H),7.46(td,J=7.3,2.0Hz,1H),7.31(dq,J=1.8,1.1Hz,1H),7.21(d,J=7.4Hz,1H),7.00(dt,J=7.6,1.3Hz,1H), 5.09(t,J=1.0Hz,2H),4.77(d,J=7.5Hz,2H),4.70(d,J=1.1Hz,2H),3.71(t,J=7.7Hz,1H),3.58(q,J=8.0Hz,2H),2. 57(t,J=7.1Hz,2H),2.30(s,2H),1.73–1.63(m,2H),1.57–1.46(m,2H),1.19(t,J=8.0Hz,3H),0.94(t,J=8.0Hz,3H).
[1477] Example 113
[1478] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-propoxy-[1,1'-biphenyl]-2-sulfonamide
[1479]
[1480] Example 107 (100 mg, 0.18 mmol) and potassium carbonate (45 mg, 0.36 mmol) were dissolved in dichloromethane (5 mL). Propane bromoacetate (44 mg, 0.36 mmol) was then added to the reaction mixture, which was stirred at room temperature for 2 h. Saturated brine (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried, concentrated, and purified to afford Example 113 (52 mg, 49.1% yield).
[1481] MS m / z(ESI):593.3[M+1] + .
[1482] 1H NMR (400MHz, DMSO) δ10.86 (s, 1H), 7.96 (d, J = 7.1Hz, 2H), 7.63–7.15 (m, 2H), 7.20–6.91 (m, 2H ),6.75–6.45(m,2H),4.63(s,2H),3.75(dd,J=36.1,7.0Hz,2H),3.31(s,3H),2.29(dd,J=25. 0,17.5Hz,2H),2.18(s,3H),1.78(d,J=7.2Hz,6H),1.62(d,J=7.3Hz,2H),1.46(dt,J=15.2,7 .5Hz,2H),1.22(ddd,J=20.5,14.1,6.6Hz,3H),0.94(t,J=6.9Hz,3H),0.76(t,J=7.3Hz,3H).
[1483] Example 114
[1484] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(5-methyl-4-(trifluoromethyl)isoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1485]
[1486] The synthesis method of Example 114 was similar to that of Example 1, except that 4,5-dimethylisoxazolamine was replaced with 5-methyl-4-(trifluoromethyl)isoxazol-3-amine to obtain Example 114 (12.5 mg, yield: 8.6%).
[1487] MS m / z(ESI):647.2[M+1] + .
[1488] 1H NMR (400MHz, DMSO-d6) δ8.00-7.98(m,1H),7.38-7.32(m,2H),7.10(s,1H),6.99(d,J=7.6Hz,1 H),6.94-6.91(m,1H),6.88(d,J=8.0Hz,1H),4.70(s,2H),4.08(d,J=13.2Hz,1H),3.98(d,J=1 3.2Hz,1H),3.23-3.18(m,2H),2.37(t,J=7.6Hz,2H),2.26(s,3H),1.91-1.82(m,6H),1.72-1. 66(m,2H),1.57–1.50(m,2H),1.34-1.28(m,2H),1.02(t,J=6.8Hz,3H),0.84(t,J=7.2Hz,3H).
[1489] Example 115
[1490] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-cyano-3-methylisoxazol-5-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1491]
[1492] The synthesis method of Example 115 was similar to that of Example 1, except that 4,5-dimethylisoxazolamine was replaced with 5-amino-3-methylisoxazole-4-carbonitrile to obtain Example 115 (5.1 mg, yield: 6.6%).
[1493] MS m / z(ESI):604.2[M+1] + .
[1494] 1H NMR(400MHz,DMSO-d6)δ8.02-7.99(m,1H),7.49-7.45(m,2H),7.13(s,1H),7.07-7.05(m,1H), 7.02(d,J=7.6Hz,1H),6.95(d,J=8.0Hz,1H),4.72(s,2H),4.08(d,J=13.2Hz,1H),3.96(d,J=1 3.2Hz,1H),3.26-3.18(m,2H),2.35(t,J=7.6Hz,2H),2.01(s,3H),1.91-1.82(m,6H),1.73-1. 66(m,2H),1.55-1.48(m,2H),1.32-1.24(m,2H),1.02(t,J=6.8Hz,3H),0.83(t,J=7.2Hz,3H).
[1495] Example 116
[1496] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-ethoxy-[1,1'-biphenyl]-2-sulfonamide
[1497]
[1498] The synthesis method of Example 116 was similar to that of Example 113, except that iodoethane was used instead of iodopropane to obtain Example 116 (27.0 mg, yield: 34.5%).
[1499] MS m / z(ESI):599.0[M+1] + .
[1500] 1 H NMR(400MHz,DMSO-d6)δ10.91(br s,1H),8.03(d,J=8.0Hz,1H),7.58-7.47(m,2H),7.20-6.97(m,2H),6.72(s,1 H),6.63(d,J=8.0Hz,1H),4.70(s,2H),3.91-3.83(m,1H),3.79-3.72(m,1H),2 .38(t,J=7.6Hz,2H),2.25(s,3H),1.92-1.82(m,6H),1.71-1.65(m,2H),1.56 -1.49(m,2H),1.33-1.27(m,2H),1.01(t,J=6.8Hz,3H),0.83(t,J=7.2Hz,3H).
[1501] Example 117
[1502] Methyl 1-((2'-(N-(4-chloro-5-methylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-ethyl-2-propyl-1H-imidazole-5-carboxylate
[1503]
[1504] Example 117-1 (300 mg, 0.55 mmol) (prepared according to WO2010114801A1) was dissolved in acetonitrile (15 mL). Methyl 4-ethyl-2-propyl-1H-imidazole-5-carboxylate (108 mg, 0.55 mmol) and potassium carbonate (160 mg, 1.1 mmol) were added. The reaction mixture was heated under reflux for 6 h. The reaction mixture was concentrated, and the crude product was purified by reverse-phase HPLC to afford Example 117-2 (300 mg, 82.5% yield).
[1505] MS m / z(ESI):659.2[M+1]+.
[1506] Step 2
[1507] Preparation of methyl 1-((2'-(N-(4-chloro-5-methylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-ethyl-2-propyl-1H-imidazole-5-carboxylate Example 117-2 (300 mg, 0.46 mmol) was dissolved in 4M HCl / dioxane (5 mL) and the reaction mixture was heated to 70°C for 2 h. The reaction mixture was concentrated and the crude product was purified by reverse phase HPLC to give Example 117 (200 mg, 71.4% yield).
[1508] MS m / z(ESI):615.2[M+1] + .
[1509] 1H NMR(400MHz, DMSO-d6)δ9.07(s,1H),8.26(dd,J=7.4,1.4Hz,1H),7.68–7.59(m,2H),7.46(td,J=7.3,2.0H z,1H),7.30(dq,J=2.0,1.0Hz,1H),7.21(d,J=7.4Hz,1H),7.00(dq,J=7.5,1.1Hz,1H),5.43(t,J=1.0Hz,2H ),4.70(d,J=1.1Hz,2H),3.94(s,3H),3.58(q,J=8.0Hz,2H),2.99(q,J=8.0Hz,2H),2.58(s,3H),2.29(s,2 H),1.71(dtd,J=15.1,8.0,7.1Hz,2H),1.37(t,J=8.0Hz,3H),1.19(t,J=8.0Hz,3H),1.01(t,J=8.0Hz,3H).
[1510] Example 118
[1511] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-N-(5-methoxy-4-methylisoxazol-3-yl)-(1,1'-biphenyl)-2-sulfonamide
[1512]
[1513] The synthesis method of Example 118 was similar to that of Example 1, except that 4,5-dimethylisoxazolamine was replaced with 5-methoxy-4-methylisoxazol-3-amine to obtain Example 118 (11.5 mg, yield: 8.3%).
[1514] MS m / z(ESI):609.3[M+1] + .
[1515] 1H NMR(400MHz,DMSO-d6)δ7.98-7.96(m,1H),7.38-7.36(m,2H),7.09(s,1H),7.01(d,J=7.6Hz ,1H),6.97-6.91(m,2H),4.71(s,2H),4.03(d,J=13.2Hz,1H),3.96(d,J=13.2Hz,1H),3.67( s,3H),3.25-3.17(m,2H),2.35(t,J=7.6Hz,2H),1.90-1.81(m,6H),1.72-1.66(m,2H),1.54 -1.48(m,2H),1.35(s,3H),1.32-1.26(m,2H),1.01(t,J=6.8Hz,3H),0.83(t,J=7.2Hz,3H).
[1516] Example 119
[1517] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(5-cyclopropyl-4-methylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1518]
[1519] The synthesis method of Example 119 was similar to that of Example 1, except that 4,5-dimethylisoxazolamine was replaced with 5-cyclopropyl-4-methylisoxazol-3-amine to obtain Example 119 (13.2 mg, yield: 9.6%).
[1520] MS m / z(ESI):619.3[M+1] + .
[1521] 1H NMR(400MHz,DMSO-d6)δ8.02-7.99(m,1H),7.50-7.42(m,2H),7.12(s,1H),7.06-7.00(m ,1H),6.95(s,2H),4.72(s,2H),4.00-3.91(m,2H),3.22-3.17(m,2H),2.36(t,J=7.6Hz, 2H),1.92-1.81(m,8H),1.74-1.65(m,2H),1.59(s,3H),1.55-1.51(m,2H),1.32-1.27(m ,2H),1.01(t,J=6.8Hz,3H),0.89-0.86(m,2H),0.83(t,J=7.6Hz,3H),0.77-0.74(m,2H).
[1522] Example 120
[1523] Methyl 1-((2'-(N-(4-chloro-5-methylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-yl)methyl)-4-ethyl-2-propyl-1H-imidazole-5-carboxylic acid
[1524]
[1525] Compound 117 (100 mg, 0.16 mmol) and NaOH (2 M, 1.5 mL) were added to tetrahydrofuran (10 mL). The reaction solution was stirred at 25°C for 4 hours, 1 M HCl (10 mL) was added, and the mixture was extracted with dichloromethane (30 mL x 2). The combined extracts were dried over Na2SO4 and spin-dried. The crude product was purified by silica gel column chromatography to afford the title compound 120 (60 mg, 61% yield).
[1526] MS m / z(ESI):601.2[M+1] +
[1527] 1H NMR (400MHz, DMSO-d6) δ11.07(s,1H),9.07(s,1H),8.26(dd,J=7.4,1.4 Hz,1H),7.65(dd,J=7.5,1.9Hz,1H),7.63(td,J=7.2,1.4Hz,1H),7.46(td,J=7.3,2.0Hz,1H),7.31( dq,J=1.8,1.1Hz,1H),7.21(d,J=7.4Hz,1H),7.00(dt,J=7.6,1.2Hz,1H),5.42(t,J=1.0Hz,2H),4.70 (d,J=1.1Hz,2H),3.58(q,J=8.0Hz,2H),2.96(q,J=8.0Hz,2H),2.58(t,J=7.1Hz,3H),2.29(s,2H),1. 71(dtd,J=15.1,8.0,7.1Hz,2H),1.37(t,J=8.0Hz,3H),1.19(t,J=8.0Hz,3H),1.01(t,J=8.0Hz,3H).
[1528] Example 121
[1529] N-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl)-4'-(4-oxy-2-(4,4,4-trifluorobutyl)-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1530]
[1531] The synthesis method of Example 121 was similar to that of Example 1, except that 4-chloro-5-methylisoxazolamine was used instead of 4,5-dimethylisoxazolamine to obtain Example 121 (27 mg, yield: 51.5%).
[1532] MS: m / z(ESI):667.2[M+1] +
[1533] 1H NMR (400MHz, DMSO-d6) δ9.07(s,1H),8.26(dd,J=7.4,1.4Hz,1H),7.65(dd,J=7.5,1.9Hz,1H),7.63(t d,J=7.2,1.4Hz,1H),7.51–7.43(m,2H),7.33(dq,J=7.5,1.1Hz,1H),7.28(d,J=7.5Hz,1H),5.00(t,J= 1.0Hz,2H),4.70(d,J=1.1Hz,2H),3.58(q,J=8.0Hz,2H),2.70(t,J=7.1Hz,2H),2.34(qt,J=9.0,7.1Hz ,2H),2.29(s,3H),2.11–2.00(m,6H),1.99–1.89(m,2H),1.74(p,J=7.1Hz,2H),1.19(t,J=8.0Hz,3H).
[1534] Example 122
[1535] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(phenoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1536]
[1537]
[1538] first step
[1539] Preparation of 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(phenoxymethyl)-N-((2-(trimethylsilyl)ethoxy)methyl)-[1,1'-biphenyl]-2-sulfonamide
[1540] Compound 69-6 (60 mg, 0.077 mmol) was dissolved in anhydrous acetonitrile (3 mL), and phenol (22 mg, 0.231 mmol) and cesium carbonate (75 mg, 0.231 mmol) were added. The mixture was heated to 50°C for 2 hours. The reaction mixture was poured into 30 mL of water and extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title product 122-1 (60 mg, 98.3% yield).
[1541] MS: m / z(ESI):791.3[M+1]
[1542] Step 2
[1543] Preparation of 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(phenoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1544] The synthesis method of compound 122 was similar to that of Example 12. Compound 122-1 was used as the starting material to obtain the title compound Example 122 (30.3 mg, yield: 60.1%).
[1545] MS m / z(ESI):661.2[M+1] + .
[1546] 1 H NMR(400MHz,DMSO-d6)δ12.70(br s,1H),8.01-7.99(m,1H),7.47-7.37(m,2H),7.20-7.15(m,3H),7.09-7.00(m,3 H),6.88-6.84(m,1H),6.70(d,J=8.0Hz,2H),4.73(d,J=13.2Hz,1H),4.71(s,2H ),4.51(d,J=13.2Hz,1H),2.31(t,J=7.6Hz,2H),2.13(s,3H),1.90-1.79(m,6H) ,1.68-1.61(m,2H),1.52-1.45(m,2H),1.29-1.24(m,2H),0.82(t,J=7.2Hz,3H).
[1547] Intermediate 3
[1548] 2'-(Bromomethyl)-4'-(2-butyl-4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1549]
[1550] The first step is the preparation of 1-pentaaminocyclohexane-1-carboxamide
[1551] To a solution of 1-aminocyclohexanecarboxamide (8.0 g, 56 mmol) in dichloromethane (200 mL) was added valeryl chloride (7.2 g, 60 mmol) and triethylamine (17 mL, 120 mmol) under ice-cooling. The reaction was stirred under ice-cooling for 1 hour. After completion of the reaction, 50 mL of water was added, and the mixture was extracted with DCM (80 mL x 3). The organic layer was dried over MgSO₄. After filtration, the solvent was removed under reduced pressure to obtain the desired product, 1-pentaminocyclohexane-1-carboxamide (12 g, 94.3% yield).
[1552] MS m / z(ESI):227.1[M+1] + .
[1553] Step 2 Preparation of 2-butyl-1,3-diazaspiro-[4,5]dec-1-en-4-one
[1554] To a solution of Intermediate B (12.0 g, 53 mmol) in methanol (80 mL) was slowly added sodium hydroxide (10 M, 50 mL). The reaction was stirred at 60°C for 3 hours. After completion of the reaction, water (30 mL) and dichloromethane (60 mL x 3) were added for extraction. The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford the desired product, Intermediate C (8 g, yield: 70.2%). MS m / z (ESI): 209.1 [M+1] + .
[1555] Step 3 Preparation of 4-bromo-3-methylbenzyl methanesulfonate
[1556] Dissolve (4-bromo-3-methylphenyl)methanol (2.0 g, 10.0 mmol) and triethylamine (1.4 g, 11.0 mmol) in dichloromethane (5 mL). Add methylsulfonyl chloride (1.24 g, 11.0 mmol) under ice-cooling and stir at room temperature for 1 hour. Extract with water and dichloromethane (20 mL x 3). The combined organic layers are dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to yield the desired product, 4-bromo-3-methylbenzyl methanesulfonate (2.6 g, 93.5% yield).
[1557] MS m / z(ESI):278.9[M+1] + .
[1558] Step 4 Preparation of 3-(4-bromo-3-methylbenzyl)-2-butyl-1,3-diazaspiro[4.5]dec-1-en-4-one
[1559] To a solution of intermediate 3b (2.0 g, 7.2 mmol) in N,N-dimethylformamide (5 mL) was added sodium hydride (0.34 g, 8.6 mmol) under ice-cooling, and the reaction was stirred under ice-cooling for 1 hour. 2-Butyl-1,3-diazaspiro[4.5]dec-1-en-4-one (1.7 g, 8.2 mmol) was added, and the reaction mixture was stirred at room temperature for 1 hour. Water and dichloromethane (20 mL x 3) were added for extraction. The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford the desired product, 3-(4-bromo-3-methylbenzyl)-2-butyl-1,3-diazaspiro[4.5]dec-1-en-4-one (2.3 g, 82.1% yield).
[1560] MS m / z(ESI):391.1[M+1] + .
[1561] Step 5 Preparation of 2-butyl-3-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,3-diazaspiro[4.5]dec-1-en-4-one
[1562] Intermediate 3c (2.07 g, 5.3 mmol), pinacol diboronate (1.6 g, 6.4 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (42 mg, 0.05 mmol), and potassium acetate (1.1 g, 10.6 mmol) were dissolved in dioxane (35 mL). The reaction mixture was stirred at 80°C under nitrogen for 16 hours. Water and dichloromethane (50 mL x 2) were then added for extraction. The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford the desired product, 2-butyl-3-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,3-diazaspiro[4.5]dec-1-en-4-one (1.8 g, 77.6% yield).
[1563] MS m / z(ESI):439.3[M+1] + .
[1564] Step 6 Preparation of 3-(3-(bromomethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-2-butyl-1,3-diazaspiro[4.5]dec-1-en-4-one
[1565] To a solution of intermediate 3d (1.55 g, 3.5 mmol) in acetonitrile (5 mL) was added N-bromosuccinimide (0.75 g, 4.2 mmol) under ice-cooling. The reaction mixture was stirred at room temperature for 1 hour. Water and dichloromethane (3 x 20 mL) were then added for extraction. The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford the desired product, 3-(3-(bromomethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-2-butyl-1,3-diazaspiro[4.5]dec-1-en-4-one (1.62 g, 88.5% yield).
[1566] MS m / z(ESI):517.2[M+1] + .
[1567] Step 7 Preparation of 2'-(bromomethyl)-4'-(((2-butyl-4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1568] Intermediate 3e (100 mg, 0.19 mmol), (2-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)phenyl)boronic acid (75 mg, 0.2 mmol) (prepared according to WO2010135350A2), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (16 mg, 0.02 mmol), and cesium carbonate (291 mg, 0.9 mmol) were dissolved in dioxane (4 mL) and water (1 mL). The reaction solution was stirred in a microwave at 100°C for 1 hour. Water and dichloromethane (20 mL x 3) were then added for extraction. The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford Intermediate 3 (110 mg, 83% yield).
[1569] MS m / z(ESI):685.2[M+1] + .
[1570] Intermediate 4
[1571] 2'-Butylspiro[bicyclo[3.1.0]hexane-3,4'-imidazole]-5'(1'H)-one
[1572]
[1573] The first step is the preparation of bicyclo[3.1.0]hexane-3-ol
[1574] Under nitrogen, cyclopent-3-en-1-ol (2 g, 24 mmol) was dissolved in 200 mL of dichloromethane. Diethylzinc (5.9 g, 48 mmol) and diiodomethane (12.7 mL, 48 mmol) were added and stirred for 3 hours under ice. After completion, 50 mL of water was added, and the mixture was extracted with DCM (80 mL x 3). The organic layer was dried over MgSO₄. After filtration, the solvent was removed under reduced pressure to obtain the target product, Intermediate 4b (2 g, 86% yield).
[1575] MS m / z(ESI):99.1[M+1] + .
[1576] Step 2 Preparation of bicyclo[3.1.0]hexane-3-one
[1577] Intermediate 4b (2.0 g, 20 mmol) was dissolved in dichloromethane (40 mL), and Dess-Martin (10 g, 24 mmol) was slowly added. The reaction was stirred at 20°C for 3 hours. Water (30 mL) and dichloromethane (30 mL x 3) were added for extraction. The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford the desired product, Intermediate 4c (1.7 g, 87% yield).
[1578] MS m / z(ESI):97.1[M+1] + .
[1579] Step 3 Preparation of 3-aminobicyclo[3.1.0]hexane-3-carbonitrile
[1580] Intermediate 4c (1.7 g, 17.7 mmol) and ammonium chloride (1.42 g, 26.5 mmol) were dissolved in DMF (5 mL) and water (25 mL). Potassium cyanide (1.73 g, 26.5 mmol) was added under ice-cooling, and the reaction mixture was stirred at room temperature for 2 hours. Water and dichloromethane (20 mL x 3) were then added for extraction. The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford the desired product, Intermediate 4d (1.5 g, 69.4% yield).
[1581] MS m / z(ESI):123.1[M+1] + .
[1582] Step 4 Preparation of 3-aminobicyclo[3.1.0]hexane-3-carboxamide
[1583] To a solution of intermediate 4d (1.5 g, 12.3 mmol) in dichloromethane (15 mL) was added sulfuric acid (5 mL) under ice-cooling. The reaction mixture was stirred under ice-cooling for 3 hours. Water and dichloromethane (20 mL x 3) were then added for extraction. The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford the desired intermediate 4e (1.6 g, 93% yield).
[1584] MS m / z(ESI):141.1[M+1] + .
[1585] Step 5 Preparation of 3-pentaamide bicyclo[3.1.0]hexane-3-carboxamide
[1586] To a solution of intermediate 4e (1.6 g, 11.4 mmol) in 30 mL of dichloromethane was added valeryl chloride (1.5 g, 12.55 mmol) and triethylamine (2.8 mL, 22.8 mmol) under ice-cooling. The reaction mixture was stirred under ice-cooling for 1 hour. After completion of the reaction, 50 mL of water was added, and the mixture was extracted with DCM (80 mL x 3). The organic layer was dried over MgSO₄. After filtration, the solvent was removed under reduced pressure to obtain the target product, intermediate 4f (2.3 g, 89.8% yield).
[1587] MS m / z(ESI):225.1[M+1] + .
[1588] Step 6 Preparation of 2'-butylspiro[bicyclo[3.1.0]hexane-3,4'-imidazole]-5'(1'H)-one
[1589] To a solution of intermediate 4f (2.3 g, 10.25 mmol) in methanol (40 mL) was slowly added sodium hydroxide (10 M, 30 mL). The reaction mixture was stirred at 60°C for 3 hours. Water (30 mL) and dichloromethane (60 mL x 3) were then added for extraction. The combined organic layers were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (petroleum ether / ethyl acetate) to afford the desired product, intermediate 4 (1.3 g, 61.3% yield).
[1590] MS m / z(ESI):207.1[M+1] + .
[1591] 1H NMR (400MHz, DMSO-d6) δ13.30(s,1H),2.71(t,J=7.7Hz,2H),2.37(dd,J=14.7,4.0Hz,2H),2.09(d,J=14.4Hz,2H),1.68(p ,J=7.6Hz,2H),1.53(dt,J=8.5,4.1Hz,2H),1.33(dt,J=14.6,7.4Hz,2H),0.99–0.81(m,4H),0.60(td,J=8.3,4.8Hz,1H).
[1592] Intermediate 5
[1593]
[1594] The synthesis method of intermediate 5 refers to the synthesis method of steps 4 to 7 in intermediate 3, and replaces 2-butyl-1,3-diazaspiro-[4,5]dec-1-en-4-one with 2'-butylspiro[bicyclo[3.1.0]hexane-3,4'-imidazole]-5'(1'H)-one to obtain intermediate 5 (2 g) with a yield of 65.8%.
[1595] MS m / z(ESI):683.2[M+1] + .
[1596] Example 123
[1597] 4'-((2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-2'-((cyclopropylmethoxy)methyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1598]
[1599] first step
[1600] Preparation of 4'-((2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-2'-((cyclopropylmethoxy)methyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1601] Dissolve cyclopropylmethanol (46 mg, 0.642 mmol) in N,N-dimethylformamide (5 mL), add sodium hydride (25 mg, 60% wt, 0.642 mmol), and react at room temperature for 30 minutes. Add Intermediate 5 (88 mg, 0.129 mmol), and react at room temperature for 1 hour. Pour the reaction mixture into 30 mL of ice water and extract with ethyl acetate (30 mL x 2). The combined organic phases are washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain Example 123-1 (70 mg) in an 80.6% yield, which is used directly in the next step.
[1602] MS m / z(ESI):675.3[M+1] + .
[1603] Step 2
[1604] Preparation of 4'-((2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-2'-((cyclopropylmethoxy)methyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1605] Example 123-1 (70 mg, 0.104 mmol) was dissolved in 4 M hydrochloric acid in dioxane (4 mL) and heated to 60°C for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by reverse-phase HPLC to afford Example 123 (30 mg) in a 45.8% yield.
[1606] MS m / z(ESI):631.2[M+1] + .
[1607] Example 124
[1608] 4'-((2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1609]
[1610] first step
[1611] Preparation of 4'-((2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-N,2'-bis(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1612] Methanol (20.5 mg, 0.642 mmol) was dissolved in N,N-dimethylformamide (5 mL), and sodium hydride (25 mg, 60% wt, 0.642 mmol) was added. The mixture was allowed to react at room temperature for 30 minutes. Intermediate 5 (88 mg, 0.128 mmol) was added and allowed to react at room temperature for 1 hour. The reaction mixture was poured into 30 mL of ice water and extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to afford Example 124-1 (65 mg) in a yield of 79.6%, which was used directly in the next step.
[1613] MS m / z(ESI):635.3[M+1] + .
[1614] Step 2
[1615] Preparation of 4'-((2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1616] Example 124-1 (65 mg, 0.102 mmol) was dissolved in 4 M hydrochloric acid in dioxane (4 mL) and heated to 60°C for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by reverse-phase HPLC to afford Example 124 (38 mg) in a 62.8% yield.
[1617] MS m / z(ESI):591.2[M+1] + .
[1618] Example 125
[1619] 4'-((2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-2'-(cyclobutyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1620]
[1621] first step
[1622] Preparation of 4'-(2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-2'-(cyclobutyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1623] Dissolve cyclobutanol (46 mg, 0.642 mmol) in N,N-dimethylformamide (5 mL), add sodium hydride (25 mg, 60% wt, 0.642 mmol), and react at room temperature for 30 minutes. Add Intermediate 5 (88 mg, 0.129 mmol), and react at room temperature for 1 hour. Pour the reaction mixture into 30 mL of ice water and extract with ethyl acetate (30 mL x 2). The combined organic phases are washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain Example 125-1 (70 mg) in an 80.6% yield, which is used directly in the next step.
[1624] MS m / z(ESI):675.3[M+1] + .
[1625] Step 2
[1626] Preparation of 4'-((2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-2'-(cyclobutyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1627] Example 125-1 (70 mg, 0.104 mmol) was dissolved in 4 M hydrochloric acid in dioxane (4 mL) and heated to 60°C for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by reverse-phase HPLC to afford Example 125 (40 mg) in a 61.2% yield.
[1628] MS m / z(ESI):631.2[M+1] + .
[1629] Example 126
[1630] 4'-((2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(deuterated methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1631]
[1632] first step
[1633] Preparation of 4'-((2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-((methoxy-d3)methyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1634] Deuterated methanol (22.5 mg, 0.644 mmol) was dissolved in N,N-dimethylformamide (5 mL), and sodium hydride (26 mg, 60% wt, 0.644 mmol) was added. The mixture was allowed to react at room temperature for 30 minutes. Intermediate 5 (88 mg, 0.129 mmol) was added and allowed to react at room temperature for 1 hour. The reaction mixture was poured into 30 mL of ice water and extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain Example 126-1 (65 mg) in a yield of 79.3%, which was used directly in the next step.
[1635] MS m / z(ESI):638.3[M+1] + .
[1636] Step 2
[1637] Preparation of 4'-((2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(deuterated methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1638] Example 126-1 (65 mg, 0.102 mmol) was dissolved in 4 M hydrochloric acid in dioxane (4 mL) and heated to 60°C for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by reverse-phase HPLC to afford Example 126 (42 mg) in a 69.4% yield.
[1639] MS m / z(ESI):594.2[M+1] + .
[1640] Example 127
[1641] 4'-(2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-2'-(cyclopropyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1642]
[1643] first step
[1644] Preparation of 4'-(2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-2'-(cyclopropyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1645] Dissolve cyclopropanol (36 mg, 0.64 mmol) in N,N-dimethylformamide (5 mL), add sodium hydride (24 mg, 60% wt, 0.64 mmol), and react at room temperature for 30 minutes. Add Intermediate 5 (87.5 mg, 0.128 mmol), and react at room temperature for 1 hour. Pour the reaction mixture into 30 mL of ice water and extract with ethyl acetate (30 mL x 2). The combined organic phases are washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain Example 127-1 (60 mg) in a yield of 70.9%, which is used directly in the next step.
[1646] MS m / z(ESI):661.3[M+1] + .
[1647] Step 2
[1648] Preparation of 4'-(2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-2'-(cyclopropyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1649] Example 127-1 (60 mg, 0.91 mmol) was dissolved in 4 M hydrochloric acid in dioxane (4 mL) and heated to 60°C for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by reverse-phase HPLC to afford Example 127 (37 mg) in a 66.1% yield.
[1650] MS m / z(ESI):617.2[M+1] + .
[1651] Example 128
[1652] 4'-((2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(isopropoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1653]
[1654] first step
[1655] Preparation of 4'-((2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(isopropoxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1656] Dissolve isopropyl alcohol (38.5 mg, 0.64 mmol) in N,N-dimethylformamide (5 mL), add sodium hydride (24 mg, 60% wt, 0.642 mmol), and react at room temperature for 30 minutes. Add Intermediate 5 (87.5 mg, 0.128 mmol), and react at room temperature for 1 hour. Pour the reaction mixture into 30 mL of ice water and extract with ethyl acetate (30 mL x 2). The combined organic phases are washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain Example 128-1 (65 mg) in a 76.6% yield, which is used directly in the next step.
[1657] MS m / z(ESI):663.3[M+1] + .
[1658] Step 2
[1659] Preparation of 4'-((2'-butyl-5'-oxopyrrolo[bicyclo[3.1.0]hexane-3,4'-imidazole]-1'(5'H)-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(isopropoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1660] Example 128-1 (65 mg, 0.098 mmol) was dissolved in 4 M hydrochloric acid in dioxane (4 mL) and heated to 60°C for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by reverse-phase HPLC to afford Example 128 (43 mg) in a 70.8% yield.
[1661] MS m / z(ESI):619.2[M+1] + .
[1662] Example 129
[1663] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-2'-((cyclopropylmethoxy)methyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1664]
[1665] first step
[1666] Preparation of 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-2'-(cyclopropylmethoxy)methyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1667] Dissolve cyclopropylmethanol (46 mg, 0.642 mmol) in N,N-dimethylformamide (5 mL), add sodium hydride (25 mg, 60% wt, 0.642 mmol), and react at room temperature for 30 minutes. Add Intermediate 3 (88 mg, 0.129 mmol), and react at room temperature for 1 hour. Pour the reaction mixture into 30 mL of ice water and extract with ethyl acetate (30 mL x 2). The combined organic phases are washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain Example 129-1 (70 mg) in an 80.6% yield, which is used directly in the next step.
[1668] MS m / z(ESI):677.3[M+1] + .
[1669] Step 2
[1670] 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-2'-((cyclopropylmethyl)
[1671] Preparation of (4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1672] Example 129-1 (70 mg, 0.103 mmol) was dissolved in 4 M hydrochloric acid in dioxane (4 mL) and heated to 60°C for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was subjected to reverse-phase HPLC to afford Example 129 (35.5 mg) in a 54.2% yield.
[1673] MS m / z(ESI):633.3[M+1] + .
[1674] Example 130
[1675] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-2'-(cyclobutyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1676]
[1677] first step
[1678] Preparation of 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-2'-(cyclobutyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1679] Dissolve cyclobutanol (46 mg, 0.642 mmol) in N,N-dimethylformamide (5 mL), add sodium hydride (25 mg, 60% wt, 0.642 mmol), and react at room temperature for 30 minutes. Add Intermediate 3 (88 mg, 0.129 mmol), and react at room temperature for 1 hour. Pour the reaction mixture into 30 mL of ice water and extract with ethyl acetate (30 mL x 2). The combined organic phases are washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain Example 130-1 (70 mg) in an 80.6% yield, which is used directly in the next step.
[1680] MS m / z(ESI):677.3[M+1] + .
[1681] Step 2
[1682] Preparation of 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-2'-(cyclobutyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1683] Example 130-1 (70 mg, 0.103 mmol) was dissolved in 4 M hydrochloric acid in dioxane (4 mL) and heated to 60°C for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by reverse-phase HPLC to afford Example 130 (35.5 mg) in a 54.3% yield.
[1684] MS m / z(ESI):633.3[M+1] + .
[1685] Example 131
[1686] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-2'-(cyclopropyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1687]
[1688] first step
[1689] Preparation of 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-2'-(cyclopropyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1690] Dissolve cyclopropanol (37 mg, 0.642 mmol) in N,N-dimethylformamide (5 mL), add sodium hydride (25 mg, 60% wt, 0.642 mmol), and react at room temperature for 30 minutes. Add Intermediate 3 (88 mg, 0.129 mmol), and react at room temperature for 1 hour. Pour the reaction mixture into 30 mL of ice water and extract with ethyl acetate (30 mL x 2). The combined organic phases are washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain Example 131-1 (65 mg) in a yield of 75.8%, which is used directly in the next step.
[1691] MS m / z(ESI):663.3[M+1] + .
[1692] Step 2
[1693] Preparation of 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-2'-(cyclopropyloxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1694] Example 131-1 (65 mg, 0.1 mmol) was dissolved in 4 M hydrochloric acid in dioxane (4 mL) and heated to 60°C for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by reverse-phase HPLC to afford Example 131 (35 mg) in a 57.7% yield.
[1695] MS m / z(ESI):619.3[M+1] + .
[1696] Example 132
[1697] 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-2'-(isopropoxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1698]
[1699] first step
[1700] Preparation of 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-2'-(isopropoxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
[1701] Dissolve isopropyl alcohol (39 mg, 0.642 mmol) in N,N-dimethylformamide (5 mL), add sodium hydride (25 mg, 60% wt, 0.642 mmol), and react at room temperature for 30 minutes. Add Intermediate 3 (88 mg, 0.129 mmol), and react at room temperature for 1 hour. Pour the reaction mixture into 30 mL of ice water and extract with ethyl acetate (30 mL x 2). The combined organic phases are washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain Example 132-1 (65 mg) in a yield of 76.2%, which is used directly in the next step.
[1702] MS m / z(ESI):665.3[M+1] + .
[1703] Step 2
[1704] Preparation of 4'-(2-butyl-4-oxo-1,3-diazaspiro[4.5]dec-1-en-3-yl)methyl)-2'-(isopropoxymethyl)-N-(4,5-dimethylisoxazol-3-yl)-[1,1'-biphenyl]-2-sulfonamide
[1705] Example 132-1 (65 mg, 0.1 mmol) was dissolved in 4 M hydrochloric acid in dioxane (4 mL) and heated to 60°C for 4 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The resulting crude product was purified by reverse-phase HPLC to afford Example 132 (40 mg) in a 65.9% yield.
[1706] MS m / z(ESI):621.3[M+1] + .
[1707] Biological test evaluation
[1708] The present invention is further described and explained below in conjunction with test examples, but these examples are not intended to limit the scope of the present invention.
[1709] 1. Cell Function Experiment
[1710] Test Example 1: Determination of the Effect of the Compounds of the Invention on Calcium Flux in Cells Stably Expressing AT1 Receptors
[1711] 1. Experimental purpose:
[1712] Antagonistic effect of test compounds on HEK293-AT1 cell activity
[1713] 2. Experimental instruments and reagents:
[1714] 2.1 Instruments:
[1715] 384-well assay plate (Corning: 3764);
[1716] 384-well Echo compound plate (Labcyte: LP-0200);
[1717] 384-well compound plate (PE: 6008590);
[1718] Bravo Tip (Agilent: 10734-202);
[1719] FLIPR Tip (Molecular Device: 9000-0764);
[1720] plate reader FLIPR Tetra (Molecular Device);
[1721] Bravo pipetting workstation (Agilent);
[1722] ECHO 550 (LABCYTE);
[1723] Liquid pipette Multidrop Combi (ThermoFisher).
[1724] 2.2 Reagents:
[1725] DMEM, high glucose (Gibco: 12100);
[1726] Fetal bovine serum (Biosera: FB-1058 / 500);
[1727] P / S (Biosera: XC-A4122);
[1728] 5X Matrigel(Corning: 354230);
[1729] HBSS (Sigma: H1387);
[1730] HEPES (Invitrogen: 15630080);
[1731] Fluo-8 AM (AAT Bioquest: 21080);
[1732] Probenecid (Sigma: P8761);
[1733] Pluronic F-127 (Sigma: P2443-250G);
[1734] Angiotensin III TFA (MCE: HY-113035A);
[1735] Irbesartan (MCE: HY-B0202);
[1736] 1000X Fluo-8 AM (2 mM): Dissolve Fluo-8 AM in DMSO, shake for 1-2 minutes, aliquot, and store at -20°C.
[1737] Complete culture medium: DMEM + 10% FBS + 1X P / S;
[1738] Cell seeding medium: DMEM + 10% FBS + 1X PS;
[1739] Assay buffer 1: 1X HBSS + 20 mM HEPES + 1 mM Probenecid + 0.025% Pluronic F-127;
[1740] Assay buffer 2: 1X HBSS + 20 mM HEPES + 0.075% Pluronic F-127; 1X Matrigel: 5X Matrigel diluted with DMEM;
[1741] Cell line: HDB HEK293-AT1.
[1742] 3. Experimental methods:
[1743] 1) HEK293-AT1 cells were cultured in complete medium at 37°C in 5% CO2 until they reached 70% to 90% confluency.
[1744] 2) Coat a 384-well cell plate with 1X Matrigel, coating each well with 5 μL of the solution at room temperature for 10 to 30 minutes.
[1745] 3) The digested cells were resuspended in cell seeding medium, and 8,000 cells / well / 20 μL were seeded into a 384-well cell culture plate, and cultured at 37° C., 5% CO 2 for 24 hours.
[1746] 4) Take the cell culture plate out of the CO2 incubator and equilibrate at room temperature for 10 minutes.
[1747] 5) Take out 1000X Fluo-8 AM and dilute it to 1X Fluo-8 AM with assay buffer 1 equilibrated to room temperature, with a concentration of 2 μM.
[1748] 6) Remove the culture medium from the cell culture plate, add 20 μL of 1X Fluo-8 AM to each well, centrifuge at 300 rpm for 60 seconds, and incubate at room temperature in the dark for 1 hour.
[1749] 7) Prepare the positive control compound and the test compound working solution (3X):
[1750] ① Using the Bravo instrument, dilute the compound to 11 concentration points on a 384-well Echo compound plate (LABCYTE: LP-0200);
[1751] ② Use the ECHO instrument to transfer 90nL of compound per well (compound storage concentration, such as the highest concentration point 10mM) to a 384-well compound plate (PE: 6008590);
[1752] ③ Use Multidrop Combi to add 30 μL of assay buffer 2 to 384-well compound plates (PE: 6008590), dilute the positive control compound and the test compound to 30 μM (3X), and place at room temperature for use.
[1753] 8) Add 10 μL of the diluted 3X compound to the experimental wells of the corresponding 384-well cell plate using FLIPR Tetra. Incubate the compound and cells at room temperature for 10 minutes. Then add 10 μL of the diluted 4X agonist and read and collect data simultaneously.
[1754] 4. Experimental data processing method:
[1755] FLIPR Tetra was used to collect fluorescence signal values (RFU). The maximum RFU value was taken. Based on the readings of the Low control (DMSO control) and High control (100 nM positive compound) experimental groups, the percentage activation data {% activation rate = (RFUsample-RFUlow control) / (RFUhigh control-RFUlow control) × 100} was calculated. The concentration of the test compound after the reaction system was diluted 3 times was 11 concentrations ranging from 10 uM to 0.17 nM. XLFit was used to fit the percentage activation rate and the 11-point concentration data to the parametric nonlinear logic formula to calculate the compound's IC 50 value.
[1756] 5. Experimental results:
[1757] Table 1 IC of compounds on calcium flux in cells stably expressing AT1 receptor 50 value
[1758] IC 50 (nM) Example 1310.0 Example 146.9 Example 446.2 Example 453.2
[1759] Example 463.9 Example 497.2 Example 528.6 Example 539.1 Example 553.7 Example 654.4 Example 688.8 Example 726.1 Example 855.2 Example 862.2 Example 879.6
[1760] 6. Experimental conclusions:
[1761] It can be seen from the data in the table that the example compounds of the present invention show good antagonistic effect in the experiment on the effect of stably expressing AT1 receptor on calcium flux.
[1762] Test Example 2: Determination of the Effect of the Compounds of the Invention on Calcium Flux in Cells Stably Expressing ETA Receptors 1. Experimental Purpose:
[1763] The compounds were tested for their antagonistic effects on HEK293-ETA cell viability.
[1764] 2. Experimental instruments and reagents:
[1765] 2.1 Instruments:
[1766] 384-well assay plate (Corning: 3764);
[1767] 384-well Echo compound plate (Labcyte: LP-0200);
[1768] 384-well compound plate (PE: 6008590);
[1769] Bravo Tip (Agilent: 10734-202);
[1770] FLIPR Tip(Molecular Device:9000-0764)
[1771] plate reader FLIPR Tetra (Molecular Device);
[1772] Bravo (Agilent) and ECHO 550 (LABCYTE) pipetting workstations;
[1773] Liquid pipette Multidrop Combi (ThermoFisher).
[1774] 2.2 Reagents:
[1775] DMEM, high glucose (Gibco: 12100);
[1776] Fetal bovine serum (Biosera: FB-1058 / 500);
[1777] P / S (Biosera: XC-A4122);
[1778] 5X Matrigel(Corning: 354230);
[1779] HBSS (Sigma: H1387);
[1780] HEPES (Invitrogen: 15630080);
[1781] Fluo-8 AM (AAT Bioquest: 21080);
[1782] Probenecid (Sigma: P8761);
[1783] Pluronic F-127 (Sigma: P2443-250G);
[1784] Endothelin 1 (MCE: HY-P0202);
[1785] Zibotentan (MCE: HY-10088);
[1786] 1000X Fluo-8 AM (2 mM): Dissolve Fluo-8 AM in DMSO, shake for 1-2 minutes, aliquot, and store at -20°C.
[1787] Complete culture medium: DMEM + 10% FBS + 1X P / S;
[1788] Cell seeding medium: DMEM + 10% FBS + 1X PS;
[1789] Assay buffer 1: 1X HBSS + 20 mM HEPES + 1 mM Probenecid + 0.025% Pluronic F-127;
[1790] Assay buffer 2: 1X HBSS + 20 mM HEPES + 0.075% Pluronic F-127; 1X Matrigel: 5X Matrigel diluted with DMEM;
[1791] Cell line: HDB HEK293-ETA.
[1792] 3. Experimental methods:
[1793] 1) HEK293-ETA cells were cultured in complete medium at 37°C in 5% CO2 until they reached 70% to 90% confluency.
[1794] 2) Coat a 384-well cell plate with 1X Matrigel, coating each well with 5 μL of the solution at room temperature for 10 to 30 minutes.
[1795] 3) The digested cells were resuspended in cell seeding medium, and 8,000 cells / well / 20 μL were seeded into a 384-well cell culture plate, and cultured at 37° C., 5% CO 2 for 24 hours.
[1796] 4) Take the cell culture plate out of the CO2 incubator and equilibrate at room temperature for 10 minutes.
[1797] 5) Take out 1000X Fluo-8 AM and dilute it to 1X Fluo-8 AM with assay buffer 1 equilibrated to room temperature, with a concentration of 2 μM.
[1798] 6) Remove the culture medium from the cell culture plate, add 20 μL of 1X Fluo-8 AM to each well, centrifuge at 300 rpm for 60 seconds, and incubate at room temperature in the dark for 1 hour.
[1799] 7) Prepare the positive control compound and the test compound working solution (3X):
[1800] ① Using the Bravo instrument, dilute the compound to 11 concentration points on a 384-well Echo compound plate (LABCYTE: LP-0200);
[1801] ② Use the ECHO instrument to transfer 90nL of compound per well (compound storage concentration, such as the highest concentration point 10mM) to a 384-well compound plate (PE: 6008590);
[1802] ③ Use Multidrop Combi to add 30 μL of assay buffer 2 to 384-well compound plates (PE: 6008590), dilute the positive control compound and the test compound to 30 μM (3X), and place at room temperature for use.
[1803] 8) Add 10 μL of the diluted 3X compound to the experimental wells of the corresponding 384-well cell plate using FLIPR Tetra. Incubate the compound and cells at room temperature for 10 minutes. Then add 10 μL of the diluted 4X agonist and read and collect data simultaneously.
[1804] 4. Experimental data processing method:
[1805] FLIPR Tetra was used to collect fluorescence signal values (RFU). The maximum RFU value was taken. Based on the readings of the Low control (DMSO control) and High control (100 nM positive compound) experimental groups, the percentage activation data {% activation rate = (RFU sample - RFU low control) / (RFU high control - RFU low control) × 100} was calculated. The concentration of the test compound was diluted 3-fold in the reaction system to 11 concentrations ranging from 10 μM to 0.17 nM. XLFit was used to fit the percentage activation rate and the 11-point concentration data to the parametric nonlinear logic formula to calculate the compound's IC 50 value.
[1806] 5. Experimental results:
[1807] Table 2 IC values of compounds on calcium flux in cells stably expressing ETA receptors 50 value
[1808] IC 50 (nM) Example 44 15.1 Example 45 14.9 Example 49 12.9 Example 65 7.2 Example 68 18.7 Example 86 13.9 Example 87 8.2
[1809] 6. Experimental conclusions:
[1810] It can be seen from the data in the table that the example compounds of the present invention showed good antagonistic effects in the experiment on the effect of stably expressing ETA receptor on calcium flux.
[1811] 2. Pharmacokinetic evaluation test in rats
[1812] 1. Research objectives:
[1813] SD rats were used as test animals to study the pharmacokinetic behavior of the compound of the present invention in rats (plasma) after oral administration at a dose of 5 mg / kg.
[1814] 2. Experimental plan:
[1815] 2.1 Experimental drugs:
[1816] The compounds of the present invention were prepared in-house.
[1817] 2.2 Experimental Animals
[1818] Three male SD rats were used in each group. They were purchased from Shanghai Jiesijie Experimental Animal Co., Ltd. with an animal production license number of (SCXK (Shanghai) 2013-0006 No. 311620400001794).
[1819] 2.3 Preparation prescription:
[1820] 0.5% CMC-Na (1% Tween 80), dissolved by ultrasonication, prepared as a clear solution or homogeneous suspension.
[1821] 2.4 Administration:
[1822] Rats were fasted overnight and then given po;
[1823] The oral dose is 5 mg / kg, and the administration volume is 10 mL / kg.
[1824] 2.5 Sample collection:
[1825] 0.2 mL of blood was collected from the jugular vein of rats at 0.25 h, 0.5 h,...
Claims
1. A compound represented by the general formula (II), its stereoisomer or pharmaceutically acceptable salt: where all of X1, X2 and X3 are CH; L1 is selected from the group consisting of -CH2- or -CD2-; R1 is selected from the group consisting of -(CH2)n5O(CH2)n6RA2; R7 is selected from chlorine and bromine; R8 is selected from methyl; RA2 is selected from C1-3alkyl, C1-3deuteroalkyl, C1-3haloalkyl, C3-6cycloalkyl, 4-7-membered heterocyclyl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, C3-6cycloalkylC1-3alkyl and 4-7-membered heterocyclyl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, C1-3alkyl; n5 and n6 are equal to 0, 1, 2, or 3.
2. A compound or a stereoisomer or pharmaceutically acceptable salt thereof according to claim 1, wherein said compound is a compound of formula (II-1): where L1 is selected from -CH2- or -CD2-; R1 is selected from -(CH2)n5O(CH2)n6RA2; R7 is selected from chlorine and bromine; R8 is selected from methyl; RA2 is selected from C1-3alkyl, C1-3deuteroalkyl, C1-3haloalkyl, C3-6cycloalkyl, 4-7-membered heterocyclyl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, C3-6cycloalkylC1-3alkyl and 4-7-membered heterocyclyl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, C1-3alkyl; n5 is 0, 1, 2 or 3; n6 is 0, 1, or 2.
3. A compound or its stereoisomer or pharmaceutically acceptable salt according to claim 2, wherein R1 is selected from 4. A compound of general formula (VIII-2), its stereoisomer or pharmaceutically acceptable salt: X1 represents N or CR1; X2 represents N or CR2; X3 represents N or CR3; R1, R2 and R3 are each independently selected from hydrogen and halogen; L1 is selected from -CH2-, -CD2- or -CH2O-; R1 is selected from the group consisting of hydroxy, C1-6alkoxy, C1-6haloalkoxy, C3-12cycloalkyl, -(CH2)n5O(CH2)n6RA2, -(CH2)n5C(O)RA2, -(CH2)n5NRA2C(O)RB2, -(CH2)n5C(O)NRA2RB2, -(CH2)n5OC(O)NRA2RB2 and -(CH2)n5NRA2C(O)ORB2, wherein C1-6alkoxy, C1-6haloalkoxy and C3-12cycloalkyl are optionally further substituted with one or more substituents selected from deuterium, halogen, amino, hydroxy, cyano, oxo, thioxo, C1-6alkyl, C1-6deuteroalkyl, C1-6haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C3-12cycloalkyl, 3-12-membered heterocyclyl containing 1-4 heteroatoms selected from nitrogen, oxygen and sulfur, C6-14aryl and 5-14-membered heteroaryl containing 1-4 heteroatoms selected from nitrogen, oxygen and sulfur, each of RA2 and RB2 is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, hydroxy, cyano, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6deuteroalkyl, C1-6haloalkyl, C1-6hydroxyalkyl, C1-6alkoxy, C1-6alkylthio, C1-6haloalkoxy, C3-12cycloalkyl,3-12-membered heterocyclyl containing 1-4 heteroatoms selected from nitrogen, oxygen and sulfur, C6-14 aryl and 5-14-membered heteroaryl containing 1-4 heteroatoms selected from nitrogen, oxygen and sulfur, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 deuteroalkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkoxy, C3-12 cycloalkyl, 3-12-membered heterocyclyl containing 1-4 heteroatoms selected from nitrogen, oxygen and sulfur, C6-14 aryl and 5-14-membered heteroaryl containing 1-4 heteroatoms selected from nitrogen, oxygen and sulfur are optionally further substituted with one or more substituents selected from deuterium, halogen, amino, hydroxy, cyano, oxo, thioxo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 deuteroalkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkoxy, C3-12 cycloalkyl, 3-12-membered heterocyclyl containing 1-4 heteroatoms selected from nitrogen, oxygen and sulfur, C6-14 aryl and 5-14-membered heteroaryl,containing 1-4 heteroatoms selected from nitrogen, oxygen and sulfur; each of R7 and R8 is independently selected from hydrogen, halogen, cyano, C1-6alkyl, C1-6deuteroalkyl, C1-6haloalkyl, C1-6alkoxy and C3-12cycloalkyl; or R7 and R8 are joined to form a C3-8cycloalkyl; n5 and n6 are equal to 0, 1, 2, or 3.
5. The compound or its stereoisomer or pharmaceutically acceptable salt according to claim 4, wherein all of X1, X2 and X3 are CH; L1 is selected from -CH2- or -CD2-; R1 is selected from the group consisting of hydroxy, C1-6alkoxy, C1-6haloalkoxy, C3-12cycloalkyl, -(CH2)n5O(CH2)n6RA2, -(CH2)n5C(O)RA2, -(CH2)n5NRA2C(O)RB2, -(CH2)n5C(O)NRA2RB2, -(CH2)n5OC(O)NRA2RB2 and -(CH2)n5NRA2C(O)ORB2, wherein C1-6alkoxy, C1-6haloalkoxy and C3-12cycloalkyl are optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, amino, hydroxy, cyano, oxo, thioxo, C1-6alkyl, C1-6deuteroalkyl, C1-6haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C3-12cycloalkyl, 3-12-membered heterocyclyl containing 1-4 heteroatoms selected from nitrogen, oxygen and sulfur, C6-14aryl and 5-14-membered heteroaryl containing 1-4 heteroatoms selected from nitrogen, oxygen and sulfur; R7 is selected from the group consisting of hydrogen, halogen, cyano, C1-3alkyl, C1-3deuteroalkyl, C1-3haloalkyl, C1-3alkoxy and C3-8cycloalkyl; R8 is selected from the group consisting of hydrogen, halogen, cyano, C1-3alkyl, C1-3deuteroalkyl, C1-3haloalkyl, C1-3alkoxy and C3-8cycloalkyl.
6. A compound or its stereoisomer or pharmaceutically acceptable salt according to claim 5, wherein L1 is -CH2; R1 is -(CH2)n5O(CH2)n6RA2; RA2 is selected from the group consisting of C1-3alkyl, C1-3deuteroalkyl, C1-3haloalkyl, C3-6cycloalkyl, 4-7-membered heterocyclyl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, C3-6cycloalkyl-C1-3alkyl and 4-7-membered heterocyclyl containing 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, -C1-3alkyl; R7 is selected from the group consisting of fluorine, chlorine, bromine and C1-3 alkyl; R8 is C1-3 alkyl; n5 is 0, 1, 2, or 3; and n6 is 0, 1, or 2.
7. The compound or its stereoisomer or pharmaceutically acceptable salt according to claim 6, wherein R1 is selected from the group consisting of R7 is selected from the group consisting of fluorine, chlorine, bromine and methyl; and R8 is methyl.
8. A compound or a stereoisomer or pharmaceutically acceptable salt thereof which is:
9. A compound represented by the general formula (M-1), its stereoisomer or pharmaceutically acceptable salt: where L1, X1, X2, and R1 are as defined in paragraph 1; R9 is a 10. A method for producing a compound or its stereoisomer or pharmaceutically acceptable salt according to claim 1, wherein said method comprises the following steps, in which: a compound of general formula (M-1) is reacted with a compound of general formula (M-3) to obtain a compound of general formula (M-2) and the protecting group in the compound of general formula (M-2) is removed to obtain a compound of general formula (II), where L1, X1, X2, X3, R1, R7 and R8 are as defined in paragraph 1; R2' is selected from chlorine or bromine; R9 is selected from chlorine or bromine; Pg is selected from (trimethylsilyl)ethoxymethyl, methoxymethyl ether, allyloxycarbonyl, trifluoroacetyl, 2,4-dimethoxybenzyl, nitrobenzenesulfonyl, trityl, fluorenylmethoxycarbonyl, p-toluenesulfonyl, formate, acetyl, benzyloxycarbonyl, tert-butoxycarbonyl, benzyl or p-methoxyphenyl.
11. A method for producing a compound or its stereoisomer or pharmaceutically acceptable salt according to claim 1, wherein said method comprises the following steps, in which: a compound of general formula (M-4) is reacted with a compound of general formula (M-5) to obtain a compound of general formula (M-2) and the protecting group in the compound of general formula (M-2) is removed to obtain a compound of general formula (II), where L1, X1, X2, X3, R1, R7 and R8 are as defined in paragraph 1; R1' is selected from methanesulfonyloxy or bromine; Pg is selected from (trimethylsilyl)ethoxymethyl, methoxymethyl ether, allyloxycarbonyl, trifluoroacetyl, 2,4-dimethoxybenzyl, nitrobenzenesulfonyl, trityl, fluorenylmethoxycarbonyl, p-toluenesulfonyl, formate, acetyl, benzyloxycarbonyl, tert-butoxycarbonyl, benzyl or p-methoxyphenyl.
12. The method according to claim 10 or 11, wherein Pg is selected from (trimethylsilyl)ethoxymethyl or methoxymethyl ether.
13. A pharmaceutical composition comprising a therapeutically effective dose of a compound, its stereoisomer or pharmaceutically acceptable salt according to any one of claims 1 to 8 and one or more pharmaceutically acceptable carriers or excipients.
14. Use of a compound, its stereoisomer or pharmaceutically acceptable salt according to any one of claims 1 to 8 and a pharmaceutical composition according to claim 13 for the production of a medicinal product for the treatment of an angiotensin-II-dependent or endothelin-dependent disease.
15. The use according to paragraph 14, aimed at obtaining a medicinal product for the treatment of angiotensin-dependent and endothelin-dependent disease with dual action.
16. The use of a compound, a stereoisomer thereof, or a pharmaceutically acceptable salt according to any one of claims 1 to 8 and a pharmaceutical composition according to claim 13 for the preparation of a medicament for the treatment of pain, sexual dysfunction, hypoxia and ischemic disease, dementia, neurological disease, liver disease, cancer, hypertension, diabetes, or kidney disease, where the kidney disease is a disease or condition associated with the function of the kidneys, glomeruli, or glomerular mesangial cells.
17. The use according to claim 16, wherein the kidney disease is selected from focal segmental glomerulosclerosis or IgA nephropathy.
